Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in J Neurooncol Retrieve available abstracts of 861 articles: HTML format

Single Articles

December 2025
1. SUN L, Li J, Lv Y, Li L, et al
   Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis.
   J Neurooncol. 2025;175:1163-1176.
   PubMed     Abstract available
   
   
   
2. JIANG Z, Jin X, Xue H, Zhang J, et al
   TMEM164 enhances radioresistance of GBM cells by inhibiting the FASN-NADPH-ROS axis.
   J Neurooncol. 2025;175:1011-1026.
   PubMed     Abstract available
   
   
   
3. SONKSEN M, Bison B, Bussenius L, Rascon J, et al
   One-year follow-up of the new European reference network for pediatric cancers (ERN PaedCan) tumor board for pediatric CNS tumors: lessons learnt and future prospects.
   J Neurooncol. 2025;175:1415-1423.
   PubMed     Abstract available
   
   
   
4. BRAND A, Agolli L, Tas KT, Lishwiski P, et al
   Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience.
   J Neurooncol. 2025;175:1039-1050.
   PubMed     Abstract available
   
   
   
5. ZHAO J, Liang L, Li J, Li Q, et al
   Prediction of double expression status of primary CNS lymphoma using multiparametric MRI radiomics combined with habitat radiomics: a double-center study.
   J Neurooncol. 2025;175:1103-1113.
   PubMed     Abstract available
   
   
   
6. CHAKRAVARTI S, Oak A, Tang L, Mao Y, et al
   Community-level social capital and postoperative outcomes following intracranial tumor surgery: an exploration of the Social Capital Atlas in neurosurgical oncology.
   J Neurooncol. 2025;175:1455-1463.
   PubMed     Abstract available
   
   
   
7. ARRIETA O, Diaz-Alba A, Moreno-Jimenez S, Rodriguez-Camacho A, et al
   Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period.
   J Neurooncol. 2025;175:1227-1234.
   PubMed     Abstract available
   
   
   
8. MAHAPATRA S, Seltzer L, Osorio N, Miller M, et al
   A prospective study of minimally invasive keyhole craniotomy and stereotactic brachytherapy for new brain oligometastases.
   J Neurooncol. 2025;175:1051-1064.
   PubMed     Abstract available
   
   
   November 2025
9. CHANDLER KE, Grigorian JN, Pisharody VA, Chisango Z, et al
   Clinical and genomic factors differ in pediatric and adult pilocytic astrocytoma: a single-center experience with over 350 patients.
   J Neurooncol. 2025;175:539-547.
   PubMed     Abstract available
   
   
   
10. KIM S, Son Y, Oh J, Kim S, et al
    Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022.
    J Neurooncol. 2025;175:673-685.
    PubMed     Abstract available
    
    
    
11. BLOBNER J, Ruf V, Weller J, Teske N, et al
    Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.
    J Neurooncol. 2025;175:763-774.
    PubMed     Abstract available
    
    
    
12. PAN Z, Ye X, Huang Y, Tai P, et al
    Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I/II study.
    J Neurooncol. 2025;175:857-868.
    PubMed     Abstract available
    
    
    
13. CARDONA JJ, Park DJ, Al Gharyani MF, Wang JY, et al
    Stereotactic radiosurgery for intracranial and spinal adenoid cystic carcinoma: systematic review and illustrative case presentation.
    J Neurooncol. 2025;175:493-505.
    PubMed     Abstract available
    
    
    
14. IUSUPOVSKAIA E, Isaev N, Antonian A, Boromangnaeva AK, et al
    Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation.
    J Neurooncol. 2025;175:741-752.
    PubMed     Abstract available
    
    
    
15. ZAYED S, Ruschin M, Atenafu EG, Chen H, et al
    Prognostic factors for local failure and overall survival in patients with epidural disease at the cauda equina following stereotactic body radiotherapy: a clinical, anatomic and dosimetric analysis.
    J Neurooncol. 2025;175:621-631.
    PubMed     Abstract available
    
    
    
16. HUGHES JG, Cozzi FM, Phillips V, Price SJ, et al
    Shared decision-making interventions in neuro-oncology practice: a systematic review.
    J Neurooncol. 2025;175:471-479.
    PubMed     Abstract available
    
    
    October 2025
17. VAZIRI T, Liu IC, Bettegowda C, Croog V, et al
    Stereotactic radiosurgery for patients with extensive brain metastases across the disease course.
    J Neurooncol. 2025;176:24.
    PubMed     Abstract available
    
    
    
18. HARLAY V, Bequet C, Appay R, Bertucci A, et al
    Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.
    J Neurooncol. 2025;176:20.
    PubMed     Abstract available
    
    
    
19. DASGUPTA P, Dagher SA, Chi X, Soomro Z, et al
    Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.
    J Neurooncol. 2025;176:19.
    PubMed    
    
    
    
20. GOULENKO V, Sinha S, Madhugiri VS, Almeida ND, et al
    Modulating the pace: systemic targeted therapy, brain metastasis velocity, and outcomes after Gamma Knife radiosurgery in breast cancer brain metastases.
    J Neurooncol. 2025;176:21.
    PubMed    
    
    
    
21. ROUX A, Tauziede-Espariat A, Simboli GA, Elia A, et al
    High-grade glioma, IDH- and H3-wildtype in young adults: a rare condition with a distinct epigenetic landscape.
    J Neurooncol. 2025;176:22.
    PubMed     Abstract available
    
    
    
22. BASELGA M, Berna S, Perez VMM, Soriano M, et al
    Three-dimensional ultrastructural analysis of glioblastoma reveals spheresome-mediated intercellular communication.
    J Neurooncol. 2025;176:23.
    PubMed    
    
    
    
23. NECHAEVA A, Ulitin A, Sitovskaya D, Yudintceva N, et al
    Fluorescence molecular imaging of high-grade gliomas and brain metastases using the RAS70 peptide targeting plasma membrane-bound Hsp70 on tumor cells.
    J Neurooncol. 2025;176:15.
    PubMed     Abstract available
    
    
    
24. JHANDI S, Goold E, Jensen RL
    Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up.
    J Neurooncol. 2025;176:18.
    PubMed     Abstract available
    
    
    
25. BHARDWAJ S, Singh J, Singh S, Roy C, et al
    Unveiling MMR deficiency in pediatric and AYA high-grade gliomas: insights from multiomic profiling.
    J Neurooncol. 2025;176:16.
    PubMed    
    
    
    
26. HONG S, Takami H, Umekawa M, Shinya Y, et al
    Systemic immune-inflammation index as a prognostic biomarker to predict overall survival after primary stereotactic radiosurgery for brain metastases.
    J Neurooncol. 2025;176:12.
    PubMed     Abstract available
    
    
    
27. YUILE A, Wei JQ, McKelvey KJ, Colvin EK, et al
    Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
    J Neurooncol. 2025;176:10.
    PubMed     Abstract available
    
    
    
28. EL GHALBOUNI A, Snijders TJ, Amerein A, Tolboom N, et al
    Efficacy of Intra-arterial [(177)Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma.
    J Neurooncol. 2025;176:8.
    PubMed     Abstract available
    
    
    
29. NGUYEN TT, Pham TM, Quy PN, Chalise L, et al
    Premature mortality due to malignancies of the central nervous system in Japan: a nationwide descriptive analysis from 2000 to 2020.
    J Neurooncol. 2025;176:11.
    PubMed     Abstract available
    
    
    
30. VAN DEN BERG L, Wilbers J, de Vos FYFL, van Kouwenhoven MCM, et al
    Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort study.
    J Neurooncol. 2025;176:7.
    PubMed     Abstract available
    
    
    
31. ANDREOTTI A, Ferroni E, Guzzinati S, Baracco S, et al
    Incidence and survival of adult central nervous system tumors in the Veneto region: a population-based registry study (2016-2020).
    J Neurooncol. 2025;176:9.
    PubMed     Abstract available
    
    
    
32. GUZZINO J, Crompton DJ, Agarwal S, Kern S, et al
    Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker.
    J Neurooncol. 2025;176:5.
    PubMed     Abstract available
    
    
    
33. DAI X, He S, Qi Y, Li H, et al
    Predictive markers for molecular subtypes and WHO grade: T1rho-MRI in adult-type diffuse gliomas.
    J Neurooncol. 2025;176:6.
    PubMed     Abstract available
    
    
    
34. KIM E, Lee HI, Roh TH, Kim YZ, et al
    Hypofractionated vs. conventional fractionated radiotherapy in the temozolomide era for elderly patients with glioblastoma: a systematic review and meta-analysis by the Korean society for neuro-oncology.
    J Neurooncol. 2025;176:3.
    PubMed     Abstract available
    
    
    
35. KOAY JM, Dion C, Michaelides L, Chaichana K, et al
    Cognitive impact of repeated surgical resections for the management of high-grade glioma.
    J Neurooncol. 2025;176:4.
    PubMed     Abstract available
    
    
    
36. DAS S, Walker-Dilks C, Nicholas G, Sahgal A, et al
    Executive summary of organizational guidance for the care of patients with central nervous system tumours in Ontario: consensus recommendations.
    J Neurooncol. 2025;175:419-429.
    PubMed     Abstract available
    
    
    
37. CHEN W, Yuan J, Liu G, Cui L, et al
    Metagenomic next-generation sequencing and chromosomal copy number variation analysis in cerebrospinal fluid for the detection of meningeal carcinomatosis.
    J Neurooncol. 2025;175:175-181.
    PubMed     Abstract available
    
    
    
38. WEI CZ, Deng H, Ashwat E, Albano L, et al
    Tumor control and motor function in patients with metastases located in the primary motor cortex after stereotactic radiosurgery.
    J Neurooncol. 2025;175:63-70.
    PubMed     Abstract available
    
    
    
39. ABIKENARI M, Liu J, Ha JH, Annagiri S, et al
    Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.
    J Neurooncol. 2025;175:1-20.
    PubMed     Abstract available
    
    
    
40. SARIKAYA C, Yaltirik CK, Varol E, Yuvruk E, et al
    The role of MRI patterns in predicting neurologic deficits in spinal ependymomas.
    J Neurooncol. 2025;175:313-322.
    PubMed     Abstract available
    
    
    
41. ARENDT CT, Lohlau M, Roder L, Burger MC, et al
    Susceptibility- and T2*-weighted MRI features of CNS large B-cell lymphoma in a large single-center cohort: prevalence, patterns, and clinical associations.
    J Neurooncol. 2025;175:231-241.
    PubMed     Abstract available
    
    
    
42. IVREN M, Yalman D, Ishak B, Ille S, et al
    Beyond surgical radicality in intramedullary spinal cord metastases: neurological function and systemic disease burden drive patient outcomes.
    J Neurooncol. 2025;175:431-442.
    PubMed     Abstract available
    
    
    
43. GENSLER R, Xia Y, Horowitz MA, Abdulrahim M, et al
    Outcomes of leptomeningeal disease after only vertebral osseous metastases: a real-world analysis using the TriNetX database.
    J Neurooncol. 2025;175:219-229.
    PubMed     Abstract available
    
    
    
44. ORSMOND A, De Sousa SMC, McCormack A
    The landscape of germline variants in breast and colorectal cancer susceptibility genes in patients with pituitary tumours.
    J Neurooncol. 2025;175:379-388.
    PubMed     Abstract available
    
    
    
45. BECKHAM TH, Cha EE, Rooney MK, Tom MC, et al
    Cesium-131 collagen tile brachytherapy for salvage of recurrent intracranial metastases.
    J Neurooncol. 2025;175:165-174.
    PubMed     Abstract available
    
    
    
46. SHAH KH, Khalafallah AM, Knott MV, Berke CN, et al
    Predictors of prolonged length of stay in patients undergoing laser interstitial thermal therapy for intracranial tumors.
    J Neurooncol. 2025;175:91-99.
    PubMed     Abstract available
    
    
    
47. RAMMELOO E, Young JS, Schouten JW, Bos EM, et al
    Preoperative assessment of tumor eloquence and resectability: an international survey.
    J Neurooncol. 2025;175:47-59.
    PubMed     Abstract available
    
    
    September 2025
48. KHATRI VM, Mestres-Villanueva MA, Daniel S, Yarlagadda S, et al
    Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.
    J Neurooncol. 2025 Sep 30. doi: 10.1007/s11060-025-05230.
    PubMed     Abstract available
    
    
    
49. SHIBAHARA I, Kumabe T
    Comment on: "Anatomical distribution and prognostic heterogeneity in glioma: unique clinical features of occipital glioblastoma".
    J Neurooncol. 2025 Sep 30. doi: 10.1007/s11060-025-05226.
    PubMed     Abstract available
    
    
    
50. AN X, Wang J, Yuan J, Zhou X, et al
    Prognostic value of temporal muscle thickness in pediatric medulloblastoma patients aged 3-12 years.
    J Neurooncol. 2025 Sep 29. doi: 10.1007/s11060-025-05229.
    PubMed     Abstract available
    
    
    
51. DIAZ LS, Agrup M, Asklid A, Embring A, et al
    Correction to: Acute side effects of proton and photon radiotherapy for medulloblastoma: a retrospective national multicenter study.
    J Neurooncol. 2025 Sep 29. doi: 10.1007/s11060-025-05235.
    PubMed    
    
    
    
52. PEDERSEN V, Knudsen AM, Michaelsen SR, Dahlrot RH, et al
    Tumor and immune cell distribution in the tumor core and outer part of glioblastoma, IDH wildtype.
    J Neurooncol. 2025 Sep 25. doi: 10.1007/s11060-025-05232.
    PubMed     Abstract available
    
    
    
53. TINI P, Donnini F, Marampon F, Pastina P, et al
    Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups.
    J Neurooncol. 2025 Sep 25. doi: 10.1007/s11060-025-05215.
    PubMed     Abstract available
    
    
    
54. BASHIR S, Jian S, Hong W, Wang H, et al
    Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery.
    J Neurooncol. 2025 Sep 18. doi: 10.1007/s11060-025-05220.
    PubMed     Abstract available
    
    
    
55. GURANDA A, Guresir E, Ruder AM, Giordano FA, et al
    Intra-cavitary radiotherapy for surgically resected brain metastases: a comprehensive analysis including an individual patient data meta-analysis of intraoperative radiotherapy (IORT) and brachytherapy (IBT).
    J Neurooncol. 2025 Sep 17. doi: 10.1007/s11060-025-05227.
    PubMed     Abstract available
    
    
    
56. DEBOEUF L, Keraudy A, Picart T, Haddad G, et al
    Prevalence, natural history and surgical outcome of spinal meningiomas in NF2-related schwannomatosis.
    J Neurooncol. 2025 Sep 16. doi: 10.1007/s11060-025-05231.
    PubMed     Abstract available
    
    
    
57. ROH H, Park C, Kim W, Choi J, et al
    Impact of EGFR mutation subtypes and TKI generations on clinical outcomes in lung adenocarcinoma patients with brain metastases treated with gamma knife radiosurgery.
    J Neurooncol. 2025 Sep 16. doi: 10.1007/s11060-025-05149.
    PubMed     Abstract available
    
    
    
58. OI Y, Minamoto H, Taniyama I, Fukuzawa M, et al
    Novel predictors of tumor growth by exploratory quantitative analysis of radiomics features from MRI data for incidentally discovered meningioma.
    J Neurooncol. 2025 Sep 16. doi: 10.1007/s11060-025-05186.
    PubMed     Abstract available
    
    
    
59. NAEWWAN N, Talabnin K, Trasaktaweesakul T, Khuansonthi P, et al
    Piperlongumine induces meningioma cell death via the ROS-mediated endoplasmic reticulum stress and the alteration of the ubiquitin-proteasome system.
    J Neurooncol. 2025 Sep 15. doi: 10.1007/s11060-025-05219.
    PubMed     Abstract available
    
    
    
60. PAHWA B, Mahajan S, Pahwa N, Panico N, et al
    Linear regression models predict survival and complication rates in patients undergoing gamma knife radiosurgery for recurrent and residual craniopharyngiomas: a meta-analysis of 743 tumors.
    J Neurooncol. 2025 Sep 15. doi: 10.1007/s11060-025-05196.
    PubMed     Abstract available
    
    
    
61. TREWIN-NYBRATEN CB, Lambert PC, Marienhagen K, Andreassen L, et al
    Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry.
    J Neurooncol. 2025 Sep 11. doi: 10.1007/s11060-025-05218.
    PubMed     Abstract available
    
    
    
62. RENOVANZ M, Hippler M, Kuchen R, Doerner L, et al
    Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).
    J Neurooncol. 2025 Sep 10. doi: 10.1007/s11060-025-05223.
    PubMed     Abstract available
    
    
    
63. SU M, Duan H, Lei Q, Tan Z, et al
    Utility and performance of cerebrospinal fluid cytology in discriminating central nervous system infections and brain tumors.
    J Neurooncol. 2025 Sep 10. doi: 10.1007/s11060-025-05214.
    PubMed     Abstract available
    
    
    
64. AKUTAGAWA K, Miki S, Yamada E, Sakamoto N, et al
    Correction to: PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05203.
    PubMed    
    
    
    
65. PRICE G, Frederico SC, Colan J, Rentzeperis F, et al
    Photodynamic therapy for glioblastoma: a narrative review.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05217.
    PubMed     Abstract available
    
    
    
66. KOJUNDZIC I, Fritz JL, Said BI, Vuong S, et al
    Clinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05212.
    PubMed     Abstract available
    
    
    
67. KAMBE A, Ochiai R, Makishima K, Yasuda S, et al
    Microvessel density as a prognostic and predictive biomarker in newly diagnosed glioblastoma: correlations with radiological features and bevacizumab efficacy.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05210.
    PubMed     Abstract available
    
    
    
68. KESUMAYADI I, Kambe A, Amisaki H, Hosoya T, et al
    Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05209.
    PubMed     Abstract available
    
    
    
69. EIBL T, Liebert A, Ritter L, Neher M, et al
    Role of patient frailty in resection of newly diagnosed motor eloquent glioblastomas guided by a navigated transcranial magnetic stimulation and tractography approach.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05206.
    PubMed     Abstract available
    
    
    
70. DOIG M, Lee J, Kwok Y, MacEwan I, et al
    Impact of substructure radiation dose on health-related quality of life in children with brain tumors: a Pediatric Proton/Photon Consortium Registry (PPCR) study.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05211.
    PubMed     Abstract available
    
    
    
71. SADAGOPAN NS, Gomez M, Tripathi S, Billingham LK, et al
    NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05208.
    PubMed     Abstract available
    
    
    
72. HALL JC, Goel K, Lozko Y, Chang SD, et al
    Repeat stereotactic radiosurgery for treatment of brain metastases locally recurrent following initial radiosurgery.
    J Neurooncol. 2025 Sep 7. doi: 10.1007/s11060-025-05201.
    PubMed     Abstract available
    
    
    
73. HO A, Horbinski C, Sachdev S
    Thromboembolism in gliomas: an under-recognized danger.
    J Neurooncol. 2025 Sep 5. doi: 10.1007/s11060-025-05204.
    PubMed    
    
    
    
74. ZARE A, Zare A, Hajikarimloo B, Mohammadi B, et al
    Radiosurgery for central nervous system ependymomas: a systematic review and meta-analysis.
    J Neurooncol. 2025;174:315-327.
    PubMed     Abstract available
    
    
    
75. XIE Q, Hu J, Liu Y, Tabengwa GT, et al
    Retrospective study of leptomeningeal metastasis: unveiling the indolent and rapid progression phases.
    J Neurooncol. 2025;174:357-368.
    PubMed     Abstract available
    
    
    
76. LIPATNIKOVA A, Kling T, Denes A, Carstam L, et al
    CDKN2A/B status versus morphology in diagnosing WHO grade 4 IDH-mutated astrocytomas: what is the clinical relevance?
    J Neurooncol. 2025;174:449-458.
    PubMed     Abstract available
    
    
    
77. KRISCH JM, Ermoian RP, Indelicato DJ, Lee JY, et al
    Outcomes following radiation therapy for embryonal tumor with multilayered rosettes (ETMR): results from the Pediatric Proton/Photon Consortium Registry (PPCR).
    J Neurooncol. 2025;174:369-380.
    PubMed     Abstract available
    
    
    
78. GIANTINI-LARSEN AM, Brown S, Reiner AS, Giandalone SD, et al
    Financial toxicity in pediatric and adolescent neurosurgical oncology.
    J Neurooncol. 2025;174:349-356.
    PubMed     Abstract available
    
    
    
79. KHALAFALLAH AM, Susic N, Shah KH, Knott MV, et al
    Evaluating safety and feasibility of same-day discharge after laser interstitial thermal therapy: a pilot study with a matched control group.
    J Neurooncol. 2025;174:341-347.
    PubMed     Abstract available
    
    
    
80. AREGA G, Hailu D, Fikad G, Nigusie M, et al
    Patterns, clinical presentations, and time to diagnosis in pediatric central nervous system tumors: insights from a pediatric neuro-oncology tumor board team at a tertiary referral hospital in Ethiopia.
    J Neurooncol. 2025;174:587-598.
    PubMed     Abstract available
    
    
    
81. WANG J, Yang Q, Li X, Li Q, et al
    Engineering overexpressing SYNGR1 inhibited the progression of GBM cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.
    J Neurooncol. 2025;174:667-687.
    PubMed     Abstract available
    
    
    
82. CHEN JY, Schultz A, Khoury NM, Rangavajhula K, et al
    Optimizing workflows for metastatic central nervous system disease: a systematic review and proposed guidelines.
    J Neurooncol. 2025;174:557-585.
    PubMed     Abstract available
    
    
    August 2025
83. ARACELI T, Haj A, Doenitz C, Stoerr EM, et al
    Complete resection of brain metastases - when does it matter?
    J Neurooncol. 2025 Aug 22. doi: 10.1007/s11060-025-05193.
    PubMed     Abstract available
    
    
    
84. SHIH JJ, Jain B, Patel R, Jain U, et al
    Stereotactic radiosurgery for brain metastases: evolving practice patterns from the national cancer database (2004-2020).
    J Neurooncol. 2025 Aug 22. doi: 10.1007/s11060-025-05178.
    PubMed    
    
    
    
85. GIORDANO C, Sassu CM, Marchetti C, Guerri G, et al
    Brain metastases from ovarian cancer: neuroradiological profile and survival overview of neurosurgical cases.
    J Neurooncol. 2025 Aug 21. doi: 10.1007/s11060-025-05192.
    PubMed     Abstract available
    
    
    
86. WANG CY, Lin CF, Yang HC, Liu CY, et al
    Gamma knife radiosurgery for breast cancer brain metastasis: survival outcomes, prognotic factors, and the role of repeat treatment.
    J Neurooncol. 2025 Aug 21. doi: 10.1007/s11060-025-05188.
    PubMed     Abstract available
    
    
    
87. LIN CA, Lin C, Rhodes CT, Moseley MC, et al
    Takeaways from meta-analysis: indications of combinational treatments for glioblastoma.
    J Neurooncol. 2025 Aug 21. doi: 10.1007/s11060-025-05205.
    PubMed     Abstract available
    
    
    
88. YOGENDRAN LV, Kareddy A, Abbas SO, Scharf Z, et al
    Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression.
    J Neurooncol. 2025 Aug 20. doi: 10.1007/s11060-025-05087.
    PubMed     Abstract available
    
    
    
89. PENG TC, Hsieh MH, Lin CF, Kuan AS, et al
    Repeated stereotactic radiosurgery for high grade meningioma.
    J Neurooncol. 2025 Aug 13. doi: 10.1007/s11060-025-05165.
    PubMed     Abstract available
    
    
    
90. NEU M, Shiban E, Krauss P, Sommer B, et al
    Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis.
    J Neurooncol. 2025 Aug 13. doi: 10.1007/s11060-025-05152.
    PubMed     Abstract available
    
    
    
91. SUN MZ, Contreras E, Treger J, Imbroane M, et al
    Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells.
    J Neurooncol. 2025 Aug 13. doi: 10.1007/s11060-025-05200.
    PubMed     Abstract available
    
    
    
92. MAO M, Li Z, Zheng W, Xia H, et al
    Collagen type I alpha 1 induces radio-resistance in hypoxic glioblastoma cells by promoting autophagy.
    J Neurooncol. 2025 Aug 12. doi: 10.1007/s11060-025-05132.
    PubMed     Abstract available
    
    
    
93. RAMIREZ FERRER E, Zuluaga-Garcia JP, Alzate JD, Mayorga-Corvacho J, et al
    Impact of healthcare disparities on the treatment and survival of patients with high-grade gliomas in Colombia: a multicenter inverse probability-weighted cohort analysis.
    J Neurooncol. 2025 Aug 12. doi: 10.1007/s11060-025-05198.
    PubMed     Abstract available
    
    
    
94. BRASCHI EL, Trumble O, Casper A, Amdur RJ, et al
    Pattern of recurrence with 1.0 cm CTV in brain glioblastoma treated with radiotherapy.
    J Neurooncol. 2025 Aug 11. doi: 10.1007/s11060-025-05195.
    PubMed     Abstract available
    
    
    
95. NISHIWAKI T, Kudo U, Nakamura S, Kuse Y, et al
    Synergistic antitumor and radiosensitizing effects of alpha-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K/Akt inhibition and DNA repair impairment in glioblastoma.
    J Neurooncol. 2025 Aug 11. doi: 10.1007/s11060-025-05194.
    PubMed     Abstract available
    
    
    
96. URIAS E, DeCesaris C
    Comment on "A comparison of outcomes after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases: an international multi-center study".
    J Neurooncol. 2025 Aug 8. doi: 10.1007/s11060-025-05187.
    PubMed    
    
    
    
97. KHATUA S, Bouffet E
    Summary of the collection on 'immunotherapy in pediatric brain tumors-an update'.
    J Neurooncol. 2025 Aug 6. doi: 10.1007/s11060-025-05191.
    PubMed    
    
    
    
98. JENSEN LR, Maier AD, Juratli TA, Goutagny S, et al
    The concept, intention, and evaluation of the term treatment-refractory meningioma.
    J Neurooncol. 2025 Aug 4. doi: 10.1007/s11060-025-05154.
    PubMed     Abstract available
    
    
    
99. CRISPI V, Peat S, Bolton WS, Chapman S, et al
    Mixed reality with 3D brain imaging for patient consultation in neurosurgery: an IDEAL stage 2a feasibility study.
    J Neurooncol. 2025;174:143-156.
    PubMed     Abstract available
    
    
    
100. MO C, Liu X, Guo Y, Liang D, et al
     Clinical characteristics and pathological features of growth hormone-secreting pituitary adenoma combined with hyperprolactinemia.
     J Neurooncol. 2025;174:131-141.
     PubMed     Abstract available
     
     
     
101. GARCIA CR, Highsmith K, Knight S, Andrade IP, et al
     Single center experience of IDH inhibitors in recurrent high-grade gliomas.
     J Neurooncol. 2025 Aug 1. doi: 10.1007/s11060-025-05183.
     PubMed     Abstract available
     
     
     July 2025
102. HAGAN AJ, Hill RM, Kingston A, Bailey S, et al
     The utility of long-term methylphenidate in preserving intellectual development in survivors of childhood brain tumour.
     J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05177.
     PubMed     Abstract available
     
     
     
103. BEVER N, Shukla IY, Ebada A, Wan B, et al
     Disparities in meningioma resection outcomes: a retrospective analysis of patients with public versus private insurance.
     J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05179.
     PubMed    
     
     
     
104. LAN TL, Lin CF, Lee YY, Chang FC, et al
     Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates.
     J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05184.
     PubMed     Abstract available
     
     
     
105. JAIN TK, Vohra M, Sharma BS, Loyal A, et al
     Is 18F-PSMA PET/CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?
     J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05167.
     PubMed     Abstract available
     
     
     
106. BANDOPADHAY J, Pichardo-Rojas PS, Cho R, Tavakkol E, et al
     Assessment of the RANO-resect criteria in elderly patients with glioblastoma.
     J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05168.
     PubMed     Abstract available
     
     
     
107. CHEN D, Ye L, Yu Z, Lei T, et al
     Whole exome sequencing study of adamantinomatous craniopharyngioma reveals the mutational characteristics of recurrent cases.
     J Neurooncol. 2025 Jul 29. doi: 10.1007/s11060-025-05061.
     PubMed     Abstract available
     
     
     
108. LARIBI L, Scheepens JCC, Zamanipoor Najafabadi AH, Vos MJ, et al
     Correction to: Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning.
     J Neurooncol. 2025 Jul 28. doi: 10.1007/s11060-025-05147.
     PubMed    
     
     
     
109. MATSUDA R, Takatani T, Hayashi H, Matsuoka R, et al
     Intraoperative neuromonitoring with direct cortical stimulation motor-evoked potentials in supratentorial glioma surgeries with preoperative moderate-to-severe motor weakness.
     J Neurooncol. 2025 Jul 28. doi: 10.1007/s11060-025-05185.
     PubMed     Abstract available
     
     
     
110. PICHARDO-ROJAS PS, Bandopadhay J, Nunez LC, Dono A, et al
     Impact of maximal and supramaximal resections on postoperative diffusion-weighted imaging changes and clinical outcomes in IDH-wildtype glioblastoma.
     J Neurooncol. 2025 Jul 28. doi: 10.1007/s11060-025-05169.
     PubMed     Abstract available
     
     
     
111. PIENKOWSKI T, Mojsak P, Kowalczyk T, Cysewski D, et al
     Proteomic profiling reveals dynamic regulation of vesicle trafficking across glioma grades.
     J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05151.
     PubMed     Abstract available
     
     
     
112. AYDEMIR I, Tutkun G, Akcit ET, Kocak O, et al
     Combined effects of escitalopram and vitamin E on phoenixin-20 secretion and neuroregulatory mechanisms in glioblastoma cells: a neuro-nutritional perspective.
     J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05176.
     PubMed     Abstract available
     
     
     
113. LO SS, Halasz LM, Choi S, Kumthekar P, et al
     Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiotherapy in the management of patients with diffuse low grade glioma in adults: update.
     J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05074.
     PubMed     Abstract available
     
     
     
114. LANMAN TA, Gross H, Faria CM, Miller JJ, et al
     Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors.
     J Neurooncol. 2025 Jul 23. doi: 10.1007/s11060-025-05155.
     PubMed     Abstract available
     
     
     
115. DELGADO-LOPEZ PD, Montalvo-Afonso A, Garcia-Leal R, Martin-Garcia S, et al
     Surgical outcomes in octogenarian meningioma patients: a multicenter retrospective analysis of frailty and radiological predictors : Frailty in octogenarians undergoing meningioma resection.
     J Neurooncol. 2025 Jul 22. doi: 10.1007/s11060-025-05174.
     PubMed     Abstract available
     
     
     
116. DU Z, Luo Y, Sun J, Long H, et al
     (18)F-NOTA-NFB PET/MRI in glioma recurrence: comparison with (11)C-methionine PET/MRI and contrast-enhanced MRI.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05159.
     PubMed     Abstract available
     
     
     
117. KITE T, Bossinger B, Yadlapalli V, Jaffee S, et al
     Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05156.
     PubMed     Abstract available
     
     
     
118. ALFONZO HOROWITZ M, Li M, Parker M, Arbuiso A, et al
     Incidence, demographics, and survival of patients with brain metastases from stage IV colorectal cancer: a population-based study from 2013 to 2023.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05107.
     PubMed     Abstract available
     
     
     
119. ISHIKAWA T, Matsuda M, Kaneda Y, Ishikawa E, et al
     Hemagglutinating virus of Japan envelope encapsulating microRNA-34a-5p robustly induces apoptosis of malignant meningioma cells by suppressing survivin.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05172.
     PubMed     Abstract available
     
     
     
120. HAEDENKAMP TM, Gotz L, Ansafi T, Gerken M, et al
     Dietary habits in relation to outcome and therapy-related toxicity in patients with glioblastoma - a retrospective cohort study.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05137.
     PubMed    
     
     
     
121. PICHARDO-ROJAS PS, Hajikarimloo B, Sheehan JP
     Further points to consider regarding the resection strategy of eloquent brain metastasis in the era of postoperative stereotactic radiotherapy.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05153.
     PubMed     Abstract available
     
     
     
122. VENKATARATNAM Y, Mukherjee V, Rai N, Mahalingaswamy M, et al
     Tunneling nanotubes between glioblastoma cells and T cells and hijack of mitochondria.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05150.
     PubMed     Abstract available
     
     
     
123. PARKER M, Jiang K, Kalluri A, Arbuiso AG, et al
     Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05139.
     PubMed     Abstract available
     
     
     
124. CAO H, Yan Z, Li M, Wang J, et al
     SIN1 facilitates glioma progression and is associated with the KRAS/ERK pathway.
     J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05166.
     PubMed     Abstract available
     
     
     
125. LIU J, Meng Z, Wang R, Zhao G, et al
     CLOCK promotes proliferation of glioblastoma cells through acetylating PRPS1/2.
     J Neurooncol. 2025 Jul 19. doi: 10.1007/s11060-025-05163.
     PubMed     Abstract available
     
     
     
126. SEOL MY, Choi SH, Yoon HI
     Targeting ataxia-telangiectasia mutated and cystine/glutamate antiporter enhances radiotherapy efficacy and tumor suppression in glioblastoma.
     J Neurooncol. 2025 Jul 17. doi: 10.1007/s11060-025-05128.
     PubMed     Abstract available
     
     
     
127. CORAZZELLI G, Corvino S, Sigona L, Cioffi V, et al
     Evaluating the role of gross total resection in primary spinal cord glioblastoma: evidence from a multicenter cohort and meta-analysis.
     J Neurooncol. 2025 Jul 16. doi: 10.1007/s11060-025-05158.
     PubMed     Abstract available
     
     
     
128. LU MJS, Michaelsen SR, Locallo A, Eickhart-Dalboge CS, et al
     Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study.
     J Neurooncol. 2025 Jul 16. doi: 10.1007/s11060-025-05162.
     PubMed     Abstract available
     
     
     
129. CHEUNKARNDEE T, Ritter Z, Saint-Germain M, Ghanem P, et al
     Distinct size and spatial distribution patterns of ALK-inhibitor-naive versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases.
     J Neurooncol. 2025 Jul 16. doi: 10.1007/s11060-025-05148.
     PubMed     Abstract available
     
     
     
130. POUR-RASHIDI A, Zandpazandi S, Hsu S, Shakeri A, et al
     Comparative analysis of monotherapy versus duotherapy with antiseizure medications for intraoperative and early postoperative seizure control in glioma patients undergoing awake craniotomy.
     J Neurooncol. 2025 Jul 15. doi: 10.1007/s11060-025-05133.
     PubMed     Abstract available
     
     
     
131. HAISRAELY O, Vedala S, Al-Sharfeen A, Manzar GS, et al
     Glioblastoma in young adult patients: contemporary patterns of care and survival in the United States.
     J Neurooncol. 2025 Jul 15. doi: 10.1007/s11060-025-05135.
     PubMed    
     
     
     
132. LAN R, Zhang N, Chen R, Chen J, et al
     Correction to: Identification of RASL11A as a gene conferring radiosensitivity in glioblastoma.
     J Neurooncol. 2025 Jul 8. doi: 10.1007/s11060-025-05142.
     PubMed    
     
     
     
133. TORRES J, Bundrant BE, Dono A, Pichardo-Rojas PS, et al
     Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.
     J Neurooncol. 2025 Jul 3. doi: 10.1007/s11060-025-05143.
     PubMed     Abstract available
     
     
     
134. MALLEREAU CH, Dannhoff G, Todeschi J, Severac F, et al
     Tips and tricks of spinal cord biopsy: insights from a multicenter series of 61 patients.
     J Neurooncol. 2025;173:719-729.
     PubMed     Abstract available
     
     
     
135. LESHA E, Laird DG, Nichols CS, Miller LE, et al
     Variables associated with 90-day readmission following craniotomy for tumor in the pediatric population.
     J Neurooncol. 2025;173:759-767.
     PubMed     Abstract available
     
     
     
136. DAGHER SA, Johnson JM, Mohamed RMM, Ansari S, et al
     Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy.
     J Neurooncol. 2025 Jul 1. doi: 10.1007/s11060-025-05146.
     PubMed     Abstract available
     
     
     
137. ZHAO C, Liang B, Li X, Ma P, et al
     Anatomical distribution and prognostic heterogeneity in glioma: unique clinical features of occipital glioblastoma.
     J Neurooncol. 2025 Jul 1. doi: 10.1007/s11060-025-05144.
     PubMed     Abstract available
     
     
     June 2025
138. KOCYIGIT S, Chavez MM, Orhun O, O'Brien J, et al
     Posterior parasagittal meningiomas display aggressive features independent of size: a multicenter analysis.
     J Neurooncol. 2025 Jun 26. doi: 10.1007/s11060-025-05103.
     PubMed     Abstract available
     
     
     
139. DASGUPTA P, Lin H, Kumar G, Soomro Z, et al
     Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma.
     J Neurooncol. 2025 Jun 25. doi: 10.1007/s11060-025-05131.
     PubMed     Abstract available
     
     
     
140. LIKHOMANOVA R, Oganesyan E, Yudintceva N, Fofanov G, et al
     Glioblastoma cell motility and invasion is regulated by membrane-associated heat shock protein Hsp70.
     J Neurooncol. 2025 Jun 24. doi: 10.1007/s11060-025-05127.
     PubMed    
     
     
     
141. KRAUS LM, Goldberg M, Ursu E, Demirbag K, et al
     Postoperative hydrocephalus in patients with infratentorial brain metastases may be influenced by preoperative treatment: a single-center cohort study.
     J Neurooncol. 2025 Jun 23. doi: 10.1007/s11060-025-05125.
     PubMed     Abstract available
     
     
     
142. NOCERA G, Sanvito F, Yao J, Oshima S, et al
     Independent histological validation of MR-derived radio-pathomic maps of tumor cell density using image-guided biopsies in human brain tumors.
     J Neurooncol. 2025 Jun 21. doi: 10.1007/s11060-025-05105.
     PubMed     Abstract available
     
     
     
143. MADHUGIRI VS, Goulenko V, Seth L, Wang R, et al
     Evaluation of clinical and volumetric outcomes following adaptive gamma knife radiosurgery for brain metastases.
     J Neurooncol. 2025 Jun 20. doi: 10.1007/s11060-025-05138.
     PubMed     Abstract available
     
     
     
144. ZULUAGA-GARCIA JP, Ramirez-Ferrer E, Peeters SF, DeMonte F, et al
     Management of skull base meningiomas with extracranial extension: resection, recurrence, and prognostic factors.
     J Neurooncol. 2025 Jun 19. doi: 10.1007/s11060-025-05111.
     PubMed     Abstract available
     
     
     
145. JUNG K, Sivadas SD, Fitzgerald X, Phillips C, et al
     Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastases.
     J Neurooncol. 2025 Jun 19. doi: 10.1007/s11060-025-05121.
     PubMed     Abstract available
     
     
     
146. ROSE ML, Bajaj BVM, Jimenez R, Dennehy S, et al
     Quality of life in pediatric patients treated with adjuvant proton radiation for craniopharyngiomas.
     J Neurooncol. 2025 Jun 18. doi: 10.1007/s11060-025-05112.
     PubMed     Abstract available
     
     
     
147. WANG Q, Wang H, Hong W, Bashir S, et al
     Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis.
     J Neurooncol. 2025 Jun 18. doi: 10.1007/s11060-025-05045.
     PubMed     Abstract available
     
     
     
148. LOESCHNER D, Wagle PR, Jung A, Neumeister A, et al
     The communication of a high-grade glioma diagnosis- patients' reflections and perspectives based on a study-specific questionnaire.
     J Neurooncol. 2025 Jun 17. doi: 10.1007/s11060-025-05129.
     PubMed     Abstract available
     
     
     
149. SHEN H, Li J, Jia Y, Liu F, et al
     The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.
     J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05090.
     PubMed     Abstract available
     
     
     
150. FAN H, Li X, Zhao Y, Song L, et al
     Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies.
     J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05116.
     PubMed     Abstract available
     
     
     
151. SEIDEL JA, Alder L, Salama AKS, Anders CK, et al
     Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.
     J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05120.
     PubMed     Abstract available
     
     
     
152. CHAKRAVARTI S, Tang L, Shah HA, Singh A, et al
     Patient nutritional status is associated with surgical site infections in meningioma patients undergoing craniotomy for tumor resection.
     J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05123.
     PubMed     Abstract available
     
     
     
153. MAO Y, Tang L, Horowitz MA, Myneni S, et al
     Automated feature learning and survival prognostication in grade 4 glioma using supervised machine learning models.
     J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05099.
     PubMed     Abstract available
     
     
     
154. YARLAGADDA S, Zhang Y, Saxena A, Kutuk T, et al
     Assessment of outcomes and machine Learning-based models to predict local failure risk following stereotactic radiosurgery for small brain metastases.
     J Neurooncol. 2025 Jun 13. doi: 10.1007/s11060-025-05092.
     PubMed     Abstract available
     
     
     
155. TURAN T, Emmez OH, Kaymaz AM, Gonenc A, et al
     Clinical utility of GAL-8, ITGBeta-1, and HIF-1alpha as non-invasive diagnostic and prognostic biomarkers for assessing glioma.
     J Neurooncol. 2025 Jun 13. doi: 10.1007/s11060-025-05110.
     PubMed     Abstract available
     
     
     
156. GIDRON Y, Katan N, Mansour N, Grossman R, et al
     The prognostic and protective roles of heart-rate variability in glioblastoma: making GBM less vague.
     J Neurooncol. 2025 Jun 12. doi: 10.1007/s11060-025-05010.
     PubMed     Abstract available
     
     
     
157. AKUTAGAWA K, Miki S, Yamada E, Sakamoto N, et al
     PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
     J Neurooncol. 2025 Jun 12. doi: 10.1007/s11060-025-05102.
     PubMed     Abstract available
     
     
     
158. KREATSOULAS DC, Kim J, Damante M, Orr A, et al
     A novel lesion severity index to predict 90-day postoperative survival in brain metastasis patients.
     J Neurooncol. 2025 Jun 11. doi: 10.1007/s11060-025-05109.
     PubMed     Abstract available
     
     
     
159. METWALLY SM, El-Ayadi M, Maher E, El-Minawi MS, et al
     Impact of partial substitution of cisplatin with cyclophosphamide on acute toxicities in standard-risk medulloblastoma.
     J Neurooncol. 2025 Jun 10. doi: 10.1007/s11060-025-05098.
     PubMed     Abstract available
     
     
     
160. SAVIOLA F, Zigiotto L, Jovicich J, Sarubbo S, et al
     Predicting attention deficits and functional recovery after glioma resection through functional executive networks: insights from dynamic properties.
     J Neurooncol. 2025 Jun 10. doi: 10.1007/s11060-025-05079.
     PubMed     Abstract available
     
     
     
161. LARIBI L, Scheepens JCC, Zamanipoor Najafabadi AH, Vos MJ, et al
     Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning.
     J Neurooncol. 2025 Jun 6. doi: 10.1007/s11060-025-05025.
     PubMed     Abstract available
     
     
     
162. JACQUERIE A, Macamo A, Hoeben A, Eekers DBP, et al
     IDO2-AhR axis as central regulator of the kynurenine pathway in glioblastoma.
     J Neurooncol. 2025 Jun 5. doi: 10.1007/s11060-025-05106.
     PubMed     Abstract available
     
     
     
163. ROBERT SM, Toth A, Lev S, Bowden SG, et al
     Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges.
     J Neurooncol. 2025 Jun 5. doi: 10.1007/s11060-025-05083.
     PubMed     Abstract available
     
     
     
164. WHITTLE IR
     Complete resolution of peritumoral FLAIR hyperintensity is infrequent in surgically treated patients with intracranial meningiomas.
     J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05097.
     PubMed    
     
     
     
165. WEI CZ, Shanahan R, Puccio D, Deng H, et al
     A comparison of outcomes after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases: an international multi-center study.
     J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05093.
     PubMed     Abstract available
     
     
     
166. MARINO S, Menna G, Doglietto F, Quaranta D, et al
     A white matter-centered approach to investigate recurrence pathways in high-grade gliomas: a single-center retrospective study.
     J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05050.
     PubMed     Abstract available
     
     
     
167. RAYMOND C, Yao J, Kolkovsky ALL, Feiweier T, et al
     Super-resolution sodium MRI of human gliomas at 3T using physics-based generative artificial intelligence.
     J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05094.
     PubMed     Abstract available
     
     
     
168. TINKA P, Pokorna P, Kyr M, Pavelka Z, et al
     Individualized therapeutic approaches for relapsed and refractory pediatric ependymomas: a single institution experience.
     J Neurooncol. 2025;173:479-488.
     PubMed     Abstract available
     
     
     
169. JIN J, Qin J, Qi X, Zhang J, et al
     Serum exosomal miRNA contributes to the diagnosis of leptomeningeal carcinomatosis.
     J Neurooncol. 2025;173:419-428.
     PubMed     Abstract available
     
     
     
170. NOBEL H, Ofer J, Borenstein SF, Limon D, et al
     Long-term impact of bevacizumab for the treatment of brain radiation necrosis.
     J Neurooncol. 2025;173:289-296.
     PubMed     Abstract available
     
     
     
171. WOO PYM, Pu JKS, Li LF, Wong DKK, et al
     Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study.
     J Neurooncol. 2025;173:317-330.
     PubMed     Abstract available
     
     
     May 2025
172. NAKHATE V, Ly I, Muzikansky A, Rapalino O, et al
     Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.
     J Neurooncol. 2025 May 28. doi: 10.1007/s11060-025-05020.
     PubMed     Abstract available
     
     
     
173. YADAV N, Xiao A, Zhong Q, Kumar P, et al
     Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-beta signaling.
     J Neurooncol. 2025 May 28. doi: 10.1007/s11060-025-05089.
     PubMed     Abstract available
     
     
     
174. IBANEZ-JULIA MJ, Bataller L, Cabello-Murgui FJ, Nguyen-Them L, et al
     Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors.
     J Neurooncol. 2025 May 27. doi: 10.1007/s11060-025-05091.
     PubMed     Abstract available
     
     
     
175. BERTOLINI G, Trombini T, Zenesini C, Mazza S, et al
     Prognostic impact of second surgical resection in IDH wildtype recurrent glioblastoma following chemo-radiation therapy: a propensity score analysis cohort study.
     J Neurooncol. 2025 May 27. doi: 10.1007/s11060-025-05096.
     PubMed     Abstract available
     
     
     
176. SCHRODER C, Haghighi N, Phillips C, Udovicich C, et al
     A feasibility trial of delayed resection for brain metastases following pre-operative stereotactic radiosurgery.
     J Neurooncol. 2025 May 26. doi: 10.1007/s11060-025-05081.
     PubMed     Abstract available
     
     
     
177. SENTURK YE, Canturk EM, Peker A, Yuzkan S, et al
     Predictive value of early DCE and DSC perfusion MRI parameters for midterm clinical outcomes in lung cancer brain metastases treated with stereotactic radiosurgery.
     J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05054.
     PubMed     Abstract available
     
     
     
178. HANI L, Nasiri D, Gachter A, Klimov A, et al
     Reconsideration of the resection strategy of eloquent brain metastasis in the era of postoperative stereotactic radiotherapy: a comparative analysis with non-eloquent metastasis.
     J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05075.
     PubMed     Abstract available
     
     
     
179. VAN DIJCK JTJM, Ardon H, Balvers RK, Bos EM, et al
     Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry.
     J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05080.
     PubMed     Abstract available
     
     
     
180. LI Y, Wang Y, Han X, Xu J, et al
     Correction to: Glioma-derived SPARCL1 promotes the formation of peritumoral neuron-glioma synapses.
     J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05069.
     PubMed    
     
     
     
181. TANG T, Wu Y, Dong X, Zhai X, et al
     Multimodal MRI radiomics enhances epilepsy prediction in pediatric low-grade glioma patients.
     J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05073.
     PubMed     Abstract available
     
     
     
182. ZHOU M, Wu W, Wang Y, Zhang B, et al
     Targeting COL5A1 enhances anoikis thus attenuating malignancy of glioblastoma via inhibiting the Wnt/beta-catenin signaling pathway.
     J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05036.
     PubMed     Abstract available
     
     
     
183. WILLIAMS A, Neth B, Webb M, Schwartz J, et al
     Diffuse hemispheric glioma, H3 G34-mutant: defining the clinical picture through a single institution case series and literature analysis.
     J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05028.
     PubMed     Abstract available
     
     
     
184. SHU Y, Dong Y, Li B, Wang Y, et al
     Knockdown of STK39 inhibits lung cancer brain metastasis by suppressing the CPSF4/NFkappaB/COX2 pathway.
     J Neurooncol. 2025 May 21. doi: 10.1007/s11060-025-05072.
     PubMed     Abstract available
     
     
     
185. ABIKENARI M, Regev A, Himic V, Choi J, et al
     The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.
     J Neurooncol. 2025 May 20. doi: 10.1007/s11060-025-05082.
     PubMed     Abstract available
     
     
     
186. ALDEEVA IA, Glebova EV, Sarkisyan RA, Romanova EN, et al
     Long-term neurocognitive sequelae in pediatric medulloblastoma survivors treated according to the HIT protocol.
     J Neurooncol. 2025 May 16. doi: 10.1007/s11060-025-05070.
     PubMed     Abstract available
     
     
     
187. BOMMIREDDY A, Mayo ZS, Reddy CA, Billena C, et al
     Development of a recursive partitioning analysis for prediction of radiation necrosis following single-fraction stereotactic radiosurgery for intact brain metastases.
     J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05062.
     PubMed     Abstract available
     
     
     
188. IYER HG, Ariwodo OK, Mckevitt C, Meade PS, et al
     Predictors of return to work following surgery in patients with glioblastoma: a retrospective multicenter study.
     J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05066.
     PubMed     Abstract available
     
     
     
189. WEIDL D, Capper D, Onken J, Liu I, et al
     Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.
     J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05068.
     PubMed     Abstract available
     
     
     
190. SHUKLA IY, Ebada A, Bever N, Traylor JI, et al
     Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.
     J Neurooncol. 2025 May 12. doi: 10.1007/s11060-025-05057.
     PubMed     Abstract available
     
     
     
191. BADVE C, Nirappel A, Lo S, Orringer DA, et al
     Congress of neurological surgeons systematic review and evidence-based guidelines for the role of imaging in newly diagnosed WHO grade II diffuse glioma in adults: update.
     J Neurooncol. 2025 May 8. doi: 10.1007/s11060-025-05043.
     PubMed     Abstract available
     
     
     
192. NA MK, Oh Y, Lee D, Park J, et al
     Comparison of the biological characteristics of glioblastoma tumorspheres obtained from fresh and cryopreserved glioblastoma tissues.
     J Neurooncol. 2025 May 5. doi: 10.1007/s11060-025-05052.
     PubMed     Abstract available
     
     
     
193. PICHARDO-ROJAS PS, Garcia-Torrico F, Espinosa-Cantu CB, Rodriguez-Elvir FA, et al
     Current trends in reoperation for recurrent glioblastoma: a meta-analysis (2007-2023).
     J Neurooncol. 2025 May 2. doi: 10.1007/s11060-025-05058.
     PubMed     Abstract available
     
     
     
194. ZHENG GH, Zhang YW, Liu YX, Liu WH, et al
     Clinical characteristics and prognostic factors of primary spinal subependymoma: a single-center cohort study and systematic review.
     J Neurooncol. 2025;172:675-685.
     PubMed     Abstract available
     
     
     
195. ANDEREGGEN L, Christ E
     Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.
     J Neurooncol. 2025;172:613-623.
     PubMed     Abstract available
     
     
     
196. GU W, Zhang W, Wu Z, Cai Y, et al
     Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance.
     J Neurooncol. 2025;172:587-597.
     PubMed     Abstract available
     
     
     
197. FILHO AM, Znaor A, Sunguc C, Zahwe M, et al
     Cancers of the brain and central nervous system: global patterns and trends in incidence.
     J Neurooncol. 2025;172:567-578.
     PubMed     Abstract available
     
     
     
198. MANSOORIAN S, Schmidt M, Weissmann T, Delev D, et al
     Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume.
     J Neurooncol. 2025 May 1. doi: 10.1007/s11060-025-05042.
     PubMed     Abstract available
     
     
     
199. FINK L, von Sass C, Golla H, Voltz R, et al
     Epidemiology and palliative care of in-patient cerebral metastases cases in Germany.
     J Neurooncol. 2025;173:37-48.
     PubMed     Abstract available
     
     
     
200. THERKELSEN KE, Cao T, Roy-O'Reilly M, Stocksdale B, et al
     Molecular testing and targeting for solid tumors with CNS metastases.
     J Neurooncol. 2025;173:1-10.
     PubMed     Abstract available
     
     
     
201. MENNA G, Riva D, Marino S, Garber J, et al
     Simulation tools in neuro-oncological surgery: a scoping review of perioperative and training applications.
     J Neurooncol. 2025;173:21-35.
     PubMed     Abstract available
     
     
     
202. FRAZZINI V, Mathon B, Shor N, Nichelli L, et al
     The Mickey Mouse's hand sign in brain MRI points out multinodular and vacuolating neuronal tumors in mesial temporal lobe structures.
     J Neurooncol. 2025;173:217-223.
     PubMed     Abstract available
     
     
     
203. LIU KX, Salans M, Easwaran TP, Phuong C, et al
     The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation.
     J Neurooncol. 2025;173:167-177.
     PubMed     Abstract available
     
     
     
204. RYU H, Li X, Lee TH, Kim TM, et al
     Distribution and failure patterns of primary central nervous system lymphoma related to the hippocampus: implications for hippocampal avoidance irradiation.
     J Neurooncol. 2025;173:95-104.
     PubMed     Abstract available
     
     
     April 2025
205. WAGNER-BALLON C, Moreira A, Houessinon A, Boone M, et al
     Defining end-of-life in glioblastoma multiforme: a systematic review.
     J Neurooncol. 2025 Apr 29. doi: 10.1007/s11060-025-05051.
     PubMed     Abstract available
     
     
     
206. LA ROSA A, Mittauer KE, Rzepczynski AE, Chuong MD, et al
     Temporospatial tumor dynamic changes in glioblastoma during radiotherapy.
     J Neurooncol. 2025 Apr 29. doi: 10.1007/s11060-025-05060.
     PubMed     Abstract available
     
     
     
207. MICHEL A, Rauschenbach L, Karadachi H, Gumus M, et al
     Surgical treatment of multiple breast cancer brain metastases: clinical characteristics and factors impacting postoperative survival.
     J Neurooncol. 2025 Apr 29. doi: 10.1007/s11060-025-05048.
     PubMed     Abstract available
     
     
     
208. DIN SU, Sufiyan S, Shah AA, Fatima H, et al
     HMGA1 as a prognostic biomarker for gliomas: expression patterns, survival correlations, and clinical insights from a Pakistani cohort.
     J Neurooncol. 2025 Apr 28. doi: 10.1007/s11060-025-05031.
     PubMed     Abstract available
     
     
     
209. MARWAHA AS, Shepard MJ, Karlovits SM, Herbst J, et al
     Advancements in adaptive MR-guided radiotherapy for high-grade gliomas.
     J Neurooncol. 2025 Apr 24. doi: 10.1007/s11060-025-05053.
     PubMed     Abstract available
     
     
     
210. YI GZ, Lin JF, Lu YX, Li ZY, et al
     Clinical, pathological, radiological features and prognosis of epithelioid glioblastoma: a retrospective single center study.
     J Neurooncol. 2025 Apr 23. doi: 10.1007/s11060-025-05046.
     PubMed     Abstract available
     
     
     
211. AKDEMIR EY, Gurdikyan S, Reyes TC, Odia Y, et al
     Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients.
     J Neurooncol. 2025 Apr 22. doi: 10.1007/s11060-025-05038.
     PubMed     Abstract available
     
     
     
212. LALLY AR, Ghosh SR, Pecorari IL, Reynolds J, et al
     Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis.
     J Neurooncol. 2025 Apr 22. doi: 10.1007/s11060-025-05049.
     PubMed     Abstract available
     
     
     
213. PERRON R, Iorio-Morin C, Chytka T, Simonova G, et al
     International multicenter study of stereotactic radiosurgery for bladder cancer brain metastases.
     J Neurooncol. 2025 Apr 18. doi: 10.1007/s11060-025-05039.
     PubMed     Abstract available
     
     
     
214. YUN YC, Jende JME, Garhofer F, Wolf S, et al
     Combined peritumoral radiomics and clinical features predict 12-month progression free survival in glioblastoma.
     J Neurooncol. 2025 Apr 17. doi: 10.1007/s11060-025-05037.
     PubMed     Abstract available
     
     
     
215. DUFFAU H
     The capability to successfully study and to be graduated in students who underwent awake surgical resection for a low-grade glioma.
     J Neurooncol. 2025 Apr 17. doi: 10.1007/s11060-025-05044.
     PubMed     Abstract available
     
     
     
216. LAPIDUS AH, Devitt B, Herbison H, Tran S, et al
     A Delphi study of current practices and establishing consensus regarding assessment of fitness to drive among patients with brain tumours.
     J Neurooncol. 2025 Apr 16. doi: 10.1007/s11060-025-05030.
     PubMed     Abstract available
     
     
     
217. LIU X, Hao S, Sun S, Xie J, et al
     Increased cortical iron deposition in glioma patients: a quantitative susceptibility mapping study.
     J Neurooncol. 2025 Apr 16. doi: 10.1007/s11060-025-05027.
     PubMed     Abstract available
     
     
     
218. RASHID NS, Lamba N, Catalano PJ, Elhalawani H, et al
     Impact of brain metastasis size at the time of radiotherapy on local control and radiation necrosis.
     J Neurooncol. 2025 Apr 15. doi: 10.1007/s11060-025-05023.
     PubMed     Abstract available
     
     
     
219. DIAZ LS, Agrup M, Askild A, Embring A, et al
     Acute side effects of proton and photon radiotherapy for medulloblastoma: a retrospective national multicenter study.
     J Neurooncol. 2025 Apr 15. doi: 10.1007/s11060-025-05016.
     PubMed     Abstract available
     
     
     
220. ZSCHERNACK V, Pinto G, Friker LL, Klein R, et al
     Pitfalls in the evaluation of CDKN2A copy number status in meningioma.
     J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05029.
     PubMed     Abstract available
     
     
     
221. LI Y, Wang Y, Han X, Xu J, et al
     Glioma-derived SPARCL1 promotes the formation of peritumoral neuron-glioma synapses.
     J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05007.
     PubMed     Abstract available
     
     
     
222. SANVITO F, Kryukov I, Yao J, Teraishi A, et al
     Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.
     J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05019.
     PubMed     Abstract available
     
     
     
223. BAXTER SM, Bjorge T, Bjerkvig R, Cardwell C, et al
     Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales.
     J Neurooncol. 2025 Apr 10. doi: 10.1007/s11060-025-04996.
     PubMed     Abstract available
     
     
     
224. SUFIYAN S, Salam H, Ilyas S, Amin W, et al
     Prognostic implications of DNA methylation machinery (DNMTs and TETs) expression in gliomas: correlations with tumor grading and patient survival.
     J Neurooncol. 2025 Apr 10. doi: 10.1007/s11060-025-05032.
     PubMed     Abstract available
     
     
     
225. NOGUCHI M, Koide Y, Shindo Y, Aoyama T, et al
     Repeat stereotactic radiosurgery for recurrent brain metastases: a retrospective comparison of local progression and distant brain metastases after prior radiosurgery.
     J Neurooncol. 2025 Apr 9. doi: 10.1007/s11060-025-05035.
     PubMed     Abstract available
     
     
     
226. PANDEY K, Mishra S, Garg K, Garg A, et al
     Patterns of response following gamma knife radiosurgery for tectal plate gliomas.
     J Neurooncol. 2025 Apr 9. doi: 10.1007/s11060-025-05034.
     PubMed     Abstract available
     
     
     
227. SUN Y, Estevez-Ordonez D, Atchley TJ, Nabors B, et al
     The association of neighborhood-level deprivation with glioblastoma outcomes: a single center cohort study.
     J Neurooncol. 2025 Apr 7. doi: 10.1007/s11060-025-05002.
     PubMed     Abstract available
     
     
     
228. FU AY, Bernstein K, Zhang J, Silverman J, et al
     Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melanoma brain metastases.
     J Neurooncol. 2025 Apr 4. doi: 10.1007/s11060-025-05026.
     PubMed     Abstract available
     
     
     
229. ZHUANG L, Yin X, Liu X, Liu D, et al
     Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single?center retrospective study.
     J Neurooncol. 2025;172:461-470.
     PubMed     Abstract available
     
     
     
230. ZHAO X, Zhang Y, Wang Y, Ren X, et al
     Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.
     J Neurooncol. 2025;172:481-490.
     PubMed     Abstract available
     
     
     
231. BAKES E, Cheng R, Manucat-Tan N, Ramaswamy V, et al
     Advances in molecular prognostication and treatments in ependymoma.
     J Neurooncol. 2025;172:317-326.
     PubMed     Abstract available
     
     
     
232. LAN R, Zhang N, Chen R, Chen J, et al
     Identification of RASL11A as a gene conferring radiosensitivity in glioblastoma.
     J Neurooncol. 2025 Apr 1. doi: 10.1007/s11060-025-05013.
     PubMed     Abstract available
     
     
     March 2025
233. RIEGEL DC, Bureau BL, Conlon P, Chavez G, et al
     Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting.
     J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-04946.
     PubMed     Abstract available
     
     
     
234. TAORI S, Wei Z, Hadjipanayis CG, Niranjan A, et al
     Long-term outcomes following upfront single-session gamma knife stereotactic radiosurgery for large volume meningiomas.
     J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-05000.
     PubMed     Abstract available
     
     
     
235. TOSI U, Schwartz TH
     Resection of craniopharyngiomas: comparison between gross total resection and subtotal resection with adjuvant radiation.
     J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-05017.
     PubMed     Abstract available
     
     
     
236. GUO H, Li X, Tong H, Fang J, et al
     Longitudinal analysis of radiologic progression patterns in glioblastoma: investigating prognosis using a multi-state model.
     J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-05022.
     PubMed     Abstract available
     
     
     
237. HOROWITZ MA, Brown NJ, Gendreau J, Pennington Z, et al
     The association of hospital volume status with treatment and survival outcomes of intracranial meningioma patients: a multivariable analysis of the National Cancer Database.
     J Neurooncol. 2025 Mar 28. doi: 10.1007/s11060-025-05011.
     PubMed     Abstract available
     
     
     
238. SHEN H, Zhou Z, Zhang X, Xu M, et al
     Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patients.
     J Neurooncol. 2025 Mar 26. doi: 10.1007/s11060-025-05015.
     PubMed     Abstract available
     
     
     
239. GHOSH SR, Lally AR, Pecorari IL, Reynolds J, et al
     The impact of sociodemographic background on clinical presentation of high-grade gliomas: a multi-institutional retrospective analysis.
     J Neurooncol. 2025 Mar 25. doi: 10.1007/s11060-025-05012.
     PubMed     Abstract available
     
     
     
240. MAZA EJL, Pavoni JF, Leoni RF
     Early and late structural brain changes after radiation therapy: an MRI study in glioma patients.
     J Neurooncol. 2025 Mar 21. doi: 10.1007/s11060-025-05008.
     PubMed     Abstract available
     
     
     
241. NEIMANTAITE A, Carstam L, Gomez Vecchio T, Haggstrom I, et al
     Survival prediction with radiomics for patients with IDH mutated lower-grade glioma.
     J Neurooncol. 2025 Mar 18. doi: 10.1007/s11060-025-05006.
     PubMed     Abstract available
     
     
     
242. MULLER HL
     Long-term quality of life and hypothalamic dysfunction after craniopharyngioma.
     J Neurooncol. 2025 Mar 17. doi: 10.1007/s11060-025-04987.
     PubMed     Abstract available
     
     
     
243. DE DOMENICO P, Gagliardi F, Roncelli F, Snider S, et al
     Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.
     J Neurooncol. 2025 Mar 13. doi: 10.1007/s11060-025-04989.
     PubMed     Abstract available
     
     
     
244. MA ST, Ahn YC, Lim DH, Lee JI, et al
     Gamma Knife Radiosurgery for optic nerve sheath meningioma: comparison of efficacy and costs with radiotherapy under Korean health insurance system.
     J Neurooncol. 2025 Mar 11. doi: 10.1007/s11060-025-04986.
     PubMed     Abstract available
     
     
     
245. CERRETTI G, Bosio A, Librizzi G, Pintacuda G, et al
     Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.
     J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-04992.
     PubMed     Abstract available
     
     
     
246. HARARY PM, Rajaram S, Hori YS, Park DJ, et al
     The spectrum of radiation therapy options for craniopharyngioma: a systematic review.
     J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-05001.
     PubMed     Abstract available
     
     
     
247. SARIKONDA A, Quraishi D, Mitchell Self D, Sami A, et al
     Introducing the operative value index for glioma surgery: an integration of quality-adjusted life years with time-driven activity-based costing.
     J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-04997.
     PubMed     Abstract available
     
     
     
248. NETH BJ, Kraft RM, Eschbacher KL, Johnson DR, et al
     Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis.
     J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04994.
     PubMed     Abstract available
     
     
     
249. LAAJAVA J, Niemela M, Korja M
     Peritumoral edema resolves infrequently in surgically treated patients with intracranial meningioma- a retrospective study of 279 meningioma patients.
     J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04964.
     PubMed     Abstract available
     
     
     
250. TORRES-TENOR JL, Garcia-Leal A, Hui D, Bruera E, et al
     Unscheduled hospitalization as a potential trigger for specialist palliative care referral in patients with high grade glioma: a retrospective analysis in a tertiary hospital.
     J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04993.
     PubMed     Abstract available
     
     
     
251. FARAJ CA, McCutcheon IE, Gubbiotti MA, Perni S, et al
     Extra-central nervous system metastasis from high-grade glioma: a single-institution experience.
     J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04977.
     PubMed     Abstract available
     
     
     
252. FARES J, Wan Y, Gurung B, Nazar T, et al
     Spatial invasion patterns of temporal lobe glioblastoma after complete resection of contrast-enhancing tumor.
     J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-025-04991.
     PubMed     Abstract available
     
     
     
253. JOSHI N, Mueller S, Kline C
     Current clinical trials for craniopharyngiomas: what's on the horizon?
     J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-024-04899.
     PubMed     Abstract available
     
     
     
254. SHIREMAN JM, Distler E, Schepp C, Tao Y, et al
     Impact of pregnancy on the treatment and outcomes of glioma: a cohort study.
     J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-025-04961.
     PubMed     Abstract available
     
     
     
255. AGNER KE, Larkins MC
     Population-based histologic analysis of craniopharyngioma demographics and treatment in the US from 2000 to 2020.
     J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-025-04988.
     PubMed     Abstract available
     
     
     
256. SAINI S, Gadet JAMA, Freeman GJ, Chiocca EA, et al
     Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.
     J Neurooncol. 2025 Mar 4. doi: 10.1007/s11060-025-04978.
     PubMed     Abstract available
     
     
     
257. ADIDA S, Sefcik RK, Gerszten PC
     Comment on "The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management".
     J Neurooncol. 2025 Mar 3. doi: 10.1007/s11060-025-04983.
     PubMed    
     
     
     
258. VERMA O, Mishra S, Tripathi M, Sheehan JP, et al
     Role of stereotactic radiosurgery for intracranial epidermoid tumors: a systematic review to assess its safety, efficacy, and complication profile.
     J Neurooncol. 2025;172:13-30.
     PubMed     Abstract available
     
     
     
259. ZHU JW, Shum M, Qazi MA, Sahgal A, et al
     Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.
     J Neurooncol. 2025;172:31-40.
     PubMed     Abstract available
     
     
     
260. DINAKARAN D, Moore-Palhares D, Yang F, Hill JB, et al
     Precision radiotherapy with molecular-profiling of CNS tumours.
     J Neurooncol. 2025;172:51-75.
     PubMed     Abstract available
     
     
     
261. JALAL AHB, Gunn H, Gunasekara B, Gan HW, et al
     Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience.
     J Neurooncol. 2025;172:257-263.
     PubMed     Abstract available
     
     
     
262. OSAKO R, Hayano A, Kawaguchi A, Yamanaka R, et al
     Single-cell RNA-seq reveals diverse molecular signatures associated with Methotrexate resistance in primary central nervous system lymphoma cells.
     J Neurooncol. 2025;172:163-173.
     PubMed     Abstract available
     
     
     
263. ONISHI S, Yamasaki F, Amatya VJ, Yonezawa U, et al
     Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant.
     J Neurooncol. 2025;172:185-194.
     PubMed     Abstract available
     
     
     
264. HASKELL-MENDOZA AP, Gonzalez AT, Reason EH, Flusche AM, et al
     The LITT Fit in neuro-oncology: indications, imaging, and adjunctive therapies.
     J Neurooncol. 2025;172:1-11.
     PubMed     Abstract available
     
     
     February 2025
265. YU J, Ren L, Wu T, Hua L, et al
     Establishment and transcriptomic characteristics of radio-resistant meningioma cell lines.
     J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-025-04966.
     PubMed     Abstract available
     
     
     
266. WU Q, Chen S, Xie X, Yan H, et al
     Glioblastoma- derived exosomes (GBM-Exo) regulate microglial M2 polarization via the RAC1/AKT/NRF2 pathway.
     J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-024-04934.
     PubMed     Abstract available
     
     
     
267. LI Y, Shi J, Liu C, Ma D, et al
     Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis.
     J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-024-04906.
     PubMed     Abstract available
     
     
     
268. REDDY SC, Mao Y, Gendreau J, Ahmed AK, et al
     Clinical predictors of overall survival in very elderly meningioma patients: a surveillance, epidemiology, and end results (SEER) database analysis.
     J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-025-04982.
     PubMed     Abstract available
     
     
     
269. KOSANAM AR, Ma J, White AJ, Murayi R, et al
     Comparison of adjuvant radiation versus observation and salvage radiation after subtotal resection of a WHO grade I skull base meningioma: a propensity score-adjusted analysis.
     J Neurooncol. 2025 Feb 25. doi: 10.1007/s11060-025-04980.
     PubMed     Abstract available
     
     
     
270. KARSY M, Kshettry VR, Little AS
     RAPID, a multicenter collaboration for the study of craniopharyngiomas: challenges, opportunities, and future directions.
     J Neurooncol. 2025 Feb 24. doi: 10.1007/s11060-025-04981.
     PubMed    
     
     
     
271. ZHU J, Wang T, Liu X, Lu T, et al
     Overexpression of LSR suppresses glioma proliferation and invasion via regulating FOXO3a.
     J Neurooncol. 2025 Feb 24. doi: 10.1007/s11060-025-04976.
     PubMed     Abstract available
     
     
     
272. WACH J, Vychopen M, Guresir E
     Prognostic revalidation of RANO categories for extent of resection in glioblastoma: a reconstruction of individual patient data.
     J Neurooncol. 2025 Feb 24. doi: 10.1007/s11060-025-04950.
     PubMed     Abstract available
     
     
     
273. 
     Correction to: Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study.
     J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-024-04924.
     PubMed    
     
     
     
274. DAMANTE M, Cua S, Kreatsoulas D, Giglio P, et al
     Papillary craniopharyngioma management in the era of BRAF and MEK inhibition.
     J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-025-04969.
     PubMed     Abstract available
     
     
     
275. VAN DER WEIDE HL, Buunk AM, Siebenga FF, Langendijk JA, et al
     Neurocognitive function in lower grade glioma patients selected for proton radiotherapy: real-world data from a prospective cohort study.
     J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-025-04973.
     PubMed     Abstract available
     
     
     
276. DUBE CJ, Lai M, Zhang Y, Saha S, et al
     T-type calcium channels regulate medulloblastoma and can be targeted for therapy.
     J Neurooncol. 2025 Feb 17. doi: 10.1007/s11060-025-04967.
     PubMed     Abstract available
     
     
     
277. BALAGUER-LLUNA L, Olaciregui NG, Aschero R, Resa-Pares C, et al
     Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.
     J Neurooncol. 2025 Feb 17. doi: 10.1007/s11060-025-04954.
     PubMed     Abstract available
     
     
     
278. GAL O, Mehta MP, Kotecha R
     The role of upfront radiation therapy for brain metastases in the era of CNS-active systemic therapies: a narrative review of clinical trial design and lessons learned.
     J Neurooncol. 2025 Feb 17. doi: 10.1007/s11060-025-04970.
     PubMed     Abstract available
     
     
     
279. ZHU X, Yuan F, Sun Q, Yang C, et al
     N-acetylcysteine remodels the tumor microenvironment of primary and recurrent mouse glioblastoma.
     J Neurooncol. 2025 Feb 15. doi: 10.1007/s11060-025-04971.
     PubMed     Abstract available
     
     
     
280. LIU J, Guo S, Li Q, Yang L, et al
     Correction to: Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
     J Neurooncol. 2025 Feb 14. doi: 10.1007/s11060-025-04960.
     PubMed    
     
     
     
281. STEC NE, Barker FG 2nd, Brastianos PK
     Targeted treatment for craniopharyngioma.
     J Neurooncol. 2025 Feb 14. doi: 10.1007/s11060-025-04942.
     PubMed     Abstract available
     
     
     
282. ONG CV, Samlowski W
     Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice.
     J Neurooncol. 2025 Feb 11. doi: 10.1007/s11060-025-04951.
     PubMed     Abstract available
     
     
     
283. WASILEWSKI D, Eitner C, Ates R, Murad S, et al
     Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charite LMD registry.
     J Neurooncol. 2025 Feb 11. doi: 10.1007/s11060-025-04937.
     PubMed     Abstract available
     
     
     
284. SAKURADA K, Sato I, Ikeda M, Narita Y, et al
     Mental health status and associated factors of caregivers of patients with malignant brain tumors.
     J Neurooncol. 2025 Feb 7. doi: 10.1007/s11060-025-04963.
     PubMed     Abstract available
     
     
     
285. JESSURUN CAC, Siddi F, Nawabi NLA, Hulsbergen AFC, et al
     Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.
     J Neurooncol. 2025 Feb 7. doi: 10.1007/s11060-025-04955.
     PubMed     Abstract available
     
     
     
286. VIOZZI I, Hannink G, Ardon H, Balvers RK, et al
     Between-hospital variation in biopsy indication for patients with newly diagnosed glioblastoma in the Dutch Quality Registry for Neurosurgery.
     J Neurooncol. 2025 Feb 6. doi: 10.1007/s11060-025-04959.
     PubMed     Abstract available
     
     
     
287. PHAM J, Cote DJ, Kang K, Briggs RG, et al
     Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database.
     J Neurooncol. 2025 Feb 5. doi: 10.1007/s11060-025-04952.
     PubMed     Abstract available
     
     
     
288. STUMMER W, Gerwing M, Bilgin SS, Thomas C, et al
     Sonodynamic therapy with a single neoadjuvant, diffuse delivery of low-intensity ultrasound with 5-ALA in treatment naive glioblastoma results in tumor-specific cytotoxic edema and increased apoptosis.
     J Neurooncol. 2025 Feb 4. doi: 10.1007/s11060-025-04957.
     PubMed     Abstract available
     
     
     
289. SHEEHAN JP
     Brain metastases from small cell lung cancer: focal therapies improve outcomes in the contemporary era.
     J Neurooncol. 2025 Feb 4. doi: 10.1007/s11060-025-04943.
     PubMed    
     
     
     
290. JANI JA, Cowan D, Ouonkap L, Adesina D, et al
     Missing the message to brain tumor patients: a 2023 twitter analysis among patients, informal caregivers, and healthcare professionals in glioblastoma multiforme.
     J Neurooncol. 2025 Feb 3. doi: 10.1007/s11060-025-04948.
     PubMed     Abstract available
     
     
     
291. LESHA E, Roach JT, Miller LE, Nichols CS, et al
     Length of stay following elective craniotomy for tumor resection in children and young adults: a retrospective case series.
     J Neurooncol. 2025;171:651-658.
     PubMed     Abstract available
     
     
     
292. RODRIGUEZ B, Rivera D, Zhang JY, Brown C, et al
     Innovations in intraoperative therapies in neurosurgical oncology: a narrative review.
     J Neurooncol. 2025;171:549-557.
     PubMed     Abstract available
     
     
     January 2025
293. HUANG JY, Yeh TC, Liu HC, Hou JY, et al
     Computerized assessment of neuropsychological functioning in pediatric brain tumor patients.
     J Neurooncol. 2025 Jan 31. doi: 10.1007/s11060-025-04945.
     PubMed     Abstract available
     
     
     
294. PETERSON RK, Choi JH, King TZ
     Demographic, medical, and neighborhood barriers to clinical neuropsychological services in pediatric medulloblastoma patients treated in the United States.
     J Neurooncol. 2025 Jan 28. doi: 10.1007/s11060-025-04940.
     PubMed     Abstract available
     
     
     
295. ROSENSTOCK T, Picht T, Engelhardt M, Grittner U, et al
     Improving postsurgical paresis in brain tumor patients by transcranial magnetic stimulation.
     J Neurooncol. 2025 Jan 23. doi: 10.1007/s11060-024-04931.
     PubMed     Abstract available
     
     
     
296. UMEDA T, Otani Y, Fujii K, Ishida J, et al
     Identification of factors related to functional prognoses in craniopharyngiomas.
     J Neurooncol. 2025 Jan 22. doi: 10.1007/s11060-024-04925.
     PubMed     Abstract available
     
     
     
297. NAHLS NS, Anttonen A, Nuutinen M, Saarto T, et al
     The impact of palliative care contact on the use of hospital resources at the end of life for brain tumor patients; a nationwide register-based cohort study.
     J Neurooncol. 2025 Jan 20. doi: 10.1007/s11060-025-04939.
     PubMed     Abstract available
     
     
     
298. YAKUBOV R, Kaloti R, Persaud P, McCracken A, et al
     It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.
     J Neurooncol. 2025 Jan 16. doi: 10.1007/s11060-024-04930.
     PubMed     Abstract available
     
     
     
299. ZHONG S, Zuo J, Fu X, Wu C, et al
     Leptomeningeal dissemination in H3 K27M- mutant diffuse midline gliomas: clinical characteristics, risk factors, and prognostic insights.
     J Neurooncol. 2025 Jan 15. doi: 10.1007/s11060-024-04933.
     PubMed     Abstract available
     
     
     
300. REDJAL N, Ziu M, Choi S, Ng PR, et al
     Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.
     J Neurooncol. 2025 Jan 13. doi: 10.1007/s11060-024-04871.
     PubMed     Abstract available
     
     
     
301. WACH J, Vychopen M, Basaran AE, Tatagiba M, et al
     Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis.
     J Neurooncol. 2025 Jan 9. doi: 10.1007/s11060-024-04917.
     PubMed     Abstract available
     
     
     
302. TINI P, Donnini F, Minniti G
     Refining target delineation strategies for multifocal glioblastoma: a step towards personalized radiotherapy.
     J Neurooncol. 2025 Jan 7. doi: 10.1007/s11060-024-04926.
     PubMed    
     
     
     
303. NARSINH KH, Kumar K, Bankiewicz K, Martin AJ, et al
     A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.
     J Neurooncol. 2025 Jan 6. doi: 10.1007/s11060-024-04904.
     PubMed     Abstract available
     
     
     
304. WU Y, Chen Z, Shi M, Qiu S, et al
     Nimotuzumab and bevacizumab combined with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme: a retrospective single-arm study.
     J Neurooncol. 2025 Jan 6. doi: 10.1007/s11060-024-04932.
     PubMed     Abstract available
     
     
     
305. KAZEMI F, Gendreau JL, Parker M, Chakravarti S, et al
     Creating a predictive model and online calculator for high-value care outcomes following glioblastoma resection: incorporating neighborhood socioeconomic status index.
     J Neurooncol. 2025 Jan 4. doi: 10.1007/s11060-024-04927.
     PubMed     Abstract available
     
     
     
306. DAI Q, Wei J, Li Z, Li T, et al
     Mifepristone achieves tumor suppression and ferroptosis through PR/p53/HO1/GPX4 axis in meningioma cells.
     J Neurooncol. 2025 Jan 3. doi: 10.1007/s11060-024-04918.
     PubMed     Abstract available
     
     
     
307. MIAO Y, Wu D, Li Y, Ji Y, et al
     Radiation therapy for childhood-onset craniopharyngioma: systematic review and meta-analysis.
     J Neurooncol. 2025 Jan 3. doi: 10.1007/s11060-024-04914.
     PubMed     Abstract available
     
     
     
308. MANDELBERG N, Hodges TR, Wang TJC, McGranahan T, et al
     Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update.
     J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04898.
     PubMed     Abstract available
     
     
     
309. LIM S, Clarke NH, Maloney SL, Sener UT, et al
     Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas.
     J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04916.
     PubMed     Abstract available
     
     
     
310. SHOSHAN Y, Gomori MJ, Moss L, Bari SE, et al
     Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors.
     J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04919.
     PubMed     Abstract available
     
     
     
311. RANDRIAN V, Portales F, Bouche O, Thezenas S, et al
     The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors.
     J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04905.
     PubMed     Abstract available
     
     
     
312. MAROUFI SF, Maroufi SP, Fallahi MS, Sheehan JP, et al
     Long-term trends of publications in journal of neuro-oncology: a bibliographic study of a core journal in the field of neuro-oncology.
     J Neurooncol. 2025;171:329-341.
     PubMed     Abstract available
     
     
     
313. KIM I, Yan M, Sourour M, Heaton R, et al
     Pituitary neuroendocrine tumors treated with stereotactic radiosurgery.
     J Neurooncol. 2025;171:423-430.
     PubMed     Abstract available
     
     
     
314. ROMANOVA E, Deviaterikova A, Tolchennikova V, Karelin A, et al
     Short-term sensorimotor training incorporating cognitive tasks for pediatric survivors of posterior fossa tumors: a pilot study.
     J Neurooncol. 2025;171:393-402.
     PubMed     Abstract available
     
     
     
315. KLEIN BR, Levi DJ, Shah AH, Ivan ME, et al
     Social media "SoMe" in neuro-oncology: a review of the literature.
     J Neurooncol. 2025;171:11-19.
     PubMed     Abstract available
     
     
     
316. RINCON-TORROELLA J, Rakovec M, Kalluri AL, Jiang K, et al
     Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
     J Neurooncol. 2025;171:35-45.
     PubMed     Abstract available
     
     
     
317. PAHWA B, Singh G, Kale SS
     The 4S of spinal astrocytoma: specific location, syrinx, spasticity and score on Modified Mccormick Scale (MMS) predict long term outcomes in patients undergoing surgical resection of intramedullary spinal astrocytomas.
     J Neurooncol. 2025;171:131-138.
     PubMed     Abstract available
     
     
     
318. LIM-FAT MJ, Roberto K, Wen PY
     Clinical trial design for novel targeted agents in neuro-oncology.
     J Neurooncol. 2025;171:21-33.
     PubMed     Abstract available
     
     
     December 2024
319. BANGASH AH, Poudel P, Alshuqayfi KM, Ahmed M, et al
     Treatment-induced ripple effect: a systematic review exploring the abscopal phenomenon in Glioblastoma multiforme.
     J Neurooncol. 2024 Dec 19. doi: 10.1007/s11060-024-04912.
     PubMed     Abstract available
     
     
     
320. GREWAL EP, Nahed BV, Carter BS, Gerstner ER, et al
     Clinical progress in the development of CAR T cells to treat malignant glioma.
     J Neurooncol. 2024 Dec 18. doi: 10.1007/s11060-024-04909.
     PubMed     Abstract available
     
     
     
321. CHEN H, Tan G, Zhong L, Hu Y, et al
     MR perfusion characteristics of pseudoprogression in brain tumors treated with immunotherapy - a comparative study with chemo-radiation induced pseudoprogression and radiation necrosis.
     J Neurooncol. 2024 Dec 17. doi: 10.1007/s11060-024-04910.
     PubMed     Abstract available
     
     
     
322. BARRAGAN-PEREZ EJ, Alvarez-Amado DE, Dies-Suarez P, Tobon SH, et al
     Retraction Note: Compassionate use of Quantum Magnetic Resonance Therapy for treatment of children with Diffuse Brainstem Glioma in Mexico City: a single institutional experience.
     J Neurooncol. 2024 Dec 16. doi: 10.1007/s11060-024-04915.
     PubMed    
     
     
     
323. OBARA T, Blonski M, Forest-Dodelin M, Rech F, et al
     Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study.
     J Neurooncol. 2024 Dec 16. doi: 10.1007/s11060-024-04888.
     PubMed     Abstract available
     
     
     
324. TAORI S, Habib A, Adida S, Gecici NN, et al
     Circulating biomarkers in high-grade gliomas: current insights and future perspectives.
     J Neurooncol. 2024 Dec 13. doi: 10.1007/s11060-024-04903.
     PubMed     Abstract available
     
     
     
325. MONDIA MWL, Hooks RE, Maragkos GA, Smith VL, et al
     Primary diffuse leptomeningeal glioblastoma: a case report and literature review.
     J Neurooncol. 2024 Dec 12. doi: 10.1007/s11060-024-04908.
     PubMed     Abstract available
     
     
     
326. MARWAHA AS, Liang Y, Shepard MJ, Yu A, et al
     Patterns of failure after stereotactic radiosurgery for brain metastases from small cell lung cancer: outcomes in the immunotherapy era.
     J Neurooncol. 2024 Dec 7. doi: 10.1007/s11060-024-04895.
     PubMed     Abstract available
     
     
     
327. MOTAMED-SANAYE A, Mortezaei A, Afshari AR, Saadatian Z, et al
     Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials.
     J Neurooncol. 2024 Dec 5. doi: 10.1007/s11060-024-04865.
     PubMed     Abstract available
     
     
     
328. WASILEWSKI D, Araceli T, Bischoff P, Fruh A, et al
     TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression.
     J Neurooncol. 2024 Dec 4. doi: 10.1007/s11060-024-04885.
     PubMed     Abstract available
     
     
     
329. ZHEN J, Chen L, Wang H, Li D, et al
     Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence.
     J Neurooncol. 2024;170:665-673.
     PubMed     Abstract available
     
     
     
330. YANG W, Chai X, Zhang N, Zhi Z, et al
     Predicting cerebellar mutism syndrome in children using lesion map combined with clinical features.
     J Neurooncol. 2024;170:591-599.
     PubMed     Abstract available
     
     
     
331. BADARY A, Kertam A, El-Ramly TA, Abomera NE, et al
     Understanding metastatic involvement of the conus medullaris: a systematic review of clinical presentations, diagnostic approaches, treatment options, and patient outcomes.
     J Neurooncol. 2024;170:495-507.
     PubMed     Abstract available
     
     
     November 2024
332. LIU Y, Cai L, Wang H, Yao L, et al
     BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression.
     J Neurooncol. 2024 Nov 28. doi: 10.1007/s11060-024-04889.
     PubMed     Abstract available
     
     
     
333. SHABO E, Potthoff AL, Zeyen T, Layer JP, et al
     Transient and permanent hydrocephalus following resection of brain metastases located in the posterior fossa: incidence, risk factors and the necessity of perioperative external ventricular drainage placement.
     J Neurooncol. 2024 Nov 28. doi: 10.1007/s11060-024-04890.
     PubMed     Abstract available
     
     
     
334. DEVARAJAN A, Seah C, Zhang JY, Vasan V, et al
     A four-hit mechanism is sufficient for meningioma development.
     J Neurooncol. 2024 Nov 25. doi: 10.1007/s11060-024-04877.
     PubMed     Abstract available
     
     
     
335. BHARDWAJ S, Sanjay, Yadav AK
     Higher isoform of hnRNPA1 confer Temozolomide resistance in U87MG & LN229 glioma cells.
     J Neurooncol. 2024 Nov 25. doi: 10.1007/s11060-024-04831.
     PubMed     Abstract available
     
     
     
336. HERMELO I, Haapala I, Makela M, Jacome Sanz D, et al
     Patient-derived glioma organoids real time identification of IDH mutation, 1p/19q-codeletion and CDKN2A/B homozygous deletion with differential ion mobility spectrometry.
     J Neurooncol. 2024 Nov 23. doi: 10.1007/s11060-024-04891.
     PubMed     Abstract available
     
     
     
337. BADANI A, Ozair A, Khasraw M, Woodworth GF, et al
     Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
     J Neurooncol. 2024 Nov 21. doi: 10.1007/s11060-024-04881.
     PubMed     Abstract available
     
     
     
338. ZIU M, Halasz LM, Kumthekar PU, McGranahan TM, et al
     Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.
     J Neurooncol. 2024 Nov 20. doi: 10.1007/s11060-024-04861.
     PubMed     Abstract available
     
     
     
339. SUERO MOLINA E, Azemi G, Ozdemir Z, Russo C, et al
     Predicting intraoperative 5-ALA-induced tumor fluorescence via MRI and deep learning in gliomas with radiographic lower-grade characteristics.
     J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04875.
     PubMed     Abstract available
     
     
     
340. KRENZLIN H, Jankovic D, Dauth A, Lange F, et al
     Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.
     J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04810.
     PubMed     Abstract available
     
     
     
341. TANG L, Chakravarti S, Li E, Mao Y, et al
     Optimal treatment regimen for very elderly patients with atypical meningioma: an analysis of survival outcomes using the National Cancer Database (NCDB).
     J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04886.
     PubMed     Abstract available
     
     
     
342. VAN OPIJNEN MP, Sadigh Y, Dijkstra ME, Young JS, et al
     The impact of intraoperative mapping during re-resection in recurrent gliomas: a systematic review.
     J Neurooncol. 2024 Nov 18. doi: 10.1007/s11060-024-04874.
     PubMed     Abstract available
     
     
     
343. PULCINI S, Beaussire-Trouvay L, Marguet F, Viailly PJ, et al
     The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort.
     J Neurooncol. 2024 Nov 16. doi: 10.1007/s11060-024-04879.
     PubMed     Abstract available
     
     
     
344. WANG B, Bukowski A, Kaidar-Person O, Choi JM, et al
     Association between tumor location and toxicity outcomes after stereotactic radiosurgery for brain metastases.
     J Neurooncol. 2024 Nov 15. doi: 10.1007/s11060-024-04866.
     PubMed     Abstract available
     
     
     
345. HERR S, Kite T, Vyas P, Karlovits S, et al
     The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management.
     J Neurooncol. 2024 Nov 14. doi: 10.1007/s11060-024-04873.
     PubMed     Abstract available
     
     
     
346. TINI P, Cinelli E, Yavorska M, Donnini F, et al
     Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol.
     J Neurooncol. 2024 Nov 14. doi: 10.1007/s11060-024-04862.
     PubMed     Abstract available
     
     
     
347. PETITT JC, Murayi R, El-Abtah ME, Momin A, et al
     Outcomes of adjuvant radiation treatment following subtotal resection of world health organization grade II meningiomas.
     J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04878.
     PubMed     Abstract available
     
     
     
348. SABAHI M, Fathi Jouzdani A, Sadeghian Z, Dabbagh Ohadi MA, et al
     CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws.
     J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04876.
     PubMed     Abstract available
     
     
     
349. MOKOENA X, Mabeta P, Cordier W, Flepisi BT, et al
     Glioblastoma cells alter brain endothelial cell homeostasis and tight junction protein expression in vitro.
     J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04870.
     PubMed     Abstract available
     
     
     
350. KALLURI AL, Lee JH, Lucas CG, Rincon-Torroella J, et al
     Implications of molecular classifications in glioma surgery.
     J Neurooncol. 2024 Nov 12. doi: 10.1007/s11060-024-04883.
     PubMed     Abstract available
     
     
     
351. EL-HAJJ VG, Ranganathan S, Hoang H, Ghaith AK, et al
     The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.
     J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04880.
     PubMed     Abstract available
     
     
     
352. IRSHAD HA, Rizvi SBA, Bajwa MH, Khalid MU, et al
     Epidemiology of glioblastoma in Pakistan: a secondary analysis of the Pakistan Brain Tumor Epidemiology Study (PBTES).
     J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04872.
     PubMed     Abstract available
     
     
     
353. LAWRENCE LSP, Maralani PJ, Das S, Sahgal A, et al
     Magnetic resonance imaging techniques for monitoring glioma response to chemoradiotherapy.
     J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04856.
     PubMed     Abstract available
     
     
     
354. FAN Z, Gao A, Zhang J, Meng X, et al
     Study of prediction model for high-grade meningioma using fractal geometry combined with radiological features.
     J Neurooncol. 2024 Nov 4. doi: 10.1007/s11060-024-04867.
     PubMed     Abstract available
     
     
     
355. BAIG MIRZA A, Fayez F, Rashed S, Burn L, et al
     Ethnicity in neuro-oncology research: How are we doing and how can we do better?
     J Neurooncol. 2024;170:223-233.
     PubMed     Abstract available
     
     
     
356. ROSE ML, Moen E, Ager B, Bajaj B, et al
     Radiotherapy dosing in intracranial ependymoma using the national cancer database.
     J Neurooncol. 2024;170:387-395.
     PubMed     Abstract available
     
     
     October 2024
357. CHEN L, Rizk E, Sherief M, Chang M, et al
     Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.
     J Neurooncol. 2024 Oct 30. doi: 10.1007/s11060-024-04859.
     PubMed     Abstract available
     
     
     
358. ZHANG P, Li C, Wang Y, Chi X, et al
     Expression features of targets for anti-glioma CAR-T cell immunotherapy.
     J Neurooncol. 2024 Oct 28. doi: 10.1007/s11060-024-04855.
     PubMed     Abstract available
     
     
     
359. CACCIOTTI C, Tabori U, Hawkins C, Bennett J, et al
     Targeting the RAS/MAPK pathway in children with glioma.
     J Neurooncol. 2024 Oct 25. doi: 10.1007/s11060-024-04857.
     PubMed     Abstract available
     
     
     
360. WON YK, Kim ES, Jo IY, Oh HJ, et al
     Comparative analysis of hypofractionated short-course versus standard radiation therapy in elderly patients with glioblastoma: analysis of nationwide database.
     J Neurooncol. 2024 Oct 21. doi: 10.1007/s11060-024-04853.
     PubMed     Abstract available
     
     
     
361. PHAM DQ, Sheehan DE, Sheehan KA, Katsos K, et al
     Quality of life after stereotactic radiosurgery for brain metastasis: an assessment from a prospective national registry.
     J Neurooncol. 2024 Oct 21. doi: 10.1007/s11060-024-04854.
     PubMed     Abstract available
     
     
     
362. WETZEL EA, Nohman AI, Hsieh AL, Reuss D, et al
     A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.
     J Neurooncol. 2024 Oct 21. doi: 10.1007/s11060-024-04852.
     PubMed     Abstract available
     
     
     
363. MADHUGIRI VS, Prasad D
     Early experience with an artificial intelligence-based module for brain metastasis detection and segmentation.
     J Neurooncol. 2024 Oct 18. doi: 10.1007/s11060-024-04851.
     PubMed     Abstract available
     
     
     
364. TERRELL D, Camarano J, Whipple S, Guthikonda B, et al
     Financial toxicity in patients with glioblastoma.
     J Neurooncol. 2024 Oct 16. doi: 10.1007/s11060-024-04835.
     PubMed     Abstract available
     
     
     
365. ARMOCIDA D, Bianconi A, Zancana G, Jiang T, et al
     DTI fiber-tracking parameters adjacent to gliomas: the role of tract irregularity value in operative planning, resection, and outcome.
     J Neurooncol. 2024 Oct 15. doi: 10.1007/s11060-024-04848.
     PubMed     Abstract available
     
     
     
366. GARDNER MM, Winter SF, Stahl F, Gerstner ER, et al
     Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas.
     J Neurooncol. 2024 Oct 14. doi: 10.1007/s11060-024-04850.
     PubMed     Abstract available
     
     
     
367. MORROW K, Sloan A, Olson JJ, Ormond DR, et al
     Congress of Neurological Surgeons systematic review and evidence?based guidelines on the management of recurrent diffuse low-grade glioma: update.
     J Neurooncol. 2024 Oct 14. doi: 10.1007/s11060-024-04838.
     PubMed     Abstract available
     
     
     
368. KAMP MA, Fink L, Forster MT, Weiss Lucas C, et al
     In-patient neurosurgical tumor treatments for malignant glioma patients in Germany.
     J Neurooncol. 2024 Oct 10. doi: 10.1007/s11060-024-04784.
     PubMed     Abstract available
     
     
     
369. GRIESSMAIR M, Schramm S, Ziegenfeuter J, Canisius J, et al
     Advanced imaging reveals enhanced malignancy in glioblastomas involving the subventricular zone: evidence of increased infiltrative growth and perfusion.
     J Neurooncol. 2024 Oct 10. doi: 10.1007/s11060-024-04849.
     PubMed     Abstract available
     
     
     
370. YAMANISHI S, Nagashima H, Tanaka K, Uno T, et al
     Association of preoperative seizures with reduced expression of soluble CD163, an M2 macrophage marker, in the cerebrospinal fluid in isocitrate dehydrogenase wild-type glioblastoma.
     J Neurooncol. 2024 Oct 8. doi: 10.1007/s11060-024-04837.
     PubMed     Abstract available
     
     
     
371. PROVLOTSKAYA I, Minnigulova A, Zyryanov A, Takmakov M, et al
     How well can simple clinical features predict long-term language recovery after left-hemisphere glioma surgery?
     J Neurooncol. 2024 Oct 6. doi: 10.1007/s11060-024-04836.
     PubMed     Abstract available
     
     
     
372. FAN KY, Jerzak KJ, Kumar S, Moravan V, et al
     Predictors of brain metastases in patients with oligometastatic solid tumours treated with stereotactic body radiation therapy.
     J Neurooncol. 2024 Oct 4. doi: 10.1007/s11060-024-04834.
     PubMed     Abstract available
     
     
     
373. NIEDER C, Aanes SG, Stanisavljevic L, Mannsaker B, et al
     Return to work in younger patients with brain metastases who survived for 2 years or more.
     J Neurooncol. 2024 Oct 1. doi: 10.1007/s11060-024-04840.
     PubMed     Abstract available
     
     
     
374. YOUNG CC, Kan P, Chen SR, Lang FF, et al
     Endovascular surgical neuro-oncology: advancing a new subspecialty.
     J Neurooncol. 2024;170:31-40.
     PubMed     Abstract available
     
     
     
375. GOMES FC, Ferreira MY, Larcipretti ALL, Freitas BCB, et al
     Sodium fluorescein and 5-aminolevulinic acid fluorescence- guided biopsy in brain lesions: a systematic review and meta-analysis.
     J Neurooncol. 2024;170:11-29.
     PubMed     Abstract available
     
     
     
376. ZHAO S, Ni K, Xie J, Cheng C, et al
     Exploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM.
     J Neurooncol. 2024;170:101-117.
     PubMed     Abstract available
     
     
     
377. KANAMORI M, Mugikura S, Iizuka O, Mori N, et al
     Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up.
     J Neurooncol. 2024;170:173-184.
     PubMed     Abstract available
     
     
     
378. ROGAWSKI D, Cao T, Ma Q, Roy-O'Reilly M, et al
     Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
     J Neurooncol. 2024;170:209-217.
     PubMed     Abstract available
     
     
     September 2024
379. YAVORSKA M, Tomaciello M, Sciurti A, Cinelli E, et al
     Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.
     J Neurooncol. 2024 Sep 27. doi: 10.1007/s11060-024-04832.
     PubMed    
     
     
     
380. OHNO M, Takahashi M, Yanagisawa S, Osawa S, et al
     Correction to: Development of a scoring system to predict local recurrence in brain metastases following complete resection and observation.
     J Neurooncol. 2024 Sep 25. doi: 10.1007/s11060-024-04822.
     PubMed    
     
     
     
381. ZHU K, Li S, Yao H, Hei J, et al
     Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-beta/Smad signal pathway.
     J Neurooncol. 2024 Sep 25. doi: 10.1007/s11060-024-04797.
     PubMed     Abstract available
     
     
     
382. KATZENDOBLER S, Niedermeyer S, Blobner J, Trumm C, et al
     Determinants of long-term survival in patients with IDH-mutant gliomas.
     J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04826.
     PubMed     Abstract available
     
     
     
383. LAVIV Y, Regev O, Kanner AA, Fichman S, et al
     Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients.
     J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04828.
     PubMed     Abstract available
     
     
     
384. AARONSON DM, Laing B, Singhal I, Boerger TF, et al
     Survival implications of postoperative restricted diffusion in high-grade glioma and limitations of intraoperative MRI detection.
     J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04767.
     PubMed     Abstract available
     
     
     
385. LANDRY AP, Yefet LS, Wang JZ, Zadeh G, et al
     Methylation profiling in the contemporary management of meningioma.
     J Neurooncol. 2024 Sep 22. doi: 10.1007/s11060-024-04825.
     PubMed     Abstract available
     
     
     
386. GAL O, Mehta MP, Kotecha R
     Radiotherapeutic advances in the management of glioblastoma.
     J Neurooncol. 2024 Sep 13. doi: 10.1007/s11060-024-04824.
     PubMed     Abstract available
     
     
     
387. HAN JS, Wenger T, Demetriou AN, Dallas J, et al
     Procedural volume is linearly associated with mortality, major complications, and readmissions in patients undergoing malignant brain tumor resection.
     J Neurooncol. 2024 Sep 12. doi: 10.1007/s11060-024-04800.
     PubMed     Abstract available
     
     
     
388. YAVORSKA M, Tomiciello M, Antonio S, Cinelli E, et al
     Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.
     J Neurooncol. 2024 Sep 11. doi: 10.1007/s11060-024-04818.
     PubMed     Abstract available
     
     
     
389. NANDOLIYA KR, Congivaram H, Youngblood MW, Chen WC, et al
     Clinical and methylomic features of spinal meningiomas.
     J Neurooncol. 2024 Sep 10. doi: 10.1007/s11060-024-04736.
     PubMed     Abstract available
     
     
     
390. BASARAN AE, Arlt F, Guresir E, Vychopen M, et al
     Sexual dysfunction after surgery for primary sporadic cranial meningiomas: prevalence and risk factors.
     J Neurooncol. 2024 Sep 10. doi: 10.1007/s11060-024-04817.
     PubMed     Abstract available
     
     
     
391. BARONE TA, Robinson DL, Qiu J, Gurova KV, et al
     FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair.
     J Neurooncol. 2024 Sep 9. doi: 10.1007/s11060-024-04819.
     PubMed     Abstract available
     
     
     
392. PALAVANI LB, Mitre LP, Camerotte R, Nogueira BV, et al
     Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.
     J Neurooncol. 2024 Sep 4. doi: 10.1007/s11060-024-04813.
     PubMed     Abstract available
     
     
     
393. SCHWARTZ C, Ueberschaer MF, Rautalin I, Grauvogel J, et al
     Frailty indices predict mortality, complications and functional improvements in supratentorial meningioma patients over 80 years of age.
     J Neurooncol. 2024 Sep 4. doi: 10.1007/s11060-024-04780.
     PubMed     Abstract available
     
     
     
394. DONG J, Chen Q, Weng S, Liu L, et al
     The effect of depression and anxiety on survival in patients with glioma: a systematic review and meta-analysis.
     J Neurooncol. 2024 Sep 3. doi: 10.1007/s11060-024-04799.
     PubMed     Abstract available
     
     
     
395. EMINOVIC S, Orth T, Dell'Orco A, Baumgartner L, et al
     Clinical and imaging manifestations of intracerebral hemorrhage in brain tumors and metastatic lesions: a comprehensive overview.
     J Neurooncol. 2024 Sep 2. doi: 10.1007/s11060-024-04811.
     PubMed     Abstract available
     
     
     
396. LANDRY AP, Zuccato JA, Patil V, Voisin MR, et al
     Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours.
     J Neurooncol. 2024;169:233-239.
     PubMed     Abstract available
     
     
     
397. SHEEHAN JP, Lee CC, Fadul CE
     Progression versus pseudoprogression: radiological differentiation with contrast clearance analysis on brain MRI.
     J Neurooncol. 2024;169:695-696.
     PubMed    
     
     
     
398. GHEZZI C, Ellingson BM, Lai A, Liu J, et al
     Effect of Jardiance on glucose uptake into astrocytomas.
     J Neurooncol. 2024;169:437-444.
     PubMed     Abstract available
     
     
     
399. OZONO I, Onishi S, Yonezawa U, Taguchi A, et al
     Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.
     J Neurooncol. 2024;169:571-579.
     PubMed     Abstract available
     
     
     
400. BAKER CR, Pease M, Sexton DP, Abumoussa A, et al
     Artificial intelligence innovations in neurosurgical oncology: a narrative review.
     J Neurooncol. 2024;169:489-496.
     PubMed     Abstract available
     
     
     
401. AHMETI H, Kiese D, Freitag-Wolf S, Kalab M, et al
     IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas.
     J Neurooncol. 2024;169:423-435.
     PubMed     Abstract available
     
     
     
402. STRACK M, Kuckelhaus J, Diebold M, Wuchter P, et al
     Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells.
     J Neurooncol. 2024;169:329-340.
     PubMed     Abstract available
     
     
     
403. IVREN M, Cherkezov A, Reuss D, Haux D, et al
     Intracranial angioleiomyoma: a case series of seven patients and review of the literature.
     J Neurooncol. 2024;169:399-408.
     PubMed     Abstract available
     
     
     August 2024
404. TANAKA T, Takei J, Sasaki H
     Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
     J Neurooncol. 2024 Aug 31. doi: 10.1007/s11060-024-04806.
     PubMed    
     
     
     
405. HO VKY, Anten MM, Garst A, Bos EM, et al
     Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021).
     J Neurooncol. 2024 Aug 29. doi: 10.1007/s11060-024-04730.
     PubMed     Abstract available
     
     
     
406. ZHU H, Allwin C, Bassous MG, Pouliopoulos AN, et al
     Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials.
     J Neurooncol. 2024 Aug 29. doi: 10.1007/s11060-024-04795.
     PubMed     Abstract available
     
     
     
407. UCKERMANN O, Ziegler J, Meinhardt M, Richter S, et al
     Raman and autofluorescence spectroscopy for in situ identification of neoplastic tissue during surgical treatment of brain tumors.
     J Neurooncol. 2024 Aug 28. doi: 10.1007/s11060-024-04809.
     PubMed     Abstract available
     
     
     
408. MATHEW-SCHMITT S, Peindl M, Neundorf P, Dandekar G, et al
     Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier.
     J Neurooncol. 2024 Aug 28. doi: 10.1007/s11060-024-04760.
     PubMed     Abstract available
     
     
     
409. HAINFELLNER A, Borkovec M, Seebrecht L, Neuhauser M, et al
     Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population.
     J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04808.
     PubMed     Abstract available
     
     
     
410. PIKIS S, Mantziaris G, Protopapa M, Tos SM, et al
     Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study.
     J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04775.
     PubMed     Abstract available
     
     
     
411. ALCICEK S, Pilatus U, Manzhurtsev A, Weber KJ, et al
     Amino acid metabolism in glioma: in vivo MR-spectroscopic detection of alanine as a potential biomarker of poor survival in glioma patients.
     J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04803.
     PubMed     Abstract available
     
     
     
412. SHAABAN A, Pham D, Tos SM, Mantziaris G, et al
     Biological effective dose as a predictor of local tumor control in stereotactic radiosurgery treated parasellar meningioma patients.
     J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04804.
     PubMed     Abstract available
     
     
     
413. CHEN H, Koul D, Zhang Y, Ghobadi SN, et al
     Pulsed focused ultrasound alters the proteomic profile of the tumor microenvironment in a syngeneic mouse model of glioblastoma.
     J Neurooncol. 2024 Aug 24. doi: 10.1007/s11060-024-04801.
     PubMed     Abstract available
     
     
     
414. RIVERA CA, Bhatia S, Morell AA, Daggubati LC, et al
     Metabolic signatures derived from whole-brain MR-spectroscopy identify early tumor progression in high-grade gliomas using machine learning.
     J Neurooncol. 2024 Aug 24. doi: 10.1007/s11060-024-04812.
     PubMed     Abstract available
     
     
     
415. ZHOU WT, Niu JH, Liao C, Ren SK, et al
     Visual deterioration outcomes following optic pathway glioma treatment: a 12-year single institution retrospective study.
     J Neurooncol. 2024 Aug 21. doi: 10.1007/s11060-024-04802.
     PubMed     Abstract available
     
     
     
416. WONG CE, Chang Y, Chen PW, Huang YT, et al
     Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis.
     J Neurooncol. 2024 Aug 21. doi: 10.1007/s11060-024-04798.
     PubMed     Abstract available
     
     
     
417. PICHARDO-ROJAS PS, Vazquez-Alva D, Alvarez-Castro JA, Flores-Patino B, et al
     Comparative effectiveness of frame-based and mask-based Gamma Knife stereotactic radiosurgery in brain metastases: A 509 patient meta-analysis.
     J Neurooncol. 2024 Aug 17. doi: 10.1007/s11060-024-04738.
     PubMed     Abstract available
     
     
     
418. TSUJI S, Kudo U, Takahashi K, Nakamura S, et al
     The role of progranulin in macrophages of a glioblastoma model.
     J Neurooncol. 2024 Aug 14. doi: 10.1007/s11060-024-04793.
     PubMed     Abstract available
     
     
     
419. ONISHI S, Yamasaki F, Akiyama Y, Kawahara D, et al
     Usefulness of synthetic MRI for differentiation of IDH-mutant diffuse gliomas and its comparison with the T2-FLAIR mismatch sign.
     J Neurooncol. 2024 Aug 12. doi: 10.1007/s11060-024-04794.
     PubMed     Abstract available
     
     
     
420. KITE T, Shepard MJ
     Comment on "Amino-acid PET as a prognostic tool after post-stupp protocol temozolomide therapy in high-grade glioma patients".
     J Neurooncol. 2024 Aug 9. doi: 10.1007/s11060-024-04796.
     PubMed    
     
     
     
421. XU H, Cao Y, Ruan J, Wang F, et al
     The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells.
     J Neurooncol. 2024 Aug 8. doi: 10.1007/s11060-024-04789.
     PubMed     Abstract available
     
     
     
422. LEE M, Karschnia P, Park YW, Choi K, et al
     Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.
     J Neurooncol. 2024 Aug 8. doi: 10.1007/s11060-024-04737.
     PubMed     Abstract available
     
     
     
423. WANG B, Qiu B, Deng X
     Comment on the paper: Wang B, Liu Y, Zhang J, Yin S, Liu B, Ding S, Qiu B, Deng X. Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study. J Neurooncol 167(1):12
     J Neurooncol. 2024 Aug 7. doi: 10.1007/s11060-024-04791.
     PubMed    
     
     
     
424. 
     Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study.
     J Neurooncol. 2024 Aug 6. doi: 10.1007/s11060-024-04705.
     PubMed     Abstract available
     
     
     
425. BELTRAN-BLESS AA, Alshamsan B, Jia J, Lo V, et al
     Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation- a patient and physician survey.
     J Neurooncol. 2024 Aug 6. doi: 10.1007/s11060-024-04764.
     PubMed     Abstract available
     
     
     
426. RILINGER RG, Guo L, Sharma A, Volovetz J, et al
     Tumor-related epilepsy in high-grade glioma: a large series survival analysis.
     J Neurooncol. 2024 Aug 5. doi: 10.1007/s11060-024-04787.
     PubMed     Abstract available
     
     
     
427. OHNO M, Takahashi M, Yanagisawa S, Osawa S, et al
     Development of a scoring system to predict local recurrence in brain metastases following complete resection and observation.
     J Neurooncol. 2024 Aug 5. doi: 10.1007/s11060-024-04790.
     PubMed     Abstract available
     
     
     
428. VANHAUWAERT D, Silversmit G, Vanschoenbeek K, Coucke G, et al
     Association of hospital volume with survival but not with postoperative mortality in glioblastoma patients in Belgium.
     J Neurooncol. 2024 Aug 2. doi: 10.1007/s11060-024-04776.
     PubMed     Abstract available
     
     
     
429. MRUGALA MM, Shi W, Iwomoto F, Lukas RV, et al
     Global post?marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022.
     J Neurooncol. 2024;169:25-38.
     PubMed     Abstract available
     
     
     
430. YU C, Xu T, Fang H, Wang X, et al
     High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer.
     J Neurooncol. 2024;169:203-213.
     PubMed     Abstract available
     
     
     
431. ZHANG S, Patel K, Dusenbery K, Alshreef A, et al
     Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience.
     J Neurooncol. 2024;169:11-23.
     PubMed     Abstract available
     
     
     
432. SCHULZ N, Nichelli L, Schenone L, Ursu R, et al
     Primary central nervous system lymphomas in immunocompromised patients require specific response criteria.
     J Neurooncol. 2024;169:51-60.
     PubMed     Abstract available
     
     
     
433. YANG Y, Wadhwani N, Shimomura A, Zheng S, et al
     Long-term outcomes of central neurocytoma - an institutional experience.
     J Neurooncol. 2024;169:195-201.
     PubMed     Abstract available
     
     
     
434. RAUSCHENBACH L, Kolbe P, Engel A, Ahmadipour Y, et al
     Predictors and surgical outcome of hemorrhagic metastatic brain malignancies.
     J Neurooncol. 2024;169:165-173.
     PubMed     Abstract available
     
     
     
435. YOUSEFI Y, Nejati R, Eslahi A, Alizadeh F, et al
     Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O(6)-methylguanine DNA methyltransferase (MGMT).
     J Neurooncol. 2024;169:129-135.
     PubMed     Abstract available
     
     
     
436. SCHLIEPER-SCHERF S, Hebach N, Hausmann D, Azorin DD, et al
     Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models.
     J Neurooncol. 2024 Aug 1. doi: 10.1007/s11060-024-04786.
     PubMed     Abstract available
     
     
     
437. KAISMAN-ELBAZ T, Blumenfeld P, Wygoda M, Feldman J, et al
     Recovery of cranial nerve neuropathies after LINAC-based stereotactic radiosurgery for benign cavernous sinus meningioma.
     J Neurooncol. 2024 Aug 1. doi: 10.1007/s11060-024-04783.
     PubMed     Abstract available
     
     
     July 2024
438. NATSUME K, Yoshida A, Sakakima H, Yonezawa H, et al
     Age-independent benefits of postoperative rehabilitation during chemoradiotherapy on functional outcomes and survival in patients with glioblastoma.
     J Neurooncol. 2024 Jul 30. doi: 10.1007/s11060-024-04785.
     PubMed     Abstract available
     
     
     
439. FERREIRA MY, Antonia O M Pereira M, Hemais M, Bocanegra-Becerra JE, et al
     Comparative efficacy and safety of sodium fluorescein-guided surgery versus standard white light for resection of brain metastases: a systematic review and meta-analysis.
     J Neurooncol. 2024 Jul 30. doi: 10.1007/s11060-024-04768.
     PubMed     Abstract available
     
     
     
440. DU H, Sun J, Wang X, Zhao L, et al
     FOSL2-mediated transcription of ISG20 induces M2 polarization of macrophages and enhances tumorigenic ability of glioblastoma cells.
     J Neurooncol. 2024 Jul 29. doi: 10.1007/s11060-024-04771.
     PubMed     Abstract available
     
     
     
441. ASFAW ZK, Young T, Brown C, Germano IM, et al
     Charting the success of neuronavigation in brain tumor surgery: from inception to adoption and evolution.
     J Neurooncol. 2024 Jul 24. doi: 10.1007/s11060-024-04778.
     PubMed     Abstract available
     
     
     
442. PANEK WK, Toedebusch RG, Mclaughlin BE, Dickinson PJ, et al
     The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.
     J Neurooncol. 2024 Jul 24. doi: 10.1007/s11060-024-04766.
     PubMed     Abstract available
     
     
     
443. BOCCUNI L, Roca-Ventura A, Buloz-Osorio E, Leno-Colorado D, et al
     Non-invasive prehabilitation to foster widespread fMRI cortical reorganization before brain tumor surgery: lessons from a case series.
     J Neurooncol. 2024 Jul 23. doi: 10.1007/s11060-024-04774.
     PubMed     Abstract available
     
     
     
444. SCANLON SE, Shanahan RM, Bin-Alamer O, Bouras A, et al
     Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.
     J Neurooncol. 2024 Jul 23. doi: 10.1007/s11060-024-04772.
     PubMed     Abstract available
     
     
     
445. FERNANDEZ-GIL BI, Schiapparelli P, Navarro-Garcia de Llano JP, Otamendi-Lopez A, et al
     Effects of PreOperative radiotherapy in a preclinical glioblastoma model: a paradigm-shift approach.
     J Neurooncol. 2024 Jul 22. doi: 10.1007/s11060-024-04765.
     PubMed     Abstract available
     
     
     
446. YAMADA S, Umehara T, Sonehara K, Kijima N, et al
     Genome-wide association study on meningioma risk in Japan: a multicenter prospective study.
     J Neurooncol. 2024 Jul 13. doi: 10.1007/s11060-024-04727.
     PubMed     Abstract available
     
     
     
447. KARABACAK M, Jagtiani P, Carrasquilla A, Jain A, et al
     Simplifying synthesis of the expanding glioblastoma literature: a topic modeling approach.
     J Neurooncol. 2024 Jul 11. doi: 10.1007/s11060-024-04762.
     PubMed     Abstract available
     
     
     
448. PICHARDO-ROJAS PS, Pichardo-Rojas D, Marin-Castaneda LA, Palacios-Cruz M, et al
     Prognostic value of surgical resection over biopsy in elderly patients with glioblastoma: a meta-analysis.
     J Neurooncol. 2024 Jul 11. doi: 10.1007/s11060-024-04752.
     PubMed     Abstract available
     
     
     
449. JEISING S, Nickel AC, Trubel J, Felsberg J, et al
     A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases.
     J Neurooncol. 2024 Jul 10. doi: 10.1007/s11060-024-04763.
     PubMed     Abstract available
     
     
     
450. MAHAJAN A, Goldberg SL, Weiss SA, Tran T, et al
     Patterns of brain metastases response to immunotherapy with pembrolizumab.
     J Neurooncol. 2024 Jul 4. doi: 10.1007/s11060-024-04754.
     PubMed     Abstract available
     
     
     
451. KAHL KH, Krauss PE, Neu M, Maurer CJ, et al
     Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.
     J Neurooncol. 2024 Jul 4. doi: 10.1007/s11060-024-04691.
     PubMed     Abstract available
     
     
     
452. WAGNER S, Ewald C, Freitag D, Herrmann KH, et al
     Radiomics and visual analysis for predicting success of transplantation of heterotopic glioblastoma in mice with MRI.
     J Neurooncol. 2024 Jul 3. doi: 10.1007/s11060-024-04725.
     PubMed     Abstract available
     
     
     
453. ZHOU J, Sun W, Li H, Song X, et al
     Application of 5T glutamate chemical exchange saturation transfer imaging in brain tumors: preliminary results.
     J Neurooncol. 2024 Jul 3. doi: 10.1007/s11060-024-04759.
     PubMed     Abstract available
     
     
     
454. SHETTY A, Wang S, Khan AB, English CW, et al
     Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data.
     J Neurooncol. 2024;168:515-524.
     PubMed     Abstract available
     
     
     
455. TAN LF, Lim M
     Reply to "Elevating the findings by substituting in 'ISarcoPRM'".
     J Neurooncol. 2024;168:563-564.
     PubMed    
     
     
     
456. DA SILVA EB JR, Ramina R, Novak Filho JL, Jung GS, et al
     Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations.
     J Neurooncol. 2024;168:555-562.
     PubMed     Abstract available
     
     
     
457. MATSUDA R, Maeoka R, Morimoto T, Nakazawa T, et al
     Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator.
     J Neurooncol. 2024;168:487-494.
     PubMed     Abstract available
     
     
     
458. KNOBLAUCH AL, Blass BI, Steiert C, Neidert N, et al
     Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease.
     J Neurooncol. 2024;168:537-545.
     PubMed     Abstract available
     
     
     
459. COLE KL, Earl ER, Findlay MC, Sherrod BA, et al
     Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era.
     J Neurooncol. 2024 Jul 1. doi: 10.1007/s11060-024-04749.
     PubMed     Abstract available
     
     
     June 2024
460. GUIDARA S, Seyve A, Poncet D, Leonce C, et al
     Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
     J Neurooncol. 2024 Jun 27. doi: 10.1007/s11060-024-04733.
     PubMed     Abstract available
     
     
     
461. IANNALFI A, Riva G, Lillo S, Ciccone L, et al
     Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes.
     J Neurooncol. 2024 Jun 25. doi: 10.1007/s11060-024-04751.
     PubMed     Abstract available
     
     
     
462. ERSOY TF, Brainman D, Coras R, Berger B, et al
     Defining the role of surgery for patients with multiple brain metastases.
     J Neurooncol. 2024 Jun 25. doi: 10.1007/s11060-024-04739.
     PubMed     Abstract available
     
     
     
463. ROUX A, Elia A, Hudelist B, Benzakoun J, et al
     Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification.
     J Neurooncol. 2024 Jun 24. doi: 10.1007/s11060-024-04747.
     PubMed     Abstract available
     
     
     
464. PARK J, Kim YJ, Lee M, Kim D, et al
     Correlation of LLT-1 and NLRC4 inflammasome and its effect on glioblastoma prognosis.
     J Neurooncol. 2024 Jun 22. doi: 10.1007/s11060-024-04750.
     PubMed     Abstract available
     
     
     
465. ROUX A, Zanello M, Pallud J
     Comment on "Clinical course after Carmustine wafer implantation for newly-diagnosed adult-type diffuse gliomas; a controlled propensity matched analysis of a single center cohort".
     J Neurooncol. 2024 Jun 21. doi: 10.1007/s11060-024-04756.
     PubMed    
     
     
     
466. NIEDERMEYER S, Schmutzer-Sondergeld M, Weller J, Katzendobler S, et al
     Neurosurgical resection of multiple brain metastases: outcomes, complications, and survival rates in a retrospective analysis.
     J Neurooncol. 2024 Jun 21. doi: 10.1007/s11060-024-04744.
     PubMed     Abstract available
     
     
     
467. DECRAENE B, Coppens G, Spans L, Solie L, et al
     A novel methylation signature predicts extreme long-term survival in glioblastoma.
     J Neurooncol. 2024 Jun 19. doi: 10.1007/s11060-024-04741.
     PubMed     Abstract available
     
     
     
468. GELMERS F, Timmerman ME, Siebenga FF, van der Weide HL, et al
     Clusters of resilience and vulnerability: executive functioning, coping and mental distress in patients with diffuse low-grade glioma.
     J Neurooncol. 2024 Jun 19. doi: 10.1007/s11060-024-04704.
     PubMed     Abstract available
     
     
     
469. GOMEZ D, Feng JJ, Cheok S, Shah I, et al
     Incidence of brain metastasis according to patient race and primary cancer origin: a systematic review.
     J Neurooncol. 2024 Jun 19. doi: 10.1007/s11060-024-04748.
     PubMed     Abstract available
     
     
     
470. CAI L, Liu Y, Li Y, Liu B, et al
     TRIM37 interacts with EZH2 to epigenetically suppress PTCH1 and regulate stemness in glioma stem cells through sonic hedgehog pathway.
     J Neurooncol. 2024 Jun 17. doi: 10.1007/s11060-024-04726.
     PubMed     Abstract available
     
     
     
471. ZHU H, Li Y, Ding Y, Liu Y, et al
     Multi-pool chemical exchange saturation transfer MRI in glioma grading, molecular subtyping and evaluating tumor proliferation.
     J Neurooncol. 2024 Jun 14. doi: 10.1007/s11060-024-04729.
     PubMed     Abstract available
     
     
     
472. JOO B, Kim JH, Ahn SG, Park M, et al
     De novo versus recurrent metastatic breast cancer affects the extent of brain metastases.
     J Neurooncol. 2024 Jun 12. doi: 10.1007/s11060-024-04735.
     PubMed     Abstract available
     
     
     
473. DHARNIPRAGADA R, Shah RA, Reynolds M, Dusenbery K, et al
     Laser interstitial thermal therapy followed by consolidation stereotactic radiosurgery (LITT-cSRS) in patients with newly diagnosed brain metastasis.
     J Neurooncol. 2024 Jun 12. doi: 10.1007/s11060-024-04712.
     PubMed     Abstract available
     
     
     
474. DAGHER R, Gad M, da Silva de Santana P, Sadeghi MA, et al
     Correction to: Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
     J Neurooncol. 2024 Jun 10. doi: 10.1007/s11060-024-04718.
     PubMed    
     
     
     
475. ZINSZ A, Ahrari S, Becker J, Mortada A, et al
     Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.
     J Neurooncol. 2024 Jun 6. doi: 10.1007/s11060-024-04722.
     PubMed     Abstract available
     
     
     
476. TOYODA M, Shibahara I, Shigeeda R, Fujitani K, et al
     Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
     J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04687.
     PubMed     Abstract available
     
     
     
477. KUTUK T, Zhang Y, Akdemir EY, Yarlagadda S, et al
     Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis.
     J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04706.
     PubMed     Abstract available
     
     
     
478. HOCKING MC, Schultz RT, Yerys BE, Minturn JE, et al
     White matter connectivity and social functioning in survivors of pediatric brain tumor.
     J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04724.
     PubMed     Abstract available
     
     
     
479. PICART T, Hervey-Jumper S
     Central nervous system regulation of diffuse glioma growth and invasion: from single unit physiology to circuit remodeling.
     J Neurooncol. 2024 Jun 4. doi: 10.1007/s11060-024-04719.
     PubMed     Abstract available
     
     
     
480. BRAY DP, Stubbs NM, Chow J, Jahangiri A, et al
     Frailty in patients with IDH-mutant gliomas: experience from a high-volume tumor center.
     J Neurooncol. 2024 Jun 4. doi: 10.1007/s11060-024-04685.
     PubMed     Abstract available
     
     
     
481. BELLOMO J, Zeitlberger AM, Padevit L, Stumpo V, et al
     Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis.
     J Neurooncol. 2024 Jun 3. doi: 10.1007/s11060-024-04728.
     PubMed     Abstract available
     
     
     
482. CAPATINA C, Hanzu FA, Hinojosa-Amaya JM, Fleseriu M, et al
     Medical treatment of functional pituitary adenomas, trials and tribulations.
     J Neurooncol. 2024;168:197-213.
     PubMed     Abstract available
     
     
     
483. LAWSON MCLEAN AC, Lawson McLean A, Ernst T, Forster MT, et al
     Benchmarking palliative care practices in neurooncology: a german perspective.
     J Neurooncol. 2024;168:333-343.
     PubMed     Abstract available
     
     
     
484. BIELAMOWICZ KJ, Littrell MB, Albert GW, Parker LS, et al
     Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse.
     J Neurooncol. 2024;168:367-373.
     PubMed     Abstract available
     
     
     
485. YAMAMURA T, Tamura K, Kobayashi D, Inaji M, et al
     Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of (11)C-methionine in IDH-mutant astrocytoma.
     J Neurooncol. 2024;168:355-365.
     PubMed     Abstract available
     
     
     
486. DUAN L, He Y, Guo W, Du Y, et al
     Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma.
     J Neurooncol. 2024;168:283-298.
     PubMed     Abstract available
     
     
     May 2024
487. HO CH, Shieh LT, Lin CH, Guo HR, et al
     The role of adjuvant radiotherapy for intracranial malignant meningiomas: analysis of a nationwide database.
     J Neurooncol. 2024 May 30. doi: 10.1007/s11060-024-04720.
     PubMed     Abstract available
     
     
     
488. LI C, Long L, Wang Y, Chi X, et al
     Constitutive type-1 interferons signaling activity in malignant gliomas.
     J Neurooncol. 2024 May 24. doi: 10.1007/s11060-024-04601.
     PubMed     Abstract available
     
     
     
489. LUCKETT PH, Olufawo MO, Park KY, Lamichhane B, et al
     Predicting post-surgical functional status in high-grade glioma with resting state fMRI and machine learning.
     J Neurooncol. 2024 May 24. doi: 10.1007/s11060-024-04715.
     PubMed     Abstract available
     
     
     
490. ONO T, Suzuki H, Nanjo H, Shimizu H, et al
     Clinical Course after Carmustine Wafer Implantation for Newly Diagnosed Adult-type Diffuse Gliomas; A controlled propensity matched analysis of a single center cohort.
     J Neurooncol. 2024 May 23. doi: 10.1007/s11060-024-04679.
     PubMed     Abstract available
     
     
     
491. SIMON M, Kuschel LP, von Hoff K, Yuan D, et al
     Rapid DNA methylation-based classification of pediatric brain tumors from ultrasonic aspirate specimens.
     J Neurooncol. 2024 May 21. doi: 10.1007/s11060-024-04702.
     PubMed     Abstract available
     
     
     
492. BLAKSTAD H, Mendoza Mireles EE, Kierulf-Vieira KS, Singireddy D, et al
     The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients.
     J Neurooncol. 2024 May 19. doi: 10.1007/s11060-024-04709.
     PubMed     Abstract available
     
     
     
493. HUDELIST B, Elia A, Roux A, Paun L, et al
     Impact of frailty on survival glioblastoma, IDH-wildtype patients.
     J Neurooncol. 2024 May 19. doi: 10.1007/s11060-024-04699.
     PubMed     Abstract available
     
     
     
494. DORON O, Wong T, Ablyazova F, Singha S, et al
     Correction to: Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
     J Neurooncol. 2024 May 17. doi: 10.1007/s11060-024-04701.
     PubMed    
     
     
     
495. RONSLEY R, Karvonen KA, Cole B, Paulson V, et al
     Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
     J Neurooncol. 2024 May 16. doi: 10.1007/s11060-024-04645.
     PubMed     Abstract available
     
     
     
496. PECIU-FLORIANU I, Vannod-Michel Q, Vauleon E, Bonneterre ME, et al
     Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240).
     J Neurooncol. 2024 May 16. doi: 10.1007/s11060-024-04693.
     PubMed     Abstract available
     
     
     
497. GOULENKO V, Madhugiri VS, Bregy A, Recker M, et al
     Histopathological correlation of brain tumor recurrence vs. radiation effect post-radiosurgery as detected by MRI contrast clearance analysis: a validation study.
     J Neurooncol. 2024 May 15. doi: 10.1007/s11060-024-04697.
     PubMed     Abstract available
     
     
     
498. RALEIGH DR, Chen WC, Gondi V, Rogers L, et al
     Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice.
     J Neurooncol. 2024 May 14. doi: 10.1007/s11060-024-04700.
     PubMed    
     
     
     
499. POLETES C, Amanirad B, Santiago AT, Yan M, et al
     The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis.
     J Neurooncol. 2024 May 13. doi: 10.1007/s11060-024-04707.
     PubMed     Abstract available
     
     
     
500. COVELL MM, Roy JM, Gupta N, Raihane AS, et al
     Frailty in intracranial meningioma resection: the risk analysis index demonstrates strong discrimination for predicting non-home discharge and in-hospital mortality.
     J Neurooncol. 2024 May 7. doi: 10.1007/s11060-024-04703.
     PubMed     Abstract available
     
     
     
501. OTTENHAUSEN M, Renovanz M, Bartz I, Poplawski A, et al
     Use of complementary therapies and supportive measures of patients with intracranial gliomas-a prospective evaluation in an outpatient clinic.
     J Neurooncol. 2024 May 6. doi: 10.1007/s11060-024-04696.
     PubMed     Abstract available
     
     
     
502. SHIN I, Sim Y, Choi SH, Park YW, et al
     Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
     J Neurooncol. 2024 May 3. doi: 10.1007/s11060-024-04656.
     PubMed     Abstract available
     
     
     
503. BAQRI W, Rzadki K, Habbous S, Das S, et al
     Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study.
     J Neurooncol. 2024 May 3. doi: 10.1007/s11060-024-04690.
     PubMed     Abstract available
     
     
     
504. GECICI NN, Gurses ME, Kaye B, Jimenez NLF, et al
     Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis.
     J Neurooncol. 2024;168:1-11.
     PubMed     Abstract available
     
     
     
505. FEHRENBACH MK, Wilhelmy F, Wende T, Guresir E, et al
     Perioperative psychological distress in patients with intracranial tumors; a single center study.
     J Neurooncol. 2024;168:151-157.
     PubMed     Abstract available
     
     
     
506. ABDULSALAM AJ, Kara M, Ozcakar L
     Elevating the findings by substituting in "ISarcoPRM".
     J Neurooncol. 2024;168:185-186.
     PubMed    
     
     
     
507. RODRIGUES AJ, Chernikova SB, Wang Y, Trinh TTH, et al
     Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
     J Neurooncol. 2024;168:125-138.
     PubMed     Abstract available
     
     
     
508. WANG M, Chen M, Ge Y
     Comment on "Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control''.
     J Neurooncol. 2024;167:525.
     PubMed    
     
     
     
509. KASATKIN VN, Romanova EN, Glebova EV, Deviaterikova AA, et al
     Effects of cognitive-motor intervention for pediatric posterior fossa tumor survivors: results of a pilot study.
     J Neurooncol. 2024;168:57-67.
     PubMed     Abstract available
     
     
     
510. LALANCETTE E, Cantin E, Routhier ME, Mailloux C, et al
     Impact of trametinib on the neuropsychological profile of NF1 patients.
     J Neurooncol. 2024;167:447-454.
     PubMed     Abstract available
     
     
     
511. BARBOUR AB, Blouw B, Taylor LP, Graber JJ, et al
     Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
     J Neurooncol. 2024;167:509-514.
     PubMed     Abstract available
     
     
     
512. TONG T, Chen H, Mo C, Zhong L, et al
     Clinical characteristics and predictive factors of delayed diagnosis in patients with sellar germ cell tumors.
     J Neurooncol. 2024;167:467-476.
     PubMed     Abstract available
     
     
     
513. DAVISON MA, Lilly DT, Patel AA, Kashkoush A, et al
     Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas.
     J Neurooncol. 2024;167:437-446.
     PubMed     Abstract available
     
     
     
514. NAKAGAWA K, Takano K, Nishino K, Ohe S, et al
     Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
     J Neurooncol. 2024;167:397-406.
     PubMed     Abstract available
     
     
     April 2024
515. LI G, Tian Q, Wang S, Li K, et al
     Superficial meningioma with bone involvement: surgical strategies and clinical outcomes.
     J Neurooncol. 2024 Apr 30. doi: 10.1007/s11060-024-04604.
     PubMed     Abstract available
     
     
     
516. BASREE MM, Li C, Um H, Bui AH, et al
     Leveraging radiomics and machine learning to differentiate radiation necrosis from recurrence in patients with brain metastases.
     J Neurooncol. 2024 Apr 30. doi: 10.1007/s11060-024-04669.
     PubMed     Abstract available
     
     
     
517. DORON O, Wong T, Ablyazova F, Singha S, et al
     Results from a first-in-human phase i safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
     J Neurooncol. 2024 Apr 26. doi: 10.1007/s11060-024-04647.
     PubMed     Abstract available
     
     
     
518. WANG S, Zhang D, Wang J, Peng X, et al
     PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
     J Neurooncol. 2024 Apr 25. doi: 10.1007/s11060-024-04655.
     PubMed     Abstract available
     
     
     
519. PARKER M, Kazemi F, Ahmed AK, Kuo CC, et al
     Exploring the impact of primary care utilization and health information exchange upon treatment patterns and clinical outcomes of glioblastoma patients.
     J Neurooncol. 2024 Apr 25. doi: 10.1007/s11060-024-04677.
     PubMed     Abstract available
     
     
     
520. JOST J, Volker K, Brandt R, Stummer W, et al
     Correction to: Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
     J Neurooncol. 2024 Apr 24. doi: 10.1007/s11060-024-04686.
     PubMed    
     
     
     
521. MAIURI F, Corvino S, Corazzelli G, Del Basso De Caro M, et al
     Single versus multiple reoperations for recurrent intracranial meningiomas.
     J Neurooncol. 2024 Apr 24. doi: 10.1007/s11060-024-04673.
     PubMed     Abstract available
     
     
     
522. OKAMOTO T, Mizuta R, Takahashi Y, Otani Y, et al
     Genomic landscape of glioblastoma without IDH somatic mutation in 42 cases: a comprehensive analysis using RNA sequencing data.
     J Neurooncol. 2024 Apr 23. doi: 10.1007/s11060-024-04628.
     PubMed     Abstract available
     
     
     
523. SUN T, Liu B, Cai L, Zhou Y, et al
     Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.
     J Neurooncol. 2024 Apr 23. doi: 10.1007/s11060-024-04689.
     PubMed     Abstract available
     
     
     
524. KOIDE Y, Nagai N, Adachi S, Ito M, et al
     Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study.
     J Neurooncol. 2024 Apr 22. doi: 10.1007/s11060-024-04681.
     PubMed     Abstract available
     
     
     
525. CZARNOTA GJ
     Comment in reply to Chen et al. Journal of Neuro-Oncology (2023) 165:535-545 "Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study".
     J Neurooncol. 2024 Apr 19. doi: 10.1007/s11060-024-04675.
     PubMed    
     
     
     
526. CONRAD K, Lober-Handwerker R, Hazaymeh M, Rohde V, et al
     Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.
     J Neurooncol. 2024 Apr 19. doi: 10.1007/s11060-024-04683.
     PubMed     Abstract available
     
     
     
527. DESAI J, Rajkumar S, Shepard MJ, Herbst J, et al
     National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario.
     J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04663.
     PubMed     Abstract available
     
     
     
528. SALAME AAM, Charchar HLS, de Oliveira Dourado JP, Mendonca B, et al
     Neuroradiological features of patients with bilateral macronodular adrenocortical disease and meningiomas associated or not with genetic variants of ARMC5- a case series.
     J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04680.
     PubMed     Abstract available
     
     
     
529. MASHIACH E, Alzate JD, De Nigris Vasconcellos F, Adams S, et al
     Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches.
     J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04651.
     PubMed     Abstract available
     
     
     
530. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
     Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).
     J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04668.
     PubMed     Abstract available
     
     
     
531. KOCHER D, Cao L, Guiho R, Langhammer M, et al
     Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
     J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04672.
     PubMed     Abstract available
     
     
     
532. WILSON L, Atallah A, Romero JM
     Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma.
     J Neurooncol. 2024 Apr 15. doi: 10.1007/s11060-024-04666.
     PubMed    
     
     
     
533. SHEEHAN JP, Trifiletti DM, Lehrer EJ
     Tissue biopsy before resection in glioblastoma: is there an opportunity to improve outcomes with liquid biopsies and pre-operative stereotactic radiosurgery?
     J Neurooncol. 2024 Apr 11. doi: 10.1007/s11060-024-04678.
     PubMed    
     
     
     
534. CHEN KT, Huang CY, Pai PC, Yang WC, et al
     Correction to: Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study.
     J Neurooncol. 2024 Apr 10. doi: 10.1007/s11060-024-04671.
     PubMed    
     
     
     
535. KONDO N, Kinouchi T, Natsumeda M, Matsuzaki J, et al
     Profile of miRNAs in small extracellular vesicles released from glioblastoma cells treated by boron neutron capture therapy.
     J Neurooncol. 2024 Apr 10. doi: 10.1007/s11060-024-04649.
     PubMed     Abstract available
     
     
     
536. MIRZAYEVA L, Ucar M, Kaymaz AM, Temel E, et al
     Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience.
     J Neurooncol. 2024 Apr 3. doi: 10.1007/s11060-024-04660.
     PubMed     Abstract available
     
     
     
537. MAHMOODIFAR S, Pangal DJ, Neman J, Zada G, et al
     Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models.
     J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04630.
     PubMed     Abstract available
     
     
     
538. DMUKAUSKAS M, Cioffi G, Waite KA, Sloan AE, et al
     Sex differences in adverse events in Medicare individuals >/= 66 years of age post glioblastoma treatment.
     J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04652.
     PubMed     Abstract available
     
     
     
539. LU VM, Brun JD, Niazi TN, Brun JD, et al
     Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States.
     J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04664.
     PubMed     Abstract available
     
     
     
540. XIANG Y, Chen Y, Xu Z, Zhou S, et al
     Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
     J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04662.
     PubMed     Abstract available
     
     
     
541. JOST J, Volker K, Brandt R, Stummer W, et al
     Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
     J Neurooncol. 2024 Apr 1. doi: 10.1007/s11060-024-04629.
     PubMed     Abstract available
     
     
     
542. ROGERS JL, Wall T, Acquaye-Mallory AA, Boris L, et al
     Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
     J Neurooncol. 2024;167:349-359.
     PubMed     Abstract available
     
     
     March 2024
543. TONG E, Horsley P, Wheeler H, Wong M, et al
     Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
     J Neurooncol. 2024 Mar 29. doi: 10.1007/s11060-024-04643.
     PubMed     Abstract available
     
     
     
544. FLORES-PACO P, Vargas-Aliaga A, Guevara MG, Lopera I, et al
     A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project.
     J Neurooncol. 2024 Mar 27. doi: 10.1007/s11060-024-04618.
     PubMed     Abstract available
     
     
     
545. WATANABE G, Young K, Rauber E, Khan MF, et al
     A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.
     J Neurooncol. 2024 Mar 26. doi: 10.1007/s11060-024-04659.
     PubMed     Abstract available
     
     
     
546. STRAUBE C, Combs SE, Bernhardt D, Gempt J, et al
     Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
     J Neurooncol. 2024 Mar 23. doi: 10.1007/s11060-024-04633.
     PubMed     Abstract available
     
     
     
547. ANDREWS CE, Zilberberg J, Perez-Olle R, Exley MA, et al
     Correction to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
     J Neurooncol. 2024 Mar 22. doi: 10.1007/s11060-024-04635.
     PubMed    
     
     
     
548. ZAKI PG, Herr S, Shepard MJ
     Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
     J Neurooncol. 2024 Mar 22. doi: 10.1007/s11060-024-04602.
     PubMed    
     
     
     
549. FINK L, van Oorschot B, von Sass C, Dibue M, et al
     Palliative care for in-patient malignant glioma patients in Germany.
     J Neurooncol. 2024 Mar 20. doi: 10.1007/s11060-024-04611.
     PubMed     Abstract available
     
     
     
550. GEENS W, Vanlaer N, Nijland L, Van Laere S, et al
     Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
     J Neurooncol. 2024 Mar 19. doi: 10.1007/s11060-024-04646.
     PubMed     Abstract available
     
     
     
551. BOBHOLZ SA, Hoefs A, Hamburger J, Lowman AK, et al
     Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
     J Neurooncol. 2024 Mar 18. doi: 10.1007/s11060-024-04641.
     PubMed    
     
     
     
552. ZHU P, Pichardo-Rojas PS, Dono A, Tandon N, et al
     The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database.
     J Neurooncol. 2024 Mar 16. doi: 10.1007/s11060-024-04644.
     PubMed     Abstract available
     
     
     
553. CHAKRAVARTI S, Kuo CC, Kazemi F, Kang A, et al
     Correction to: Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients.
     J Neurooncol. 2024 Mar 15. doi: 10.1007/s11060-024-04640.
     PubMed    
     
     
     
554. JIANG J, Li WB, Xiao SW
     Correction to: Prognostic factors analysis of diffuse midline glioma.
     J Neurooncol. 2024 Mar 15. doi: 10.1007/s11060-024-04634.
     PubMed    
     
     
     
555. PALAVANI LB, Silva GM, Borges PGLB, Ferreira MY, et al
     Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis.
     J Neurooncol. 2024 Mar 8. doi: 10.1007/s11060-024-04621.
     PubMed     Abstract available
     
     
     
556. DI NUNNO V, Lombardi G, Simonelli M, Minniti G, et al
     The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
     J Neurooncol. 2024 Mar 8. doi: 10.1007/s11060-024-04589.
     PubMed     Abstract available
     
     
     
557. GRAILLON T, Salgues B, Horowitz T, Padovani L, et al
     Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.
     J Neurooncol. 2024 Mar 7. doi: 10.1007/s11060-024-04622.
     PubMed     Abstract available
     
     
     
558. SINGH E, Gurses ME, Costello MC, Berke C, et al
     Correction to: Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
     J Neurooncol. 2024 Mar 6. doi: 10.1007/s11060-024-04619.
     PubMed    
     
     
     
559. YOKOGAMI K, Watanabe T, Yamashita S, Mizuguchi A, et al
     Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma.
     J Neurooncol. 2024 Mar 6. doi: 10.1007/s11060-024-04625.
     PubMed     Abstract available
     
     
     
560. CHAKRAVARTI S, Kuo CC, Kazemi F, Kang A, et al
     Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients.
     J Neurooncol. 2024 Mar 4. doi: 10.1007/s11060-024-04627.
     PubMed     Abstract available
     
     
     
561. LIM MJR, Zhang Z, Zheng Y, Khoo IWL, et al
     Effect of sarcopenia and frailty on outcomes among patients with brain metastases.
     J Neurooncol. 2024 Mar 2. doi: 10.1007/s11060-023-04542.
     PubMed     Abstract available
     
     
     
562. CHEN Y, Ning J, Shu L, Wen L, et al
     CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.
     J Neurooncol. 2024 Mar 1. doi: 10.1007/s11060-023-04548.
     PubMed     Abstract available
     
     
     
563. KEGOYA Y, Otani Y, Inoue Y, Mizuta R, et al
     Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
     J Neurooncol. 2024 Mar 1. doi: 10.1007/s11060-024-04587.
     PubMed     Abstract available
     
     
     
564. SHEEHAN JP, Singh R, Trifiletti DM
     Stereotactic radiosurgery for intracranial adenoid cystic carcinoma.
     J Neurooncol. 2024;167:229-230.
     PubMed    
     
     
     
565. WILSON JS, Main C, Thorp N, Taylor RE, et al
     The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review.
     J Neurooncol. 2024;167:1-34.
     PubMed     Abstract available
     
     
     
566. RANADE M, Epari S, Shetty O, Dhanavade S, et al
     CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
     J Neurooncol. 2024;167:189-198.
     PubMed     Abstract available
     
     
     February 2024
567. YU M, Ge Y, Wang Z, Zhang Y, et al
     The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
     J Neurooncol. 2024 Feb 29. doi: 10.1007/s11060-024-04609.
     PubMed     Abstract available
     
     
     
568. CEPEDA S, Garcia-Garcia S, Arrese I, Sarabia R, et al
     Non-navigated 2D intraoperative ultrasound: An unsophisticated surgical tool to achieve high standards of care in glioma surgery.
     J Neurooncol. 2024 Feb 28. doi: 10.1007/s11060-024-04614.
     PubMed     Abstract available
     
     
     
569. JALLOH M, Kankam SB
     Harnessing imaging biomarkers for glioblastoma metastasis diagnosis: a correspondence.
     J Neurooncol. 2024 Feb 23. doi: 10.1007/s11060-024-04606.
     PubMed    
     
     
     
570. YILMAZ MT, Kahvecioglu A, Yazici G, Mohammadipour S, et al
     Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years' experience of a single center.
     J Neurooncol. 2024 Feb 22. doi: 10.1007/s11060-024-04607.
     PubMed     Abstract available
     
     
     
571. JIANG J, Li WB, Xiao SW
     Prognostic factors analysis of diffuse midline glioma.
     J Neurooncol. 2024 Feb 21. doi: 10.1007/s11060-024-04605.
     PubMed     Abstract available
     
     
     
572. EHRET F, Zuhlke O, Schweizer L, Kahn J, et al
     Validation of a methylation-based signature for subventricular zone involvement in glioblastoma.
     J Neurooncol. 2024 Feb 20. doi: 10.1007/s11060-024-04570.
     PubMed     Abstract available
     
     
     
573. DASGUPTA P, Ou A, Lin H, Gregory T, et al
     The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab.
     J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-023-04551.
     PubMed     Abstract available
     
     
     
574. BACCILI CURY MEGID T, Baskurt Z, Ma LX, Barron CC, et al
     Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.
     J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-024-04576.
     PubMed     Abstract available
     
     
     
575. BOBHOLZ SA, Hoefs A, Hamburger J, Lowman AK, et al
     Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
     J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-024-04593.
     PubMed     Abstract available
     
     
     
576. UMEKAWA M, Shinya Y, Hasegawa H, Morshed RA, et al
     Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery.
     J Neurooncol. 2024 Feb 18. doi: 10.1007/s11060-023-04537.
     PubMed     Abstract available
     
     
     
577. ARNOLD LM, Hoshina Y, Lee H, Colman H, et al
     Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
     J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04588.
     PubMed     Abstract available
     
     
     
578. SHEEHAN JP, Mantziaris G, Bunevicius A
     Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma.
     J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04592.
     PubMed    
     
     
     
579. SHIRAI Y, Ueno T, Kojima S, Ikeuchi H, et al
     The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
     J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04563.
     PubMed     Abstract available
     
     
     
580. WASILEWSKI D, Onken J, Horicke P, Bukatz J, et al
     Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
     J Neurooncol. 2024 Feb 15. doi: 10.1007/s11060-024-04590.
     PubMed     Abstract available
     
     
     
581. DONO A, Torres J, Nunez L, Arevalo O, et al
     Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
     J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04575.
     PubMed     Abstract available
     
     
     
582. KOAY JM, Michaelides L, Moniz-Garcia DP, Quinones-Hinojosa A, et al
     Repeated surgical resections for management of high-grade glioma and its impact on quality of life.
     J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04600.
     PubMed     Abstract available
     
     
     
583. ANGELOVA P, Gicheva M
     Comment: Additional factors affecting cognitive function in low grade glioma patients.
     J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04598.
     PubMed    
     
     
     
584. WATANABE G, Wong JM, Estes B, Khan MF, et al
     Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
     J Neurooncol. 2024 Feb 12. doi: 10.1007/s11060-024-04584.
     PubMed     Abstract available
     
     
     
585. FAIRCHILD A, Salama JK, Godfrey D, Wiggins WF, et al
     Incidence and imaging characteristics of difficult to detect retrospectively identified brain metastases in patients receiving repeat courses of stereotactic radiosurgery.
     J Neurooncol. 2024 Feb 10. doi: 10.1007/s11060-024-04594.
     PubMed     Abstract available
     
     
     
586. MIRIAN C, Jensen LR, Juratli TA, Maier AD, et al
     The importance of considering competing risks in recurrence analysis of intracranial meningioma.
     J Neurooncol. 2024 Feb 10. doi: 10.1007/s11060-024-04572.
     PubMed     Abstract available
     
     
     
587. ALHALABI OT, Dao Trong P, Kaes M, Jakobs M, et al
     Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
     J Neurooncol. 2024 Feb 9. doi: 10.1007/s11060-024-04595.
     PubMed     Abstract available
     
     
     
588. KERIC N, Krenzlin H, Kalasauskas D, Freyschlag CF, et al
     Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
     J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04585.
     PubMed     Abstract available
     
     
     
589. AVERBUCH I, Tschernichovsky R, Yust-Katz S, Rotem O, et al
     Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
     J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04562.
     PubMed     Abstract available
     
     
     
590. TRAN S, Lapidus A, Neal A, Peters KB, et al
     A systematic review of the impact of brain tumours on risk of motor vehicle crashes.
     J Neurooncol. 2024 Feb 6. doi: 10.1007/s11060-024-04586.
     PubMed     Abstract available
     
     
     
591. SALANS M, Ni L, Morin O, Ziemer B, et al
     Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty.
     J Neurooncol. 2024 Feb 5. doi: 10.1007/s11060-024-04578.
     PubMed     Abstract available
     
     
     
592. TANG JD, Mills MN, Nakashima J, Dohm AE, et al
     Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
     J Neurooncol. 2024 Feb 3. doi: 10.1007/s11060-023-04543.
     PubMed     Abstract available
     
     
     
593. ZIMMERMANN MLM, Breedt LC, Centeno EGZ, Reijneveld JC, et al
     The relationship between pathological brain activity and functional network connectivity in glioma patients.
     J Neurooncol. 2024 Feb 3. doi: 10.1007/s11060-024-04577.
     PubMed     Abstract available
     
     
     
594. HAMMER Y, Najjar W, Kahanov L, Joskowicz L, et al
     Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline.
     J Neurooncol. 2024 Feb 1. doi: 10.1007/s11060-024-04580.
     PubMed     Abstract available
     
     
     
595. WANG B, Liu Y, Zhang J, Yin S, et al
     Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study.
     J Neurooncol. 2024 Feb 1. doi: 10.1007/s11060-024-04583.
     PubMed     Abstract available
     
     
     
596. KHOWAL S, Zhang D, Yong WH, Heaney AP, et al
     Whole-exome sequencing reveals genetic variants that may play a role in neurocytomas.
     J Neurooncol. 2024;166:471-483.
     PubMed     Abstract available
     
     
     January 2024
597. SINGH E, Gurses ME, Costello MC, Lu VM, et al
     Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
     J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-024-04582.
     PubMed     Abstract available
     
     
     
598. TANAKA T, Tamura R, Takei J, Morimoto Y, et al
     An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
     J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-023-04544.
     PubMed     Abstract available
     
     
     
599. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
     Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
     J Neurooncol. 2024 Jan 30. doi: 10.1007/s11060-024-04581.
     PubMed    
     
     
     
600. DASGUPTA P, Rousseau JF
     Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma.
     J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04574.
     PubMed     Abstract available
     
     
     
601. PETRONEK MS, Bodeker KL, Lee CY, Teferi N, et al
     Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial.
     J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04571.
     PubMed     Abstract available
     
     
     
602. VAN OPIJNEN MP, Broekman MLD, Cuppen E, Dubbink HJ, et al
     Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
     J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04568.
     PubMed     Abstract available
     
     
     
603. YEKULA A, Gessler DJ, Ferreira C, Shah R, et al
     GammaTile((R)) (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials.
     J Neurooncol. 2024 Jan 28. doi: 10.1007/s11060-023-04545.
     PubMed     Abstract available
     
     
     
604. GONZALEZ-APONTE MF, Damato AR, Trebucq LL, Simon T, et al
     Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
     J Neurooncol. 2024 Jan 26. doi: 10.1007/s11060-023-04535.
     PubMed     Abstract available
     
     
     
605. KREATSOULAS D, Damante M, Cua S, Lonser RR, et al
     Adjuvant convection-enhanced delivery for the treatment of brain tumors.
     J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-023-04552.
     PubMed     Abstract available
     
     
     
606. MULLER SJ, Khadhraoui E, Ganslandt O, Henkes H, et al
     MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis.
     J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-024-04573.
     PubMed     Abstract available
     
     
     
607. GARCIA MA, Turner A, Brachman DG
     The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.
     J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-023-04523.
     PubMed     Abstract available
     
     
     
608. REESE JC, Fadel HA, Pawloski JA, Samir M, et al
     Laser interstitial thermal therapy for deep-seated perivascular brain tumors is not associated with distal ischemia.
     J Neurooncol. 2024 Jan 19. doi: 10.1007/s11060-023-04546.
     PubMed     Abstract available
     
     
     
609. RYNDA AY, Rostovthev DM, Zabrodskaya YM, Olyushin VE, et al
     Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas - results.
     J Neurooncol. 2024 Jan 16. doi: 10.1007/s11060-023-04559.
     PubMed     Abstract available
     
     
     
610. ON J, Natsumeda M, Takahashi H, Koyama A, et al
     Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
     J Neurooncol. 2024 Jan 16. doi: 10.1007/s11060-023-04555.
     PubMed     Abstract available
     
     
     
611. ZAPANTA RINONOS S, Li T, Pianka ST, Prins TJ, et al
     dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
     J Neurooncol. 2024 Jan 15. doi: 10.1007/s11060-023-04531.
     PubMed     Abstract available
     
     
     
612. KUAH XYC, Lucas-Herald AK, McCarrison S, Boyle R, et al
     Presentation and outcomes of paediatric craniopharyngioma in the west of Scotland: a 25 year experience.
     J Neurooncol. 2024 Jan 15. doi: 10.1007/s11060-023-04490.
     PubMed     Abstract available
     
     
     
613. DOGAN E, Yildirim Z, Akalin T, Ozgiray E, et al
     Investigating the effects of PTEN mutations on cGAS-STING pathway in glioblastoma tumours.
     J Neurooncol. 2024 Jan 12. doi: 10.1007/s11060-023-04556.
     PubMed     Abstract available
     
     
     
614. DAGHER R, Gad M, da Silva de Santana P, Sadeghi MA, et al
     Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
     J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-023-04528.
     PubMed     Abstract available
     
     
     
615. MIYAKOSHI A, Ubukata N, Miyake H, Shoji-Asahina A, et al
     Risk factors for glioblastoma in adults in Japan: an exploratory cohort study based on the Shizuoka Kokuho Database, the Shizuoka study.
     J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-024-04566.
     PubMed     Abstract available
     
     
     
616. BERGER A, Mullen R, Bernstein K, Mashiach E, et al
     Volumetric growth rate of incidentally found meningiomas on immunotherapy.
     J Neurooncol. 2024 Jan 9. doi: 10.1007/s11060-023-04558.
     PubMed     Abstract available
     
     
     
617. HUDSON K, Mondia MW, Zhang Y, Saha S, et al
     The role of microRNAs in brain metastasis.
     J Neurooncol. 2024 Jan 9. doi: 10.1007/s11060-023-04541.
     PubMed     Abstract available
     
     
     
618. ZHANG Q, Dai Z, Chen Y, Li Q, et al
     Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway.
     J Neurooncol. 2024 Jan 8. doi: 10.1007/s11060-023-04527.
     PubMed     Abstract available
     
     
     
619. ZEUNER S, Vollmer J, Sigaud R, Oppermann S, et al
     Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
     J Neurooncol. 2024 Jan 7. doi: 10.1007/s11060-023-04526.
     PubMed     Abstract available
     
     
     
620. YADAV N, Purow BW
     Understanding current experimental models of glioblastoma-brain microenvironment interactions.
     J Neurooncol. 2024 Jan 5. doi: 10.1007/s11060-023-04536.
     PubMed     Abstract available
     
     
     
621. ZHANG JF, Okai B, Iovoli A, Goulenko V, et al
     Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma.
     J Neurooncol. 2024 Jan 4. doi: 10.1007/s11060-023-04524.
     PubMed     Abstract available
     
     
     
622. KAMBE A, Kitao S, Ochiai R, Hosoya T, et al
     The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.
     J Neurooncol. 2024 Jan 2. doi: 10.1007/s11060-023-04550.
     PubMed     Abstract available
     
     
     
623. HESHAM D, On J, Alshahaby N, Amer N, et al
     Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.
     J Neurooncol. 2024;166:27-38.
     PubMed     Abstract available
     
     
     
624. FADUL CE, Thakur A, Kim J, Kassay-McAllister J, et al
     Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
     J Neurooncol. 2024;166:321-330.
     PubMed     Abstract available
     
     
     
625. OBRECHT-STURM D, Pfaff E, Mynarek M, Bison B, et al
     Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment.
     J Neurooncol. 2024;166:359-368.
     PubMed     Abstract available
     
     
     
626. EBADI M, Morse M, Gooley T, Ermoian R, et al
     Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control.
     J Neurooncol. 2024;166:351-357.
     PubMed     Abstract available
     
     
     
627. SHEEHAN JP, Michalopoulos GD, Katsos K, Bydon M, et al
     The NeuroPoint alliance SRS & tumor QOD registries.
     J Neurooncol. 2024;166:257-264.
     PubMed     Abstract available
     
     
     
628. FENG J, Zhang J, Chen L, Li C, et al
     Treatment outcomes and risk factors of patients with intracranial germ cell tumour with choriocarcinoma element or beta-HCG level higher than 500 IU/L.
     J Neurooncol. 2024;166:331-339.
     PubMed     Abstract available
     
     
     
629. HONG S, Garces YI, Price KA, Shinya Y, et al
     Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients.
     J Neurooncol. 2024;166:369-376.
     PubMed     Abstract available
     
     
     December 2023
630. NORIKANE T, Mitamura K, Yamamoto Y, Manabe Y, et al
     Comparative evaluation of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma.
     J Neurooncol. 2023 Dec 31. doi: 10.1007/s11060-023-04534.
     PubMed     Abstract available
     
     
     
631. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
     A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
     J Neurooncol. 2023 Dec 28. doi: 10.1007/s11060-023-04513.
     PubMed     Abstract available
     
     
     
632. ARORA H, Mammi M, Patel NM, Zyfi D, et al
     Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
     J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04549.
     PubMed     Abstract available
     
     
     
633. YANG ZC, Yin CD, Yeh FC, Xue BW, et al
     Exploring MGMT methylation-driven structural connectivity changes in insular gliomas: a tractography and graph theoretical analysis.
     J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04539.
     PubMed     Abstract available
     
     
     
634. BENNEBROEK CA, Schouten CR, Montauban-van Swijndregt MC, Saeed P, et al
     Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
     J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04516.
     PubMed     Abstract available
     
     
     
635. REN L, Chen J, Deng J, Qing X, et al
     The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study.
     J Neurooncol. 2023 Dec 26. doi: 10.1007/s11060-023-04511.
     PubMed     Abstract available
     
     
     
636. CHOU CJ, Yang HC, Chang PY, Chen CJ, et al
     Automated identification and quantification of metastatic brain tumors and perilesional edema based on a deep learning neural network.
     J Neurooncol. 2023 Dec 22. doi: 10.1007/s11060-023-04540.
     PubMed     Abstract available
     
     
     
637. MIJAJLOVIC V, Miler M, Ilic R, Rasic D, et al
     Oncogene-induced senescence in meningiomas-an immunohistochemical study.
     J Neurooncol. 2023 Dec 20. doi: 10.1007/s11060-023-04532.
     PubMed     Abstract available
     
     
     
638. KINSLOW CJ, Siegelin MD, Iwamoto FM, Gallitto M, et al
     MGMT promoter methylation in 1p19q-intact gliomas.
     J Neurooncol. 2023 Dec 20. doi: 10.1007/s11060-023-04515.
     PubMed     Abstract available
     
     
     
639. LU VM, Khalafallah AM, Jaman E, Gurses ME, et al
     Clinical course of ventriculoperitoneal shunting for hydrocephalus following glioblastoma surgery: a systematic review and meta-analysis.
     J Neurooncol. 2023 Dec 19. doi: 10.1007/s11060-023-04538.
     PubMed     Abstract available
     
     
     
640. ABETE-FORNARA G, Bintintan Socaciu P, Fanizzi C, Fiore G, et al
     Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study.
     J Neurooncol. 2023 Dec 18. doi: 10.1007/s11060-023-04533.
     PubMed     Abstract available
     
     
     
641. CHEN Q, Wang K, Ren X, Zhao X, et al
     Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [(11)C]methionine PET.
     J Neurooncol. 2023 Dec 14. doi: 10.1007/s11060-023-04529.
     PubMed     Abstract available
     
     
     
642. CHANG CT, Chen HH, Chuang CC, Chang SH, et al
     Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis.
     J Neurooncol. 2023 Dec 8. doi: 10.1007/s11060-023-04503.
     PubMed     Abstract available
     
     
     
643. CHEN KT, Huang CY, Pai PC, Yang WC, et al
     Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study.
     J Neurooncol. 2023 Dec 7. doi: 10.1007/s11060-023-04517.
     PubMed     Abstract available
     
     
     
644. MIAO Q, Zheng X, Li L, Zheng X, et al
     Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
     J Neurooncol. 2023;165:517-525.
     PubMed     Abstract available
     
     
     
645. WILLEMS YCP, Vaassen F, Zegers CML, Postma AA, et al
     Anatomical changes in resection cavity during brain radiotherapy.
     J Neurooncol. 2023;165:479-486.
     PubMed     Abstract available
     
     
     
646. RAMMELOO E, Schouten JW, Krikour K, Bos EM, et al
     Preoperative assessment of eloquence in neurosurgery: a systematic review.
     J Neurooncol. 2023;165:413-430.
     PubMed     Abstract available
     
     
     
647. SHEN CI, Chiang CL, Huang HC, Tseng YH, et al
     Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study.
     J Neurooncol. 2023;165:459-465.
     PubMed     Abstract available
     
     
     
648. WIJAYA JH, Patel UD, Quintero-Consuegra MD, Aguilera-Pena MP, et al
     Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis.
     J Neurooncol. 2023;165:431-438.
     PubMed     Abstract available
     
     
     
649. LYNES J, Khan I, Aguilera C, Rubino S, et al
     Development of a "Geo-Tagged" tumor sample registry: intra-operative linkage of sample location to imaging.
     J Neurooncol. 2023;165:449-458.
     PubMed     Abstract available
     
     
     
650. SELT F, El Damaty A, Schuhmann MU, Sigaud R, et al
     Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow.
     J Neurooncol. 2023;165:467-478.
     PubMed     Abstract available
     
     
     November 2023
651. SHEEHAN J, Mantziaris G, Dumont C, Pikis S, et al
     Incidental meningiomas: a current and increasingly common challenge.
     J Neurooncol. 2023 Nov 30. doi: 10.1007/s11060-023-04525.
     PubMed    
     
     
     
652. BAUMGARTEN P, Prange G, Kamp MA, Monden D, et al
     Treatment of very elderly glioblastoma patients >/= 75 years of age: whom to treat.
     J Neurooncol. 2023 Nov 30. doi: 10.1007/s11060-023-04518.
     PubMed     Abstract available
     
     
     
653. ANDREWS CE, Zilberberg J, Perez-Olle R, Exley MA, et al
     Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
     J Neurooncol. 2023 Nov 29. doi: 10.1007/s11060-023-04491.
     PubMed     Abstract available
     
     
     
654. KLEINBERG L, Ye X, Supko J, Stevens GHJ, et al
     A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
     J Neurooncol. 2023 Nov 28. doi: 10.1007/s11060-023-04514.
     PubMed     Abstract available
     
     
     
655. YAVUZ BB, Kilinc F, Kanyilmaz G, Aktan M, et al
     Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients.
     J Neurooncol. 2023 Nov 27. doi: 10.1007/s11060-023-04521.
     PubMed     Abstract available
     
     
     
656. CHIANG CL, Yang HC, Liao YT, Luo YH, et al
     Treatment and survival of patients with small cell lung cancer and brain metastasis.
     J Neurooncol. 2023 Nov 20. doi: 10.1007/s11060-023-04512.
     PubMed     Abstract available
     
     
     
657. QIU X, Gao J, Hu J, Yang J, et al
     Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center.
     J Neurooncol. 2023 Nov 17. doi: 10.1007/s11060-023-04401.
     PubMed     Abstract available
     
     
     
658. QIN N, Paisana E, Picard D, Leprivier G, et al
     The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma.
     J Neurooncol. 2023 Nov 17. doi: 10.1007/s11060-023-04508.
     PubMed     Abstract available
     
     
     
659. VOGLIS S, Padevit L, van Niftrik CHB, Kalin V, et al
     Safety of microneurosurgical interventions for superficial and deep-seated brain metastases: single-center cohort study of 637 consecutive cases.
     J Neurooncol. 2023 Nov 10. doi: 10.1007/s11060-023-04478.
     PubMed     Abstract available
     
     
     
660. KHAN AB, Dang HQ, Gopakumar S, Lazaro T, et al
     Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma.
     J Neurooncol. 2023 Nov 9. doi: 10.1007/s11060-023-04475.
     PubMed     Abstract available
     
     
     
661. KIM N, Lee J, Nam DH, Lee JI, et al
     Correction to: Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
     J Neurooncol. 2023 Nov 8. doi: 10.1007/s11060-023-04498.
     PubMed    
     
     
     
662. NASLUND O, Strand PS, Solheim O, Al Masri M, et al
     Incidence, management, and outcome of incidental meningioma: what has happened in 10 years?
     J Neurooncol. 2023 Nov 8. doi: 10.1007/s11060-023-04482.
     PubMed     Abstract available
     
     
     
663. YAMAMOTO S, Okita Y, Arita H, Sanada T, et al
     Qualitative MR features to identify non-enhancing tumors within glioblastoma's T2-FLAIR hyperintense lesions.
     J Neurooncol. 2023 Nov 2. doi: 10.1007/s11060-023-04454.
     PubMed     Abstract available
     
     
     
664. LIN HT, Lin CM, Wu YY, Chang WH, et al
     Predictors for delayed awakening in adult glioma patients receiving awake craniotomy under monitored anesthesia care.
     J Neurooncol. 2023 Nov 2. doi: 10.1007/s11060-023-04494.
     PubMed     Abstract available
     
     
     
665. CHEN YH, Moore D, Lee CC, Su YH, et al
     Focused ultrasound for brain metastases: an update on global clinical trials.
     J Neurooncol. 2023 Nov 1. doi: 10.1007/s11060-023-04492.
     PubMed     Abstract available
     
     
     
666. HONG Y, Miao Q, Zheng X, Xu Y, et al
     Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
     J Neurooncol. 2023;165:301-312.
     PubMed     Abstract available
     
     
     
667. PRICE M, Neff C, Kruchko C, Barnholtz-Sloan JS, et al
     Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT.
     J Neurooncol. 2023;165:279-290.
     PubMed     Abstract available
     
     
     
668. KO MK, Kwak YK, Choi BO, Jeun SS, et al
     Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose?
     J Neurooncol. 2023;165:321-328.
     PubMed     Abstract available
     
     
     
669. ZAMARUD A, Marianayagam NJ, Park DJ, Yener U, et al
     The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
     J Neurooncol. 2023;165:373-379.
     PubMed     Abstract available
     
     
     October 2023
670. KRASSNIG S, Leber SL, Orthmann A, Golob-Schwarzl N, et al
     Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
     J Neurooncol. 2023 Oct 31. doi: 10.1007/s11060-023-04451.
     PubMed     Abstract available
     
     
     
671. LEHRER EJ, Khosla AA, Ozair A, Gurewitz J, et al
     Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients.
     J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04413.
     PubMed     Abstract available
     
     
     
672. MOHAMMAD AH, Jatana S, Ruiz-Barerra MA, Khalaf R, et al
     Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing.
     J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04485.
     PubMed     Abstract available
     
     
     
673. MA S, Lee H, Jo WY, Byun YH, et al
     The Warburg effect in patients with brain tumors: a comprehensive analysis of clinical significance.
     J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04486.
     PubMed     Abstract available
     
     
     
674. CROMPTON D, Koffler D, Fekrmandi F, Lehrer EJ, et al
     Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors.
     J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04466.
     PubMed     Abstract available
     
     
     
675. GROB ST, Miller KR, Sanford B, Donson AM, et al
     Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors.
     J Neurooncol. 2023 Oct 25. doi: 10.1007/s11060-023-04472.
     PubMed     Abstract available
     
     
     
676. ELLIS EM, Drumm MR, Rai SM, Huang J, et al
     Long-term antiseizure medication use in patients after meningioma resection: identifying predictors for successful weaning and failures.
     J Neurooncol. 2023 Oct 24. doi: 10.1007/s11060-023-04481.
     PubMed     Abstract available
     
     
     
677. STROWD R, Ellingson B, Raymond C, Yao J, et al
     Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
     J Neurooncol. 2023 Oct 21. doi: 10.1007/s11060-023-04456.
     PubMed     Abstract available
     
     
     
678. KIM N, Lee J, Nam DH, Lee JI, et al
     Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
     J Neurooncol. 2023 Oct 20. doi: 10.1007/s11060-023-04465.
     PubMed     Abstract available
     
     
     
679. YU Y, Chen H, Tian Z, Zhang Q, et al
     Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases.
     J Neurooncol. 2023 Oct 17. doi: 10.1007/s11060-023-04459.
     PubMed     Abstract available
     
     
     
680. NAKAJIMA R, Kinoshita M, Okita H, Nakada M, et al
     Glioblastomas at the white matter of temporo-parietal junction cause a poor postoperative independence level.
     J Neurooncol. 2023 Oct 17. doi: 10.1007/s11060-023-04479.
     PubMed     Abstract available
     
     
     
681. HOU C, Shi S, Gao M, Ji J, et al
     Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy.
     J Neurooncol. 2023 Oct 11. doi: 10.1007/s11060-023-04449.
     PubMed     Abstract available
     
     
     
682. DEJONCKHEERE CS, Layer JP, Hamed M, Layer K, et al
     Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes.
     J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04464.
     PubMed     Abstract available
     
     
     
683. BORST GR, Post R
     Letter to the editor: the impact of systemic treatment on brain metastases should be considered in clinical outcome analysis.
     J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04457.
     PubMed    
     
     
     
684. PANDYA SHESH B, Walter V, Palsa K, Slagle-Webb B, et al
     Sexually dimorphic effect of H-ferritin genetic manipulation on survival and tumor microenvironment in a mouse model of glioblastoma.
     J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04415.
     PubMed     Abstract available
     
     
     
685. ERNSTER AE, Body A, Deleyrolle P, St Clair J, et al
     Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors.
     J Neurooncol. 2023 Oct 7. doi: 10.1007/s11060-023-04469.
     PubMed     Abstract available
     
     
     
686. KOTCH C, Si SJ, Desai K, Caminada P, et al
     The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.
     J Neurooncol. 2023 Oct 7. doi: 10.1007/s11060-023-04468.
     PubMed     Abstract available
     
     
     
687. DADEY DYA, Medress ZA, Sharma M, Ugiliweneza B, et al
     Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018.
     J Neurooncol. 2023 Oct 4. doi: 10.1007/s11060-023-04460.
     PubMed     Abstract available
     
     
     
688. COVELL MM, Warrier A, Rumalla KC, Dehney CM, et al
     RAI-measured frailty predicts non-home discharge following metastatic brain tumor resection: national inpatient sample analysis of 20,185 patients.
     J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04461.
     PubMed     Abstract available
     
     
     
689. WELLER J, Zeyen T, Schafer N, Schaub C, et al
     The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
     J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04470.
     PubMed     Abstract available
     
     
     
690. VOLLMER J, Ecker J, Hielscher T, Valinciute G, et al
     Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
     J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04445.
     PubMed     Abstract available
     
     
     
691. QUE T, Huang G, Tan JE, Zhang P, et al
     Supramaximal resection based on en-bloc technique reduces tumor burden and prolongs survival in primary supratentorial lobar glioblastoma.
     J Neurooncol. 2023 Oct 2. doi: 10.1007/s11060-023-04399.
     PubMed     Abstract available
     
     
     
692. STOCKDILL ML, Mendoza T, Armstrong TS, Miaskowski C, et al
     Identification of health-related quality of life profiles among long-term survivors of primary central nervous system tumors.
     J Neurooncol. 2023;165:181-190.
     PubMed     Abstract available
     
     
     
693. BAI K, Chen X, Qi X, Zhang Y, et al
     Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
     J Neurooncol. 2023;165:149-160.
     PubMed     Abstract available
     
     
     
694. ONISHI S, Yamasaki F, Amatya VJ, Takayasu T, et al
     Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence.
     J Neurooncol. 2023;165:171-179.
     PubMed     Abstract available
     
     
     
695. GUTIERREZ-VALENCIA E, Sanchez I, Valles A, Diaz O, et al
     Pachymeningeal disease: a systematic review and metanalysis.
     J Neurooncol. 2023;165:29-39.
     PubMed     Abstract available
     
     
     September 2023
696. VAN T HEK R, Ortiz-Herrera JL, Salazar-Pigeon A, Ramirez-Loera C, et al
     Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis.
     J Neurooncol. 2023 Sep 29. doi: 10.1007/s11060-023-04448.
     PubMed     Abstract available
     
     
     
697. KARABACAK M, Jagtiani P, Carrasquilla A, Shrivastava RK, et al
     Advancing personalized prognosis in atypical and anaplastic meningiomas through interpretable machine learning models.
     J Neurooncol. 2023 Sep 28. doi: 10.1007/s11060-023-04463.
     PubMed     Abstract available
     
     
     
698. VAN DER MEER PB, Dirven L, Fiocco M, Vos MJ, et al
     Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study.
     J Neurooncol. 2023 Sep 27. doi: 10.1007/s11060-023-04450.
     PubMed     Abstract available
     
     
     
699. LI L, Shao MY, Zou SC, Xiao ZF, et al
     Correction to: MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44.
     J Neurooncol. 2023 Sep 22. doi: 10.1007/s11060-023-04429.
     PubMed    
     
     
     
700. MARWAH R, Xing D, Squire T, Soon YY, et al
     Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
     J Neurooncol. 2023 Sep 21. doi: 10.1007/s11060-023-04441.
     PubMed     Abstract available
     
     
     
701. SHEEHAN JP, Trifiletti DM
     Comments: neurosurgery and radiation oncology advances have improved visual outcomes for skull base meningioma patients.
     J Neurooncol. 2023 Sep 18. doi: 10.1007/s11060-023-04400.
     PubMed    
     
     
     
702. KUAN AS, Chiang CL, Wu HM, Yang HC, et al
     Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
     J Neurooncol. 2023 Sep 18. doi: 10.1007/s11060-023-04452.
     PubMed     Abstract available
     
     
     
703. FURUTA T, Negoto T, Miyoshi H, Moritsubo M, et al
     Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas.
     J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04447.
     PubMed     Abstract available
     
     
     
704. IGLSEDER S, Iglseder A, Beliveau V, Heugenhauser J, et al
     Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
     J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04414.
     PubMed     Abstract available
     
     
     
705. KATLOWITZ KA, Athukuri P, Sharma H, Dang H, et al
     Seizure outcomes after resection of primary brain tumors in pediatric patients: a systematic review and meta-analysis.
     J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04446.
     PubMed     Abstract available
     
     
     
706. JABEHDAR MARALANI P, Stewart J, Hiremath S, Lawrence L, et al
     Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma.
     J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04440.
     PubMed     Abstract available
     
     
     
707. DIMOV D, Brainman D, Berger B, Coras R, et al
     The role of cytoreductive surgery in multifocal/multicentric glioblastomas.
     J Neurooncol. 2023 Sep 12. doi: 10.1007/s11060-023-04410.
     PubMed     Abstract available
     
     
     
708. NINATTI G, Pini C, Bono BC, Gelardi F, et al
     The prognostic power of [(11)C]methionine PET in IDH-wildtype diffuse gliomas with lower-grade histological features: venturing beyond WHO classification.
     J Neurooncol. 2023 Sep 11. doi: 10.1007/s11060-023-04438.
     PubMed     Abstract available
     
     
     
709. ALZATE JD, Mullen R, Mashiach E, Bernstein K, et al
     EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.
     J Neurooncol. 2023 Sep 10. doi: 10.1007/s11060-023-04442.
     PubMed     Abstract available
     
     
     
710. SOHN B, Park K, Ahn SS, Park YW, et al
     Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
     J Neurooncol. 2023 Sep 10. doi: 10.1007/s11060-023-04435.
     PubMed     Abstract available
     
     
     
711. HOU Z, Hu J, Liu X, Yan Z, et al
     Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.
     J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04420.
     PubMed     Abstract available
     
     
     
712. WU YY, Chen KT, Chu YC, Yeh CC, et al
     Neuropsychological impairment in primary malignant brain tumor patients with awake craniotomy: a hospital-based registration study.
     J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04431.
     PubMed     Abstract available
     
     
     
713. MURTHA AN, Zaki PG, Shepard MJ
     Letter to the editor: outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
     J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04434.
     PubMed    
     
     
     
714. LUCKETT PH, Olufawo M, Lamichhane B, Park KY, et al
     Predicting survival in glioblastoma with multimodal neuroimaging and machine learning.
     J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04439.
     PubMed     Abstract available
     
     
     
715. HUNG JS, Su YH, Chen CJ, Chiang CL, et al
     Is it advisable to perform radiosurgery for EGFR-TKI-controlled brain metastases? A retrospective study of the role of radiosurgery in lung cancer treatment.
     J Neurooncol. 2023 Sep 1. doi: 10.1007/s11060-023-04425.
     PubMed     Abstract available
     
     
     
716. CIFARELLI CP, Vargo JA, Sener U, Cifarelli DT, et al
     Intracranial intraoperative radiotherapy (IORT): evaluation of electrocorticography and peri-operative seizure risk.
     J Neurooncol. 2023;164:423-430.
     PubMed     Abstract available
     
     
     
717. MINNITI G, Paolini S, Antonelli M, Gianno F, et al
     Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
     J Neurooncol. 2023;164:331-339.
     PubMed     Abstract available
     
     
     
718. HOU L, Chen X, Qiu G, Qi X, et al
     Cerebrospinal fluid exosomal protein alterations via proteomic analysis of NSCLC with leptomeningeal carcinomatosis.
     J Neurooncol. 2023;164:367-376.
     PubMed     Abstract available
     
     
     
719. FIGUEREDO LF, Shelton WJ, Tagle-Vega U, Sanchez E, et al
     The state of art of awake craniotomy in Latin American countries: a scoping review.
     J Neurooncol. 2023;164:287-298.
     PubMed     Abstract available
     
     
     
720. ID SAID B, Soliman H, Moravan V, Myrehaug S, et al
     Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
     J Neurooncol. 2023;164:437-445.
     PubMed     Abstract available
     
     
     
721. ZENG C, Yang Q, Li Z, Wei Z, et al
     Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study.
     J Neurooncol. 2023;164:643-653.
     PubMed     Abstract available
     
     
     
722. ZEYEN T, Paech D, Weller J, Schafer N, et al
     Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
     J Neurooncol. 2023;164:607-616.
     PubMed     Abstract available
     
     
     August 2023
723. PERTZ M, Schlomer S, Seidel C, Hentschel B, et al
     Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.
     J Neurooncol. 2023 Aug 30. doi: 10.1007/s11060-023-04419.
     PubMed     Abstract available
     
     
     
724. JIA W, Zhai X, Jing X, Bao Q, et al
     Prognostic value of cranial radiotherapy and optimal timing stratified by lung-molGPA for NSCLC patients with brain metastases.
     J Neurooncol. 2023 Aug 30. doi: 10.1007/s11060-023-04426.
     PubMed     Abstract available
     
     
     
725. WAGENER K, Beckhaus J, Boekhoff S, Friedrich C, et al
     Publisher Correction to: Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents.
     J Neurooncol. 2023 Aug 29. doi: 10.1007/s11060-023-04424.
     PubMed    
     
     
     
726. QURESHI HM, Tabor JK, Pickens K, Lei H, et al
     Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.
     J Neurooncol. 2023 Aug 25. doi: 10.1007/s11060-023-04416.
     PubMed     Abstract available
     
     
     
727. DE PIETRO R, Zaccaro L, Marampon F, Tini P, et al
     The evolving role of reirradiation in the management of recurrent brain tumors.
     J Neurooncol. 2023 Aug 25. doi: 10.1007/s11060-023-04407.
     PubMed     Abstract available
     
     
     
728. LEHRER EJ, Trifiletti DM, Sheehan JP
     Stereotactic radiosurgery in patients with extensive brain metastases - supporting evidence and knowledge gaps.
     J Neurooncol. 2023 Aug 21. doi: 10.1007/s11060-023-04422.
     PubMed    
     
     
     
729. EBIKO Y, Tamura K, Hara S, Inaji M, et al
     T2-FLAIR mismatch sign correlates with (11)C-methionine uptake in lower-grade diffuse gliomas.
     J Neurooncol. 2023 Aug 17. doi: 10.1007/s11060-023-04417.
     PubMed     Abstract available
     
     
     
730. GURRIERI L, Mercatali L, Ibrahim T, Fausti V, et al
     Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.
     J Neurooncol. 2023 Aug 16. doi: 10.1007/s11060-023-04357.
     PubMed     Abstract available
     
     
     
731. LAWSON MCLEAN A
     Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
     J Neurooncol. 2023 Aug 10. doi: 10.1007/s11060-023-04408.
     PubMed    
     
     
     
732. MIER-GARCIA JF, Ospina-Santa S, Orozco-Mera J, Ma R, et al
     Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.
     J Neurooncol. 2023 Aug 10. doi: 10.1007/s11060-023-04409.
     PubMed     Abstract available
     
     
     
733. JABLONSKA PA, Muniz T, Ribeiro M, Liu ZA, et al
     Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
     J Neurooncol. 2023 Aug 8. doi: 10.1007/s11060-023-04404.
     PubMed     Abstract available
     
     
     
734. OTANI R, Ikegami M, Yamada R, Yajima H, et al
     PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
     J Neurooncol. 2023 Aug 8. doi: 10.1007/s11060-023-04411.
     PubMed     Abstract available
     
     
     
735. HOLDAWAY M, Ablyazova F, Huda S, D'Amico RS, et al
     First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial.
     J Neurooncol. 2023 Aug 7. doi: 10.1007/s11060-023-04412.
     PubMed     Abstract available
     
     
     
736. LANG A, Jeron RL, Lontzek B, Kiesel B, et al
     Mapping high-grade glioma immune infiltration to 5-ALA fluorescence levels: TCGA data computation, classical histology, and digital image analysis.
     J Neurooncol. 2023 Aug 6. doi: 10.1007/s11060-023-04406.
     PubMed     Abstract available
     
     
     
737. NEUMANN B, Onken J, Konig N, Stetefeld H, et al
     Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
     J Neurooncol. 2023 Aug 2. doi: 10.1007/s11060-023-04403.
     PubMed     Abstract available
     
     
     
738. AKINDURO OO, Ghaith AK, El-Hajj VG, Ghanem M, et al
     Effect of race, sex, and socioeconomic factors on overall survival following the resection of intramedullary spinal cord tumors.
     J Neurooncol. 2023;164:75-85.
     PubMed     Abstract available
     
     
     
739. NETH BJ, Webb MJ, White J, Uhm JH, et al
     Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
     J Neurooncol. 2023;164:239-247.
     PubMed     Abstract available
     
     
     July 2023
740. NODA R, Kawashima M, Segawa M, Tsunoda S, et al
     Fractionated versus staged gamma knife radiosurgery for mid-to-large brain metastases: a propensity score-matched analysis.
     J Neurooncol. 2023 Jul 31. doi: 10.1007/s11060-023-04374.
     PubMed     Abstract available
     
     
     
741. HU T, Xuan R, Han E, Cai L, et al
     SPOPL induces tumorigenicity and stemness in glioma stem cells by activating Notch signaling.
     J Neurooncol. 2023 Jul 31. doi: 10.1007/s11060-023-04394.
     PubMed     Abstract available
     
     
     
742. MANTICA M, Drappatz J, Lieberman F, Hadjipanayis CG, et al
     Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
     J Neurooncol. 2023 Jul 29. doi: 10.1007/s11060-023-04398.
     PubMed     Abstract available
     
     
     
743. VIOZZI I, Overduin CG, Rijpma A, Rovers MM, et al
     MR-guided LITT therapy in patients with primary irresectable glioblastoma: a prospective, controlled pilot study.
     J Neurooncol. 2023 Jul 28. doi: 10.1007/s11060-023-04371.
     PubMed     Abstract available
     
     
     
744. BALLO MT, Conlon P, Lavy-Shahaf G, Kinzel A, et al
     Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
     J Neurooncol. 2023 Jul 26. doi: 10.1007/s11060-023-04348.
     PubMed     Abstract available
     
     
     
745. RAVIN R, Suarez-Meade P, Busse B, Blank PS, et al
     Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: human cells migrating in human brain.
     J Neurooncol. 2023 Jul 25. doi: 10.1007/s11060-023-04349.
     PubMed     Abstract available
     
     
     
746. KHATRI VM, Mills MN, Oliver DE, Yu HM, et al
     Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
     J Neurooncol. 2023 Jul 25. doi: 10.1007/s11060-023-04402.
     PubMed     Abstract available
     
     
     
747. SPILLE DC, Thomas C, Wagner A, Grauer OM, et al
     Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
     J Neurooncol. 2023 Jul 21. doi: 10.1007/s11060-023-04379.
     PubMed     Abstract available
     
     
     
748. LAYER JP, Hamed M, Potthoff AL, Dejonckheere CS, et al
     Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.
     J Neurooncol. 2023 Jul 21. doi: 10.1007/s11060-023-04380.
     PubMed     Abstract available
     
     
     
749. BUYUKTEPE M, Kaplan I, Bayatli E, Dogan H, et al
     Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
     J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04397.
     PubMed     Abstract available
     
     
     
750. ZHANG YT, Wang Y, Zhong XD, Chang J, et al
     Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center.
     J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04388.
     PubMed     Abstract available
     
     
     
751. TAORI S, Wei Z, Deng H, Hadjipanayis CG, et al
     Stereotactic radiosurgery for patients with brain metastases from gastroesophageal cancers.
     J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04392.
     PubMed     Abstract available
     
     
     
752. YANG X, Ji C, Qi Y, Huang J, et al
     Signal-transducing adaptor protein 1 (STAP1) in microglia promotes the malignant progression of glioma.
     J Neurooncol. 2023 Jul 18. doi: 10.1007/s11060-023-04390.
     PubMed     Abstract available
     
     
     
753. CHOJAK R, Fares J, Petrosyan E, Lesniak MS, et al
     Cellular senescence in glioma.
     J Neurooncol. 2023 Jul 17. doi: 10.1007/s11060-023-04387.
     PubMed     Abstract available
     
     
     
754. MALLICK S, Gupta S, Amariyil A, Kunhiparambath H, et al
     Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
     J Neurooncol. 2023 Jul 15. doi: 10.1007/s11060-023-04391.
     PubMed     Abstract available
     
     
     
755. ONYIAH C, Shepard MJ
     Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
     J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04376.
     PubMed    
     
     
     
756. MATSUI JK, Allen PK, Perlow HK, Johnson JM, et al
     Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience.
     J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04386.
     PubMed     Abstract available
     
     
     
757. OTANI R, Sadato D, Yamada R, Yajima H, et al
     CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer.
     J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04381.
     PubMed     Abstract available
     
     
     
758. LEI H, Tabor JK, O'Brien J, Qin R, et al
     Associations of race and socioeconomic status with outcomes after intracranial meningioma resection: a systematic review and meta-analysis.
     J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04393.
     PubMed     Abstract available
     
     
     
759. INDHARTY RS, Japardi I, Irina RS, Tandean S, et al
     Comparison of direct cortical stimulation and transcranial magnetic stimulation in brain tumor surgery: systematic review and meta analyses.
     J Neurooncol. 2023 Jul 12. doi: 10.1007/s11060-023-04378.
     PubMed     Abstract available
     
     
     
760. YADAV N, Babu D, Madigubba S, Panigrahi M, et al
     Tyrphostin A9 attenuates glioblastoma growth by suppressing PYK2/EGFR-ERK signaling pathway.
     J Neurooncol. 2023 Jul 6. doi: 10.1007/s11060-023-04383.
     PubMed     Abstract available
     
     
     
761. MISHRA A, Koffler D, Calugaru E, Rowe N, et al
     Let's make size not matter: tumor control and toxicity outcomes of hypofractionated Gamma Knife radiosurgery for large brain metastases.
     J Neurooncol. 2023 Jul 6. doi: 10.1007/s11060-023-04365.
     PubMed     Abstract available
     
     
     
762. TANRIKULU B, Yasar AH, Canpolat C, Corapcioglu F, et al
     Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas.
     J Neurooncol. 2023 Jul 4. doi: 10.1007/s11060-023-04347.
     PubMed     Abstract available
     
     
     
763. WAGENER K, Beckhaus J, Boekhoff S, Friedrich C, et al
     Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents.
     J Neurooncol. 2023 Jul 4. doi: 10.1007/s11060-023-04344.
     PubMed     Abstract available
     
     
     
764. LUO M, Tang R, Wang H
     Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
     J Neurooncol. 2023;163:663-674.
     PubMed     Abstract available
     
     
     
765. LESKINEN S, Shah HA, Yaffe B, Schneider SJ, et al
     Hippocampal avoidance in whole brain radiotherapy and prophylactic cranial irradiation: a systematic review and meta-analysis.
     J Neurooncol. 2023;163:515-527.
     PubMed     Abstract available
     
     
     June 2023
766. JONNAKUTI VS, Ji P, Gao Y, Lin A, et al
     NUDT21 alters glioma migration through differential alternative polyadenylation of LAMC1.
     J Neurooncol. 2023 Jun 30. doi: 10.1007/s11060-023-04370.
     PubMed     Abstract available
     
     
     
767. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
     Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
     J Neurooncol. 2023 Jun 29. doi: 10.1007/s11060-023-04367.
     PubMed     Abstract available
     
     
     
768. MOORE-PALHARES D, Chen H, Keith J, Wang M, et al
     Correction to: Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
     J Neurooncol. 2023 Jun 28. doi: 10.1007/s11060-023-04364.
     PubMed    
     
     
     
769. ADILE AA, Bakhshinyan D, Suk Y, Uehling D, et al
     An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma.
     J Neurooncol. 2023 Jun 24. doi: 10.1007/s11060-023-04372.
     PubMed     Abstract available
     
     
     
770. HOLDAWAY M, Starner J, Patel RR, Salama J, et al
     Improvement in visual outcomes of patients with base of skull meningioma as a result of evolution in the treatment techniques in the last three decades: a systematic review.
     J Neurooncol. 2023 Jun 24. doi: 10.1007/s11060-023-04366.
     PubMed     Abstract available
     
     
     
771. CHEN J, Li T, Zhou N, He Y, et al
     Engineered Salmonella inhibits GPX4 expression and induces ferroptosis to suppress glioma growth in vitro and in vivo.
     J Neurooncol. 2023 Jun 23. doi: 10.1007/s11060-023-04369.
     PubMed     Abstract available
     
     
     
772. TOM MC, DiFilippo FP, Jones SE, Suh JH, et al
     (18)F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study.
     J Neurooncol. 2023 Jun 21. doi: 10.1007/s11060-023-04377.
     PubMed     Abstract available
     
     
     
773. MASSIMINO M, Vennarini S, Buttarelli FR, Antonelli M, et al
     Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
     J Neurooncol. 2023 Jun 16. doi: 10.1007/s11060-023-04361.
     PubMed     Abstract available
     
     
     
774. KHAN AB, Patel R, McDonald MF, Goethe E, et al
     Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers.
     J Neurooncol. 2023 Jun 15. doi: 10.1007/s11060-023-04359.
     PubMed     Abstract available
     
     
     
775. JOST J, Muther M, Brandt R, Altuner U, et al
     Conceptual development of an intensive exercise program for glioma patients (ActiNO): summary of clinical experience.
     J Neurooncol. 2023 Jun 12. doi: 10.1007/s11060-023-04354.
     PubMed     Abstract available
     
     
     
776. MERENZON MA, Levy AS, Bhatia S, Rivera C, et al
     Towards the definition of progressive disease in brain metastasis treated with laser ablation: an evidence-based study.
     J Neurooncol. 2023 Jun 12. doi: 10.1007/s11060-023-04360.
     PubMed     Abstract available
     
     
     
777. CHO NS, Sanvito F, Thakuria S, Wang C, et al
     Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas.
     J Neurooncol. 2023 Jun 9. doi: 10.1007/s11060-023-04363.
     PubMed     Abstract available
     
     
     
778. WELLER J, Katzendobler S, Niedermeyer S, Harter PN, et al
     Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.
     J Neurooncol. 2023 Jun 8. doi: 10.1007/s11060-023-04362.
     PubMed     Abstract available
     
     
     
779. NAGAI N, Koide Y, Shindo Y, Hashimoto S, et al
     Retrospective non-inferiority study of stereotactic radiosurgery for more than ten brain metastases.
     J Neurooncol. 2023 Jun 7. doi: 10.1007/s11060-023-04358.
     PubMed     Abstract available
     
     
     
780. TOKLU S, Kemerdere R, Kacira T, Gurses MS, et al
     Tissue and plasma free amino acid detection by LC-MS/MS method in high grade glioma patients.
     J Neurooncol. 2023 Jun 6. doi: 10.1007/s11060-023-04329.
     PubMed     Abstract available
     
     
     
781. MA J, Li D, Hong Y, Zhang Y, et al
     Different clinical and cytogenetic features of primary skull base meningiomas and non-skull base meningiomas.
     J Neurooncol. 2023 Jun 2. doi: 10.1007/s11060-023-04351.
     PubMed     Abstract available
     
     
     
782. VAN SCHIE P, Rijksen BLT, Bot M, Wiersma T, et al
     Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series.
     J Neurooncol. 2023 Jun 2. doi: 10.1007/s11060-023-04343.
     PubMed     Abstract available
     
     
     
783. CACCESE M, Desideri I, Padovan M, Bruno F, et al
     Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
     J Neurooncol. 2023 Jun 1. doi: 10.1007/s11060-023-04356.
     PubMed     Abstract available
     
     
     
784. BISWAS A, Salvucci M, Connor K, Dussmann H, et al
     Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
     J Neurooncol. 2023;163:327-338.
     PubMed     Abstract available
     
     
     May 2023
785. MOORE-PALHARES D, Chen H, Keith J, Wang M, et al
     Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
     J Neurooncol. 2023 May 31. doi: 10.1007/s11060-023-04340.
     PubMed     Abstract available
     
     
     
786. BANDER ED, Kelly A, Ma X, Christos PJ, et al
     Safety and efficacy of Cesium-131 brachytherapy for brain tumors.
     J Neurooncol. 2023 May 30. doi: 10.1007/s11060-023-04352.
     PubMed     Abstract available
     
     
     
787. MCLAUGHLIN LA, Yildirim O, Rosenblum MK, Imber BS, et al
     Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.
     J Neurooncol. 2023 May 29. doi: 10.1007/s11060-023-04355.
     PubMed     Abstract available
     
     
     
788. SHEEHAN J, Cifarelli CP, Fadul C
     Contemporary care for brain metastasis patients: multidisciplinary approaches and the role of prospective national registries.
     J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04350.
     PubMed    
     
     
     
789. BUSCH N, Wegner RE, Shepard MJ
     Letter to the editor: neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases.
     J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04345.
     PubMed    
     
     
     
790. TINI P, Yavoroska M, Mazzei MA, Miracco C, et al
     Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
     J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04342.
     PubMed     Abstract available
     
     
     
791. JURATLI TA, Jungk C, Miller JJ
     Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.
     J Neurooncol. 2023 May 22. doi: 10.1007/s11060-023-04317.
     PubMed    
     
     
     
792. CROOMS RC, Taylor JW, Jette N, Morgenstern R, et al
     Palliative care referral across the disease trajectory in high-grade glioma.
     J Neurooncol. 2023 May 20. doi: 10.1007/s11060-023-04338.
     PubMed     Abstract available
     
     
     
793. FENG X, Zhu F, Dai L, Liu X, et al
     Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.
     J Neurooncol. 2023 May 17. doi: 10.1007/s11060-023-04339.
     PubMed     Abstract available
     
     
     
794. KNIGHT A, Horsley P, Yuile A, Yim J, et al
     Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.
     J Neurooncol. 2023 May 15. doi: 10.1007/s11060-023-04332.
     PubMed     Abstract available
     
     
     
795. VALINCIUTE G, Ecker J, Selt F, Hielscher T, et al
     Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
     J Neurooncol. 2023 May 15. doi: 10.1007/s11060-023-04319.
     PubMed     Abstract available
     
     
     
796. BONOSI L, Marino S, Benigno UE, Musso S, et al
     Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.
     J Neurooncol. 2023 May 14. doi: 10.1007/s11060-023-04333.
     PubMed     Abstract available
     
     
     
797. ZILIOLI A, Misirocchi F, Mutti C, Pancaldi B, et al
     Volumetric hippocampal changes in glioblastoma: a biomarker for neuroplasticity?
     J Neurooncol. 2023 May 13. doi: 10.1007/s11060-023-04315.
     PubMed     Abstract available
     
     
     
798. MA Y, Shi F, Sun T, Chen H, et al
     Histopathological auxiliary system for brain tumour (HAS-Bt) based on weakly supervised learning using a WHO CNS5-style pipeline.
     J Neurooncol. 2023 May 13. doi: 10.1007/s11060-023-04306.
     PubMed     Abstract available
     
     
     
799. MERLIN MS, Schmitt E, Mezloy-Destracque M, Dufour C, et al
     Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.
     J Neurooncol. 2023 May 12. doi: 10.1007/s11060-023-04328.
     PubMed     Abstract available
     
     
     
800. PADILLA CS, Ho VKY, Mooijenkind TWAN, Louwman MWJ, et al
     Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020).
     J Neurooncol. 2023 May 12. doi: 10.1007/s11060-023-04335.
     PubMed     Abstract available
     
     
     
801. ZABEK T, Szmatola T, Adamczyk-Grochala J, Lewinska A, et al
     Knockout of TRDMT1 methyltransferase affects DNA methylome in glioblastoma cells.
     J Neurooncol. 2023 May 11. doi: 10.1007/s11060-023-04304.
     PubMed     Abstract available
     
     
     
802. KALYVAS A, Gutierrez-Valencia E, Lau R, Ye XY, et al
     Anatomical and surgical characteristics correlate with pachymeningeal failure in patients with brain metastases after neurosurgical resection and adjuvant stereotactic radiosurgery.
     J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04325.
     PubMed     Abstract available
     
     
     
803. REGLI LKP, Huijs SMH, Pasmans RCOS, Leue C, et al
     Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
     J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04326.
     PubMed     Abstract available
     
     
     
804. SAUNDERS JT, Kumar S, Benavides-Serrato A, Holmes B, et al
     Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET.
     J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04331.
     PubMed     Abstract available
     
     
     
805. LAZZARINI E, Silvestris DA, Benvenuto G, Osti D, et al
     Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.
     J Neurooncol. 2023 May 4. doi: 10.1007/s11060-023-04287.
     PubMed     Abstract available
     
     
     
806. ZUO P, Li Y, Wang T, Lin X, et al
     A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
     J Neurooncol. 2023 May 3. doi: 10.1007/s11060-023-04323.
     PubMed     Abstract available
     
     
     
807. FISHMAN H, Monin R, Dor-On E, Kinzel A, et al
     Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
     J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04308.
     PubMed     Abstract available
     
     
     
808. TRAVERS SS, Fisher CM, Kabos P, Cittelly DM, et al
     Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience.
     J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04314.
     PubMed     Abstract available
     
     
     
809. DE GODOY LL, Chawla S, Brem S, Wang S, et al
     Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
     J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04324.
     PubMed     Abstract available
     
     
     
810. YE L, Wu BS, Xu ZA, Ji XF, et al
     Evidence for an intra-tumoral microbiome in pituitary neuroendocrine tumors with different clinical phenotypes.
     J Neurooncol. 2023;163:133-142.
     PubMed     Abstract available
     
     
     
811. DEWAN MC, Isaacs AM, Cools MJ, Yengo-Kahn A, et al
     Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network.
     J Neurooncol. 2023;163:123-132.
     PubMed     Abstract available
     
     
     
812. LI Q, Ma Y, Lin Z, Ma J, et al
     A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
     J Neurooncol. 2023;163:39-46.
     PubMed     Abstract available
     
     
     April 2023
813. AMELOT A, Terrier LM, Cognacq G, Jecko V, et al
     Correction to: Natural history of spinal cord metastasis from brain glioblastomas.
     J Neurooncol. 2023 Apr 26. doi: 10.1007/s11060-023-04320.
     PubMed    
     
     
     
814. SENGUPTA S
     Integrative neuro-oncology for brain tumor patients.
     J Neurooncol. 2023 Apr 25. doi: 10.1007/s11060-023-04309.
     PubMed    
     
     
     
815. CHANG WH, Wei KC, Chen PY, Chen YC, et al
     The impact of patient factors and tumor characteristics on language neuroplasticity in left hemispheric diffuse gliomas prior to surgical resection.
     J Neurooncol. 2023 Apr 24. doi: 10.1007/s11060-023-04311.
     PubMed     Abstract available
     
     
     
816. TRACZ JA, Donnelly BM, Ngu S, Vojnic M, et al
     The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
     J Neurooncol. 2023 Apr 22. doi: 10.1007/s11060-023-04312.
     PubMed     Abstract available
     
     
     
817. SYED HR, Kilburn L, Fonseca A, Nazarian J, et al
     First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication.
     J Neurooncol. 2023 Apr 12. doi: 10.1007/s11060-023-04269.
     PubMed    
     
     
     
818. DEMETZ M, Krigers A, Moser P, Kerschbaumer J, et al
     Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival.
     J Neurooncol. 2023 Apr 12. doi: 10.1007/s11060-023-04301.
     PubMed     Abstract available
     
     
     
819. ALTIERI R, Certo F, Pacella D, Cammarata G, et al
     Metabolic delineation of IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor extent of resection.
     J Neurooncol. 2023 Apr 11. doi: 10.1007/s11060-023-04305.
     PubMed     Abstract available
     
     
     
820. VOON NS, Manan HA, Yahya N
     Remote assessment of cognition and quality of life following radiotherapy for glioma: deep-learning-based predictive models and MRI correlates.
     J Neurooncol. 2023 Apr 4:1-9. doi: 10.1007/s11060-023-04303.
     PubMed     Abstract available
     
     
     
821. DINCER A, Morales-Valero SF, Robert SM, Tabor JK, et al
     Surgical strategies for intracranial meningioma in the molecular era.
     J Neurooncol. 2023 Apr 3. doi: 10.1007/s11060-023-04272.
     PubMed     Abstract available
     
     
     
822. YAMASHITA S, Takeshima H, Hata N, Uchida H, et al
     Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group.
     J Neurooncol. 2023;162:425-433.
     PubMed     Abstract available
     
     
     
823. FOO JC, Yaman Bajin I, Marushchak O, McKeown T, et al
     Time to dismiss boost? Outcomes of children with localized and metastatic germinoma.
     J Neurooncol. 2023;162:443-448.
     PubMed     Abstract available
     
     
     
824. ROEHRIG A, Indelicato DJ, Paulino AC, Ermoian R, et al
     Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
     J Neurooncol. 2023;162:353-362.
     PubMed     Abstract available
     
     
     
825. KEARNS K, Shepard MJ, Sheehan JP
     Social media and the Journal of Neuro-Oncology.
     J Neurooncol. 2023;162:453-454.
     PubMed    
     
     
     March 2023
826. AYMERIC A, Louis-Marie T, Gabrielle C, Vincent J, et al
     Natural history of spinal cord metastasis from brain glioblastomas.
     J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04298.
     PubMed     Abstract available
     
     
     
827. QUAN G, Wang T, Ren JL, Xue X, et al
     Prognostic and predictive impact of abnormal signal volume evolution early after chemoradiotherapy in glioblastoma.
     J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04299.
     PubMed     Abstract available
     
     
     
828. CHAMPEAUX-DEPOND C, Jecko V, Weller J, Constantinou P, et al
     Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
     J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04295.
     PubMed     Abstract available
     
     
     
829. OZKARA BB, Federau C, Dagher SA, Pattnaik D, et al
     Correlating volumetric and linear measurements of brain metastases on MRI scans using intelligent automation software: a preliminary study.
     J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04297.
     PubMed     Abstract available
     
     
     
830. ZHA B, Yang J, Dang Q, Li P, et al
     A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
     J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04292.
     PubMed     Abstract available
     
     
     
831. POPPE JP, Schwartz C
     In reply to the letter to the editor by Busch et al. regarding "Surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study".
     J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04302.
     PubMed    
     
     
     
832. KIMURA K, Deguchi S, Mitsuya K, Mamesaya N, et al
     Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center.
     J Neurooncol. 2023 Mar 28. doi: 10.1007/s11060-023-04300.
     PubMed     Abstract available
     
     
     
833. WAMELINK IJHG, Hempel HL, van de Giessen E, Vries MHM, et al
     The patients' experience of neuroimaging of primary brain tumors: a cross-sectional survey study.
     J Neurooncol. 2023 Mar 28. doi: 10.1007/s11060-023-04290.
     PubMed     Abstract available
     
     
     
834. IUS T, Sabatino G, Panciani PP, Fontanella MM, et al
     Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch(R)): a systematic review.
     J Neurooncol. 2023 Mar 24. doi: 10.1007/s11060-023-04274.
     PubMed     Abstract available
     
     
     
835. PARSONS MW, Sabsevitz DS
     Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.
     J Neurooncol. 2023 Mar 20. doi: 10.1007/s11060-023-04289.
     PubMed     Abstract available
     
     
     
836. LIANG L, Wen L, Qin S, He Z, et al
     Poor Karnofsky performance status is not a contraindication for neurosurgical resection in patients with lung cancer brain metastases: a multicenter, retrospective PSM-IPTW cohort study.
     J Neurooncol. 2023 Mar 20. doi: 10.1007/s11060-023-04293.
     PubMed     Abstract available
     
     
     
837. SHAH DS, Reddy RV, Dogruel Y, Asfour MZ, et al
     Calcified spinal meningiomas: a systematic review of clinical characteristics, treatment strategies, and outcomes.
     J Neurooncol. 2023 Mar 17. doi: 10.1007/s11060-023-04291.
     PubMed     Abstract available
     
     
     
838. QUACH S, Schwartz C, Aumiller M, Foglar M, et al
     Interstitial photodynamic therapy for newly diagnosed glioblastoma.
     J Neurooncol. 2023 Mar 16. doi: 10.1007/s11060-023-04284.
     PubMed     Abstract available
     
     
     
839. BLEEKER L, Kouwenhoven MCM, de Heer I, Lissenberg-Witte BI, et al
     Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol.
     J Neurooncol. 2023 Mar 15. doi: 10.1007/s11060-023-04285.
     PubMed     Abstract available
     
     
     
840. YAN M, Lee M, Myrehaug S, Tseng CL, et al
     Hypofractionated stereotactic radiosurgery (HSRS) as a salvage treatment for brain metastases failing prior stereotactic radiosurgery (SRS).
     J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04265.
     PubMed     Abstract available
     
     
     
841. DUFFAU H
     Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
     J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04288.
     PubMed     Abstract available
     
     
     
842. KING AL, Roche KN, Leeper HE, Vera E, et al
     Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial.
     J Neurooncol. 2023 Mar 8:1-9. doi: 10.1007/s11060-023-04271.
     PubMed     Abstract available
     
     
     
843. JUSINO S, Fadul CE, Dillon P
     Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
     J Neurooncol. 2023 Mar 8. doi: 10.1007/s11060-023-04276.
     PubMed     Abstract available
     
     
     
844. TRIFILETTI DM, Akinyelu T, Burri SH, Jeudy A, et al
     Glioma inadvertently treated with preoperative stereotactic radiosurgery: focusing on safety.
     J Neurooncol. 2023 Mar 6. doi: 10.1007/s11060-023-04278.
     PubMed    
     
     
     
845. MARTIN JA, Hart NH, Bradford N, Naumann F, et al
     Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review.
     J Neurooncol. 2023 Mar 2. doi: 10.1007/s11060-023-04270.
     PubMed     Abstract available
     
     
     
846. LI C, Guan N, Liu F
     T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
     J Neurooncol. 2023 Mar 1. doi: 10.1007/s11060-023-04257.
     PubMed     Abstract available
     
     
     
847. THIERHEIMER M, Cioffi G, Waite KA, Kruchko C, et al
     Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex.
     J Neurooncol. 2023;162:167-177.
     PubMed     Abstract available
     
     
     
848. SHARMA M, Do TH, Palzer EF, Huling JD, et al
     Comparable safety profile between neuro-oncology procedures involving stereotactic needle biopsy (SNB) followed by laser interstitial thermal therapy (LITT) and LITT alone procedures.
     J Neurooncol. 2023;162:147-156.
     PubMed     Abstract available
     
     
     
849. WEI Z, Pease M, Tang LW, Deng H, et al
     Radiosurgery outcomes in infratentorial juvenile pilocytic astrocytomas.
     J Neurooncol. 2023;162:157-165.
     PubMed     Abstract available
     
     
     
850. CACCIOTTI C, Chua IS, Cuadra J, Ullrich NJ, et al
     Pediatric central nervous system tumor survivor and caregiver experiences with multidisciplinary telehealth.
     J Neurooncol. 2023;162:191-198.
     PubMed     Abstract available
     
     
     
851. WESSELS PH, Boelens MC, Monkhorst K, Sonke GS, et al
     A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF?
     J Neurooncol. 2023;162:1-13.
     PubMed     Abstract available
     
     
     February 2023
852. TRINGALE KR, Wolden SL, Karajannis M, Haque S, et al
     Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.
     J Neurooncol. 2023 Feb 28. doi: 10.1007/s11060-022-04235.
     PubMed     Abstract available
     
     
     
853. MOLITERNO J, Brastianos PK
     Journal of Neuro-Oncology, Meningioma issue.
     J Neurooncol. 2023 Feb 27. doi: 10.1007/s11060-023-04251.
     PubMed    
     
     
     
854. PARK YW, Han K, Kim S, Kwon H, et al
     Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities.
     J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-022-04233.
     PubMed     Abstract available
     
     
     
855. WANG JZ, Nassiri F, Landry AP, Patil V, et al
     The multiomic landscape of meningiomas: a review and update.
     J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-023-04253.
     PubMed     Abstract available
     
     
     
856. PATEL Z, Cho M, Das S
     The role of immune checkpoint inhibitors in patients with intracranial metastatic disease.
     J Neurooncol. 2023;161:469-478.
     PubMed     Abstract available
     
     
     
857. AK M, Lf N, Gm I, Av K, et al
     Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular era.
     J Neurooncol. 2023;161:573-582.
     PubMed     Abstract available
     
     
     November 2022
858. IGLESIAS P, Biagetti B, Araujo-Castro M, Alcazar V, et al
     Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
     J Neurooncol. 2022;160:351-359.
     PubMed     Abstract available
     
     
     
859. RAGHIB MF, Salim A, Angez M, Ghazi SM, et al
     Prognostic implication of size on outcomes of pituitary macroadenoma: a comparative analysis of giant adenoma with non-giant macroadenoma.
     J Neurooncol. 2022;160:491-496.
     PubMed     Abstract available
     
     
     
860. SHE L, Deng D, Su L, Liu C, et al
     Comparison of surgery with or without adjuvant radiotherapy in treating central neurocytoma: a single-center retrospective real-world study.
     J Neurooncol. 2022;160:455-462.
     PubMed     Abstract available
     
     
     
861. WEBB M, Johnson DR, Mahajan A, Brown P, et al
     Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis.
     J Neurooncol. 2022;160:527-534.
     PubMed     Abstract available